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Abstract 
 
Allogeneic stem cell transplantation is associated with a powerful T cell-mediated ‘graft-
versus-leukaemia’ (GvL) effect and also ‘graft-versus-host disease’ (GvHD). Developing 
therapies to improve survival relies on greater understanding of these responses in order to 
enhance GvL and suppress GvHD. To gain an increased understanding of the mechanisms of 
GvHD I measured frequencies of Th1, Th17 and Treg subsets in the blood of 32 GvHD 
patients (during and outside of disease episodes) and in 21 patients who did not suffer 
GvHD. No associations between T cell subset frequencies or serum cytokine concentrations 
and incidence of GvHD were evident. My GvL work addressed whether T cell responses to 
cancer/testis antigens (CTAg) could be detected in a cohort of 41 patients who had 
undergone allogeneic stem cell transplantation for the management of acute myeloid 
leukaemia and multiple myeloma. CTAg-specific CD8+ T cell immune responses were 
observed within peripheral blood of five patients, with an average magnitude of 0.045% of 
the CD8+ T cell repertoire. T cell immunity was focussed against peptides derived from 
MAGE proteins and was increased within the bone marrow. These immune responses are 
likely to contribute to tumour eradication following transplantation and represent a 
potential novel mechanism for GvL. 
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1.1 Bone Marrow and Haematopoiesis 
1.1.1 Bone marrow structure and microenvironment 
The medullary cavities of bones contain blood vessels and bone marrow, a rich 
microenvironment that fosters blood and stromal cell genesis.  During foetal development, 
haematopoiesis takes place in the liver, spleen and in the medulla of a number of bones but 
throughout development is increasingly in flat bones so that by puberty blood production 
takes place predominantly in the sternum, vertebrae, iliac bones and ribs.  In these bones 
the red marrow consists of long trabeculae within a sponge-like reticular framework.  Spaces 
around this framework are filled with fat cells, stromal fibroblasts and haematopoietic 
precursors. Also found in the bone marrow are mesenchymal stem cells (MSC) which 
differentiate into fibroblasts, osteoblasts (bone formation), adipocytes, chondrocytes 
(cartilage generation) and myocytes (muscle).  Activated, antigen experienced B cells 
differentiate into plasma cells which return to, and colonise the bone marrow. 
Haematopoietic stem cells (HSC) express CD34 and stem cell antigen-1 (Sca1) which can be 
used to identify and sort HSCs. Within the bone marrow are osteoblastic and vascular niches 
(reviewed by Yin et al, 2006) formed by supporting cells. Bone marrow  cells secrete 
cytokines which are a diverse group of proteins and glycoproteins (including interleukins and 
interferons) that promote a range of functions including growth, differentiation and 
proliferation. A key subgroup of cytokines are instrumental in cell trafficking and are known 
as chemokines (see section 1.3).  Maintenance of these microenvironments is essential for 
healthy blood cell production.  Amongst the array of cytokines present are G-CSF and 
CXCL12 which mobilise CXCR4 expressing HSC.  These chemokines also play a role in HSC 
survival and proliferation (Cancelas et al., 2005, Lapidot et al., 2005). 
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1.1.2 Haematopoiesis 
Mobilised HSCs divide, with one daughter cell remaining in the bone marrow, whilst the 
other becomes a multipotent progenitor (MPP) cell, then either a common lymphoid 
progenitor (CLP) or common myeloid progenitor (CMP).  The twin functions of self-renewal 
and differentiation are crucial to the haematopoietic process.  Throughout the maturation 
process, the nascent haematopoietic cells migrate from the subendosteal region (at the 
inner bone surface) towards a central region and matured cells exit through a network of 
vascular sinuses (figure 1.1.1). 
Common myeloid progenitors ultimately differentiate into granulocytes, macrophages, 
erythrocytes or megakaryocytes.  Lymphoid progenitors form either NK cells, B cells or T 
cells (figure 1.1.2).  Early B cells commit to the B cell lineage with rearrangement and 
expression of immunoglobulin genes, acquiring antigen specificity and expressing surface 
IgM and IgD within the bone marrow before leaving as immature B cells.  Maturation occurs 
outside of the bone marrow, and mature B cells circulate through the lymphatic system until 
antigen encounter, undergoing somatic hypermutation of the immunoglobulin genes, 
altering antigen affinity.  Most B cells are unsuccessful during differentiation and only a 
minority survive the developmental process.  Activated B cells can either become short-lived 
plasma cells or enter follicles and form germinal centres (GC).  Memory B cells are antigen 
experienced cells from the GC which can ultimately migrate to the bone marrow and form 
long-lived plasma cells (reviewed (Bonilla and Oettgen, 2010)).  
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Figure 1.1.1 Structure and vascular network of bone marrow 
The structure of bone marrow, with the vascular network bringing blood into the medullary 
cavity (nutrient artery) and exit channels (emissary vein, capillaries).  Haematopoietic stem 
cells are found at the endosteum and migrate towards the central sinus as maturation 
occurs. 
Adapted from (Nagasawa, 2006) 
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Figure 1.1.2 Differentiation paths of MSCs and HSCs 
Haematopoietic stem cells differentiate into lymphoid or myeloid progenitor cells before 
leaving the bone marrow to mature into either lymphocytes (B cell, T cell & NK cell) or 
myeloid lineage cells (monocyte/macrophage, granulocyte, megakaryocyte, erythrocyte).  
Mesenchymal stem cells are also found within the bone marrow and differentiate into 
chondrocytes, osteoblasts, fibroblasts, adipocytes, myocytes or endothelial cells. 
Adapted from (Yin and Li, 2006) 
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1.1.3 Thymic Selection 
On arrival in the thymus, early T cell precursors do not express CD4 or CD8 which are cell 
surface co-receptors involved with antigen recognition, and are known as double negatives 
(DN) (figure 1.1.3). During these DN stages, the thymocytes can be subdivided on the basis of 
expression of CD44 and CD25, progressing from CD44+ CD25- to CD44+ CD25+ to CD44- 
CD25+ to CD44- CD25- which correspond to DN1 to DN4 respectively (reviewed by (Taub and 
Longo, 2005)). As they enter the DN2 stage, the cells express the interleukin-7 (IL-7) receptor 
CD127 and undergo IL-7 driven proliferation.  As they pass through DN stages across the 
cortex, greater numbers of genes that define T cell identity are expressed, leading to greater 
lineage commitment.  Up until the DN3 stage, it is still possible to differentiate along other 
pathways.   
As they enter DN3a stage, T cell lineage is set and gene rearrangement proceeds for the 
variable regions of the T cell receptor (TCR) (Taghon et al., 2006).  The TCR loci contains 
variable (V), diversity (D) and joining (J) segments, and during recombination, one of each 
are randomly spliced together. This allows an extremely diverse repertoire of TCRs, and only 
those that have successfully assembled a pre-TCR (TCRβ chain) can survive and pass through 
to DN3b stage.  The TCRα chain is expressed to make a complete TCR, complexed at the cell 
surface with CD3.  CD4 and CD8 are co-expressed to make double positive (DP) cells which 
then undergo selection based on their interactions with major histocompatibility complex 
(MHC) molecules.  Positive selection allows for those DP clones that have low avidity binding 
to self-MHC, giving rise to a pool of T cells with the capacity to recognise foreign antigen 
presented by self-MHC.  Those with a TCR that cannot recognise self-MHC are deleted.  
Negative selection eliminates DP clones that bind with a very high affinity for self-MHC/self-
peptide in order to limit the expansion of pools of self-reactive T cells.  This is known as 
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central tolerance.  Single-positive T cells emerge from the selection process, and express CD4 
following MHC class II interaction or CD8 resulting from selection by MHC class I.  Matured, 
fully-differentiated but antigen naive T cells enter into circulation (figure 1.1.3). 
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Figure 1.1.3 T Lymphocyte development in the thymus 
Early T cell precursors (ETP) progress through the DN2 stage before complete commitment 
to T cell lineage (A).  TCR gene rearrangement occurs between E3a and E3b at which point 
divergence along the αβ or γδ pathway occurs (B).  Following DN4, the nascent lymphocytes 
become double positive (DP) for CD4 and CD8.  Selection occurs after TCR formation to 
eliminate potential self reactive clones and those which cannot recognise self-MHC (C).  
Finally, T cells emerge as single positive CD4 or CD8 T cells. 
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1.2 Lymphocyte differentiation 
The traditional paradigm of T cell lineage was that CD8+ T cells were cytotoxic, (thus also 
known as ‘cytotoxic T cells’ (CTLs)) and that CD4+ T cells were primarily for support, 
described as helper T cells (Th).  Functional differences led to identification of two Th 
lineages named Th1 and Th2 based on cytokine secretion profiles (Mosmann et al., 1986).  
More recently, it has become clear that the CD4+ lymphocyte population has greater 
diversity and studies have identified an IL-17A secreting subset, the Th17 population 
(Harrington et al., 2005, Park et al., 2005) and crucially, a suppressive lineage known as 
regulatory T cells (Tregs) (figure 1.2.1).  As described in section 1.1.3, MHC interactions in the 
thymus direct T cells along the CD4 or CD8 path.  
On encounter with antigen, naive CD4+ T cells differentiate into subsets characterised by 
cytokine secretion profile and function which is used, along with lineage specific 
transcription factors to identify them.  Cytokines present in the environment when the cells 
are activated direct the lineage pathway the cells will follow.  For example, the presence of 
IFN-α, IFN-γ and IL-12 can drive a Th1 phenotype, but IL-1β and TGF-β lead to Th17 
differentiation (figure 1.2.1).  Differentiation is discussed further below, and antigen 
recognition is expanded upon in 1.4. 
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Figure 1.2.1 CD4+ T cell subsets and cytokines 
Following antigen encounter, a naive T cell can differentiate along a number of paths 
dictated by the cytokines present in the environment, this gives rise to different subsets 
which can be defined by expression of transcription factors and cytokine secretion profiles.   
Here, the cytokines shown in blue represent those in the environment which drive the 
pathway towards Th2, Th9, Th22, Treg, Th17 or Th1 subsets.  Their associated transcription 
factors are shown in brackets.  The main cytokines secreted by each of the subsets are 
shown in black. 
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1.2.1 Effector subsets 
Th1 cells produce IFN-γ and express the transcription factor Tbet.  They are 
proinflammatory, influencing macrophage activation and the production of opsonising 
antibodies.  Differentiation into this subset is thought to be induced by IL-12 and 
environmental interferons produced by dendritic cells (DC) (Parronchi et al., 1992).  These 
combined signals induce transcription factor STAT1 which subsequently leads to Tbet 
induction.  This leads to upregulation of the IL-12 receptor, enabling the cells to be IL-12 
responsive, and generate high levels of IFN-γ (Szabo et al., 1997).  
Th2 cells secrete IL-4, IL-5, IL-9 and IL-13 which are all involved in mediating responses to 
parasitic helminths.  Binding of the IL-4 receptor induces STAT-6, leading to upregulation of 
GATA-3 which, in combination with IL-2-initiated STAT-5, allow Th2 differentiation (Pai et al., 
2004, Zhu et al., 2001). 
More recently, other lineages have been described, in particular Th17 which is characterised 
by production of IL-17A, IL-17F and IL-22.  The transcription factor thought to be crucial for 
the functional characteristics of Th17 cells is RORγt.  The exact nature of conditions required 
for the direction of naive T cells along this lineage is not entirely clear.  Early murine studies 
showed that TGF-β and IL-6 were sufficient (Bettelli et al., 2006, Mangan et al., 2006).  
Subsequently, a critical role of IL-1β was reported along with suggestions that TGF-β was in 
fact unnecessary (Chung et al., 2009).  This work indicated that cytokine requirements for 
initiation of the Th17 lineage differed between mouse and human.  However, by stringent 
sorting of naive CD4+ T cells used in differentiation experiments and tightly controlling TGF-β 
concentrations, the necessity of this cytokine was confirmed (reviewed (Korn et al., 2009)).  
There were associations with an IL-12 family member known as IL-23.  However, receptors 
for IL-23 are not upregulated until the Th17 lineage has begun to be established, so this 
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cytokine may have a greater role in maintaining the Th17 phenotype (McGeachy et al., 
2009).  Human Th17 cells have been shown to express CCR4, CCR6 and CD161 (Cosmi et al., 
2008), and additionally secrete IL-26 and CCL20 (Wilson et al., 2007). 
Other subsets have been described based on secretion of IL-9 (Dardalhon et al., 2008, 
Veldhoen et al., 2008) and IL-22 (Duhen et al., 2009, Trifari et al., 2009).  Although these 
cytokines form part of the expression profiles of Th2 and Th17 respectively, these subsets 
were found to have a comparatively limited range of cytokines 
Effector T cell subsets in autoimmune inflammation 
A complication of stem cell transplantation is Graft-versus-Host Disease (GvHD) (see section 
1.8.4), where the patient’s tissues are damaged by T cells arising from the transplanted 
immune system, giving rise to symptoms that are not unlike some autoimmune conditions 
such as those affecting skin, or inflammatory bowel.  A recent proteomic study 
demonstrated a number of proteins expressed in patients with autoimmune systemic 
sclerosis and also in sclerodermatous GvHD that were not found in healthy controls (Scambi 
et al., 2010).  Therefore there may be similarities between the inflammatory processes 
affecting GvHD patients and people with autoimmune conditions.  Autoimmune conditions 
are often manifest in skin and gut, as is GvHD. 
Inflammatory bowel diseases (IBD) potentially arise from inappropriate responses to 
commensal gut flora leading to raised levels of proinflammatory cytokines such as IL-6, IL-12 
and IL-23 (reviewed by (Kaser et al., 2010)).  IL-6 has a role in promoting secretion of IFN-γ 
and TNF-α in Th1 cells (Yamamoto et al, 2000) and in directing T cells towards a Th17 
phenotype rather than to become Tregs (Bettelli et al., 2006, Lee et al., 2009, Zhou et al., 
2009).  These roles would therefore lead to an increase of a proinflammatory infiltrate with 
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elevated Th17 levels.  If a similar pathology occurs in gut GvHD, then raised serum IL-6 and 
increased frequencies of IL-17A secreting cells may be observed. 
IL-12, along with TNF-α, drive T cells towards a Th1 phenotype and promote IFN-γ secretion.  
Murine experiments have associated increased levels of IL-12 with occurrences of 
experimental autoimmune encephalitis (EAE) and collagen-induced arthritis, and also linked 
the diseases to IL-23 (Cua et al., 2003, Murphy et al., 2003).  These cytokines were shown to 
be pathogenic in uveitis.  As IL-23 has been associated with driving, or at least maintaining 
the Th17 lineage, the action of both of these cytokines expands the Th1 and Th17 
populations.  IL-12 blocking antibodies abrogated colitis in mouse models, demonstrating 
the role of this cytokine in inflammatory bowel conditions (Neurath et al., 1995), and IL-23 
was shown to drive innate and T cell-mediated intestinal inflammation (Hue et al., 2006).  
Indeed, the frequency of IL-17A secreting cells is substantially increased in Crohn’s Disease 
mucosa (Annunziato et al., 2007). 
IL-23 is overproduced by DCs in psoriasis lesions (Lee et al., 2004, Wilson et al., 2007) and 
one study found the frequency of IL-17A secreting cells was 6.2% in psoriatic plaques as 
compared to 0.5% in normal skin (Lowes et al., 2008).  This raises the possibility that IL-17A 
secreting cells may also have a role in skin GvHD pathology. 
These studies provided a rationale for investigating the frequencies of Th1 and Th17 subsets 
in GvHD patients. 
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1.2.2 Regulatory subsets 
In order to prevent excessive or inappropriate immune mediated damage, the immune 
system has a regulatory component.  T-lymphocyte mediated regulation is carried out by Tr1 
and Treg cells.  It has been suggested that the latter can either be of thymic origin, so called 
natural regulatory T cells (nTregs), or those induced in the circulatory system (iTregs) 
(Apostolou and von Boehmer, 2004, Cobbold et al., 2004, Curotto de Lafaille et al., 2001, 
Mucida et al., 2005).  Despite having different origins, nTregs and iTregs are 
indistinguishable.  Tregs are characterised by expression of the transcription factor Foxp3 
following IL-2 and high levels of TGF-β stimulation of naive T cells.  Mutations that lead to 
loss of functional Foxp3 result in fatal autoimmune conditions characterised by massive 
inflammation and a proinflammatory cytokine storm.  Discovery of Foxp3 resulted from 
investigations into a rare and severe autoimmune condition known as Immune-
Dysregulation Polyendocrinopathy Enteropathy X-linked (IPEX) (Chen et al., 2003, Fontenot 
et al., 2003, Hori et al., 2003). 
Several mechanisms of suppressive action via cell to cell contact and through cytokine-
dependent mechanisms, have been attributed to Tregs, which are either directed against 
effector T cells or antigen presenting cells (APC).  Studies have shown that an important 
method of Treg-driven, in vivo suppression is via IL-10 secretion (Belkaid, 2007, McGeachy et 
al., 2009).  This versatile cytokine causes inhibition of a number of cytokines and chemokines 
on a wide variety of cells, including APCs leading to inhibition of function and proliferation of 
effector T cells (reviewed (Moore et al., 2001)).  Tregs can also inhibit DC function by 
inactivating extracellular ATP which has inflammatory effects on DCs, through the action of 
CD39 on Tregs, catalysing the ATP to AMP reaction (Borsellino et al., 2007).  Surface LAG-3 
on Tregs interacts with MHC on DCs, delaying maturation (Liang et al., 2008).  Tregs 
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constitutively express CTLA-4 which binds to CD80 and CD86 on DCs, subsequently 
downregulating these molecules on the APC and prevents adequate co-stimulation through 
CD28 which is necessary for naive T cell activation (Wing et al., 2008).   
Direct suppressive action against effector cells includes elimination by granzyme-mediated, 
perforin-dependent killing (Grossman et al., 2004) or by expression of galectin-1 which when 
bound, inhibits proinflammatory cytokine production and can induce apoptosis (Kubach et 
al., 2007).  Tregs can suppress effector cells indirectly by secretion of immunosuppressive 
cytokines IL-10, TGF-β and IL-35, but can also upregulate IL-2Rα (CD25) and compete for 
environmental IL-2, thus reducing availability of this cytokine for effector cells (Shevach, 
2009).  Using Foxp3 to identify Tregs presents difficulties in functional studies due to the 
nature of intracellular staining protocols which affect cell function, so surface marker 
staining is essential for identification of viable Tregs, and CD25 was considered as a possible 
marker.  However, CD25 alone is insufficient as only a small proportion of CD25+ T cells are 
regulatory.  The highest 1-2% of CD25+ T cells are Tregs, but the exact boundary between 
CD25hi and CD25mid (which are not suppressive and do not express Foxp3+) is difficult to 
determine and leads to inaccuracies.  Two studies identified that Tregs lack the IL-7Rα-chain 
(CD127).  They noted that Foxp3+ CD4+ T cells with suppressive ability were highly enriched 
in the CD25hi CD127lo fraction (Liu et al., 2006, Seddiki et al., 2006). 
Tr1 cells are Foxp3 –ve and are induced in the periphery by APCs in the presence of IL-10.  
They exert suppressive effects via the secretion of IL-10 and TGF-β (Groux et al., 1997, 
Levings et al., 2001). 
1.2.3 Plasticity of T cell subsets 
As the number of studies investigating the roles of T cell subsets increases, it has become 
apparent that cells do not always fit into rigidly defined subsets.  For example, studies 
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identified CD4+, Tbet-expressing T cells that could produce both IL-17A and IFN-γ which 
were named Th17/Th1 or Th17-1.  Stimulation of Th17 cells in the presence of IL-12 led to 
downregulation of Th17-associated transcription factors, upregulation of Tbet and led to 
IFN-γ secretion, whilst still maintaining the ability to secrete IL-17A (Annunziato et al., 2007).  
This suggests that perhaps T cells have the ability to amend their function in response to 
environmental factors, which would lead to a dynamic and responsive immune system.  
Plasticity of other T cell subsets has been reported, notably in the case of Tregs. 
A number of studies have demonstrated a reorientation of Tregs into Th1, Th2, Th9 or Th17 
effector subsets (Wan, 2010).  Co-expression of Foxp3 and RORγt has been reported in both 
murine and human studies (Voo et al., 2009, Zhou et al., 2009).  There have been reports of 
effector T cells expressing high levels of CD25, or Foxp3.  It may well be that these cells are in 
transition from one phenotype to another.  It is not clear how adaptable a T cell may be 
depending on its environment.  This plasticity potentially has important implications for 
development of adoptive T cell therapies and vaccines.  The consequences of adoptively 
transferring antigen-specific T cells to treat autoimmune conditions, or graft-versus-host 
disease in stem cell transplant patients, could be catastrophic if there is a switch from 
regulatory to effector function.  Attempts to culture Tregs in vitro revealed that CD4+ Foxp3+ 
CD45RA populations would retain a regulatory phenotype, whereas those which were 
CD45RO+ switched to an effector phenotype (Hoffmann et al., 2006). 
This blurring of the boundaries of defined subsets creates difficulties for studies of in vivo 
immune activity.  The proportions of subsets could alter considerably at different times in 
different subjects and thus create a confusing picture of the dynamics of an immune 
response. 
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1.3 Chemokines and receptors in inflammation and regulation 
Chemokines are a family of cytokines that play key roles in mediating immune reactions 
through roles in leukocyte chemotaxis and adhesion.  They are described by two systems of 
nomenclature.  The original system, based on function or expression, has evolved since the 
discovery of the first chemokines. More recently a unifying, global system was developed to 
simplify understanding of interactions, particularly due to reporting of the same proteins 
under different names.  The ‘traditional’ nomenclature was often descriptive, for example, 
monokine induced by gamma interferon (MIG) or interferon-inducible protein 10 (IP-10), but 
the system was replaced by a new method based on structure and the order in which the 
chemokines were discovered (Murphy, 2002).  Based on the position of cysteine residues, 
the names begin CC or CXC followed by L (for ligand) and the number related to historical 
discovery.  For example, MIG was renamed CXCL9 and IP-10 became CXCL10.  Both 
chemokines can bind to the same receptor, CXCR3, which is expressed on activated T cells.  
These chemokines are produced at sites of inflammation by monocytes and neutrophils, 
with CXCL10 additionally being secreted by endothelial cells, fibroblasts and keratinocytes, 
and serve to attract CXCR3 expressing T cells (Loetscher et al., 1996). 
Chemokine receptor expression is thought to be related to lineage.  Th1 cells have been 
shown to express CCR5, CXCR3 and CXCR6 (Loetscher et al., 1998, Sallusto et al., 1998, 
Siveke and Hamann, 1998) whilst Th2 express CCR4 (D'Ambrosio et al., 1998).  There are 
receptors to facilitate migration to secondary lymphoid tissues, such as CCR6, CCR7, CXCR4 
and CXCR5 (Hardtke et al., 2005, Lugering et al., 2005, Phillips and Ager, 2002, Williams, 
2006). 
Some early stage memory T cells were found to express both CCR4 and CXCR3 and thought 
to be at early stages of differentiation (Song et al., 2005),   although it is possible that these 
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cells were of a lineage other than the classic Th1 or Th2 subsets, or in a transitional phase 
between subsets. 
Lim et al investigated the chemokine receptor expressing profile of Th17 cells following 
various conflicting reports (Lim et al., 2008).  They found that there was considerable overlap 
with Th1, Th2 and indeed Tregs.  Their data revealed that the Th17 subset frequently 
expressed CCR2, CCR5, CCR7, CXCR3 and CXCR6 in common with Th1.  They also share 
similarity of CCR4 and CCR7 with Th2, and like Foxp3 Tregs, express CCR4, CCR5, CCR6, 
CXCR3 and CXCR6.  It was also intriguing that around 20% of IL-17A secreting cells in their 
study, also secreted IFN-γ.  Such broad overlap in cytokine and chemokine expression with 
other subsets perhaps points to the flexibility of the Th17 phenotype, and that they are 
equally likely to migrate to sites recognised as destinations for Th1, Th2 and Tregs.  It does 
not seem likely that there is a particular niche specifically targeted by Th17.  This suggests 
that Th17, along with Th1 and Th2 are components of general inflammatory reactions. 
Chemokine secretion and receptor expression are important in disease processes in order to 
recruit leukocytes to sites of infection, but aberrant expression or overexpression can lead to 
autoimmunity or allergy.  CCR6 and its ligand, CCL20 are involved in recruitment of DCs and 
other immune cells to Peyer’s patches, therefore having a role in mediating inflammation of 
the gut epithelium.  High levels of CCL20 and upregulated CCR6 are associated with 
inflammatory bowel disease (IBD) (Cook et al., 2000, Kwon et al., 2002) (figure 1.3.1). 
Upregulation of CCR4 and CCR10 has been detected in inflamed skin, along with elevated 
levels of ligands, CCL17/CCL22 (CCR4) and CCL27 (CCR10).  This was in comparison to healthy 
skin, in which those receptors were virtually undetectable.  This implies that these 
receptor/ligand pairs are instrumental in the migration of T cells in inflammatory skin 
conditions (Ebert et al., 2005).  
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Figure 1.3.1 Selected chemokine receptors and ligands involved in recruitment of T cells and DCs to sites of intestinal inflammation 
Chemokines are released during inflammation in the gut to recruit DCs and various T cell 
subsets.  The diagram shows a selection of secreted chemokine ligands to the receptors 
expressed on DCs, Th1, Th2, Th17 and Tregs.  The leukocytes migrate to the sites of 
inflammation.  At these sites, increased levels of chemokines can be detected, along with 
high frequencies of T cell expressing the receptors (Adapted from (Nishimura et al., 2009)). 
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1.4 Antigen processing and T cell recognition 
Antigen presenting cells (APC) express proteins on the cell surface that are able to present 
peptides to T cells and are encoded by highly polymorphic genes in a locus known as the 
major histocompatibility complex (MHC).  MHC molecules that present to CD8+ T cells are 
class I type and are able to present peptides around 8 or 9 amino acids in length, whereas 
MHC class II molecules present longer peptides of around 15 amino acids to CD4+ T cells.  It 
is thought that some MHC class II peptides could be considerably longer.  
The discovery of the MHC was made by investigating rejection of transplanted skin grafts in 
mice and this concept of immune activity against cells of an allogeneic donor is known as 
alloreactivity.  In humans this is responsible for transplanted organ rejection, or graft-versus-
host disease (GvHD) and graft-versus-leukaemia (GvL) following allogeneic stem cell 
transplantation (SCT).  The encoded MHC proteins are known as human leukocyte antigens 
(HLA) and each individual inherits three genes of both classes from each parent.  Class I 
alleles are HLA-A, HLA-B and HLA-C (although a number of other alleles have been 
described), while class II are described as HLA-DP, HLA-DQ and HLA-DR.  Across a population, 
there are a large number of heritable polymorphisms of each allele, which are numbered. 
For example, an individual may have a class I HLA type such as HLA-A2, HLA-A3, HLA-B4, HLA-
B7, HLA-Cw3, HLA-Cw7, if different polymorphisms are inherited from each parent.  It is not 
uncommon to find individuals who are homozygous for one or more allele, particularly for 
polymorphisms that are particularly prevalent in a population.  Similar inheritance patterns 
occur for class II genes, so any individual may have between 6 and 12 MHC genes (Klein and 
Sato, 2000a, b). 
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1.4.1 Antigen processing 
Although any cell expressing MHC molecules can engage T cells in an antigen dependent 
manner, certain cells can process antigen with much greater efficiency.  The members of this 
group are known as professional antigen presenting cells (APCs) and include B cells, 
macrophages and particularly dendritic cells (DCs) (Mellman et al., 1998, Robadey et al., 
1996, Schneider and Sercarz, 1997). 
In general, antigens presented by MHC class I are from endogenous proteins, whereas 
exogenous proteins taken up by endocytosis are presented by MHC class II, although 
proteins from either source can be presented by both MHC molecules.  The concept of 
exogenous antigen presentation to CD8+ T cells via the MHC class I pathway is known as 
‘cross-presentation’ (Bevan, 1976).  This concept is important for tumour immunology. 
Endogenous proteins come from a variety of sources such as viral proteins and defective 
ribosomal products (DRiPs), which are ubiquitinated in the cytosol and directed to the 
proteosome to begin fragmentation (Shastri et al., 2002, Yewdell et al., 2001).  Post-
translationally modified proteins, such as phosphorylated peptides can be presented by 
MHC class I molecules (Zarling et al., 2000).  Non-contiguous sequences have been found to 
be spliced together as MHC class I presented peptides which considerably increases the 
available pool of antigens which can be recognised by CD8+ T cells (Hanada et al., 2004, 
Vigneron et al., 2004). 
The process of exogenous antigen ‘cross-presentation’ may be the principle, or only way of 
enabling CD8+ responses to tumour antigens.  These ingested antigens can be transported 
into the cytosol for proteosomal degradation and MHC class I molecule loading in a TAP-
dependent manner (Harding and Song, 1994, Kovacsovics et al., 1995, Norbury et al., 1995, 
Rodriguez et al., 1999), but can also be loaded in the endocytic pathway independently of 
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TAP (Bachmann et al., 1995, Kleijmeer et al., 2001, Pfeifer et al., 1993).  After entering the 
proteosome, a series of degradation steps occur in order to trim the antigen to a suitable 
length for loading onto MHC class I molecules (reviewed by (Shastri et al., 2002).  The 
peptides encounter the nascent MHC class I molecules which are chaperoned and stabilised 
by calnexin and calreticulin, and associated with transporter associated perotein (TAP) in the 
endoplasmic reticulum (ER) (Ortmann et al., 1994). After peptide binding, the MHC-bound 
peptide complex is transported to the cell surface for presentation to CD8+ T cells. 
MHC class II presented antigens are principally derived from exogenous proteins, although it 
seems endogenously derived peptides are not excluded (Lechler et al., 1996). Following 
endocytosis, the antigens pass along the endocytic pathway which consists of early 
endosomes (EE), late endosomes (LE) and lysosymes which subject the proteins to 
progressively more acidic pH to facilitate denaturation (Lennon-Dumenil et al., 2002).  The 
denatured proteins are exposed to a variety of enzymes, cleaving them for MHC class II 
loading. 
The MHC class II molecules themselves are formed in the ER and the peptide binding region 
is occupied by a chaperone protein known as the invariant chain, which both stabilises the 
complex and directs it to the endocytic pathway (Anderson and Miller, 1992, Ghosh et al., 
1995).  The cleaved peptide is then ‘exchanged’ for the invariant chain in a reaction 
catalysed by a protein known as HLA-DM (Sherman et al., 1995).  The peptide-MHC class II 
complex can then be presented on the surface of the cell for recognition by CD4+ T cells. 
1.4.2 Antigen recognition 
The T cell receptor (TCR) binds to the peptide/MHC complex on the DC, along with either 
CD4 or CD8 co-receptor. The CD4 and CD8 molecules determine which type of MHC 
molecule the T cell receptor can interact with. CD8 binds MHC I molecules while CD4 binds 
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MHCII, in both cases increasing the avidity of the TCR-MHC interaction. Thus, CD8-expressing 
T cells recognise peptides complexed with MHC I molecules while CD4-expressing T cells 
recognise peptides complexed with MHC II. CD80 and CD86, also expressed on the DC 
provide a co-stimulatory signal, and recruit either CD28 or CTLA-4 to this ‘immunological 
synapse’.  CD28 is more readily available, but CTLA-4 has higher affinity.  The co-stimulatory 
signals provided by these molecules determine the outcome of this T cell/APC encounter.  
CD28 signalling drives T cell proliferation and differentiation, whereas CTLA-4 signalling 
inhibits T cell activation.  The affinity of the TCR signal is proportional to the concentration of 
CTLA-4 recruited, which suggests that this is mechanism of tolerance to prevent very high 
affinity TCR clone reactions (Pentcheva-Hoang et al., 2004). 
These activated T cells can respond to antigen by lysing infected cells and/or secreting 
cytokines (as described in 1.2).  There are two principle, proposed mechanisms of killing 
infected cells. In the perforin/granzyme mediated mechanism, the T cell secretes perforin 
which binds to the target cell membrane and is polymerised to form an aqueous channel.  
Granzymes are then secreted and enter the infected cell through this channel and initiates 
the caspase-dependent apoptotic pathway.  Alternatively, T cells can express CD95L (Fas 
ligand) to utilise the Fas/Fas ligand pathway.  This is particularly important for CD4+ T cells.  
CD95L has a relatively long half-life on the surface which, even after TCR signalling has 
ceased, can lead to cell killing of neighbouring CD95 (Fas) expressing cells – a concept known 
as bystander killing (reviewed by (Russell and Ley, 2002).   
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1.5 Tumour immunology 
1.5.1 Immunosurveillance 
The concept of adaptive immune responses that clear malignantly transformed cells which 
have escaped DNA repair mechanisms and tumour suppressor pathways was proposed by 
Thomas and Burnet (Burnet, 1967, Thomas, 1959).  This process was described by Burnet as 
‘immunosurveillance’.  
However the theory is controversial, with the scientific community split as to whether 
immunosurveillance does in fact happen.  The concept that the immune system can identify 
and destroy pre-malignant or malignant growths before they become clinically apparent is 
difficult to prove.  Therefore, most evidence comes from mouse models.  It was observed 
that lymphocyte deficient mouse strains, such as RAG2 knockout strains (which results in 
lack of B, T and NKT cells), have a higher incidence of induced and spontaneous tumour 
formation as compared to wild type.  Similar findings in mice which  lacked the ability to 
form a compete TCR (TCR β-/- or TCR δ-/-) indicate a substantial role for T cells in cancer 
prevention, which argues for an important role for the adaptive immune system in 
immunosurveillance (reviewed (Dunn et al., 2004)). 
Detractors of this theory point out that tumours still develop despite the presence of a 
functioning immune system.  Spontaneous tumours do occur in otherwise healthy 
individuals, although the incidence increases with age.  This may be linked to general 
‘immunosenescence’, a progressive deterioration in functional cells, possibly due to chronic 
demands on the immune system, such as cytomegalovirus (CMV) infection.  However, 
counter arguments to the immunosurveillance theory point to childhood cancer, or the fact 
that elderly persons still have sufficient immune capabilities to combat infections as 
evidence against immune control of tumours. 
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If immune surveillance does clear some or most potential tumours, the immune system is 
also exerting selective pressures on nascent tumour cells.  If a cancerous cell is a product of 
disordered gene expression, then some of the aberrantly expressed genes may equip the 
tumour cells with immune escape mechanisms.  Therefore, those cells which can become 
tolerated by the immune system may thrive.  This is known as ‘immunoediting’ and consists 
of three stages.  Firstly, there is the classical ‘immunosurveillance’ mechanism, whereby 
potentially malignant cells are destroyed, which is described as ‘elimination’.  With the 
development of certain, limited escape mechanisms, the immune system may have reduced 
efficiency at transformed cell clearance.  However, some control is maintained and this stage 
is described as ‘equilibrium’.  Finally, further selective pressure allows the neoplastic cells to 
evolve to  evade the patient’s immune system, which is termed ‘escape’ (figure 1.5.1.1) 
(reviewed (Dunn et al., 2004)).  
1.5.2 Tumour antigens  
There are a number of ways that the immune system can be alerted to the presence of a 
tumour cell.  Tumour antigens presented by MHC class I and II molecules can be recognised 
by CD8+ and CD4+ T cells respectively and elicit adaptive immune reactions.  The first 
tumour antigen was identified in 1991 (van der Bruggen et al., 1991) and  several more have 
since been identified.  
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Figure 1.5.1.1 Process of immunoediting of tumours 
The three stages of elimination, equilibrium and escape are shown between the increasing 
presence of tumour cells (red triangle) and the decreasing tumour-suppressive influence of 
the immune system (blue triangle).  Black ovals indicate transformed cells with those being 
killed in grey.  T cell subsets are indicated by the key.  A variety of other cells such as B cells, 
NK cells, neutrophils and macrophages are also thought to be involved with the 
immunoediting process.  Relative proportions of cell numbers are not intended to be 
representative, although increasing frequencies of Tregs are likely to play a role in tolerance. 
(Adapted from (Zitvogel et al., 2006)). 
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Tumour antigens can be divided into five groups: 
1. Mutation: these are generated by point mutations in ubiquitously expressed genes.  
They are generally tumour specific, but not found in many different patients, thus 
limiting their immunotherapeutic potential.  Examples include MART-2 (Kawakami et 
al., 2001) and MUM-1 (Coulie et al., 2001). 
2. Shared Tumour-specific: Antigens expressed only by tumours and germline (or other 
immune-privileged sites).  For example Cancer-Testis Antigens (CTAgs) are expressed 
by a wide variety of tumours, but not in normal, healthy tissue.  This restricted tissue 
expression offers a potential for immunotherapy.  The MAGE family of CTAgs are 
examples of Shared Tumour-specific antigens (van der Bruggen et al., 1991).  CTAgs 
are discussed in more detail later. 
3. Differentiation: These are also expressed in the tissue of origin of the malignancy 
which could result in potentially severe autoimmune complications if used as 
immunotherapy targets.  For example, carcinoembryonic antigen (CEA) is expressed 
by many gut carcinomas, but also in normal gut epithelia.  If the normal tissue is likely 
to be surgically removed, as in the case of prostate specific antigen (PSA), then 
autoimmune reactions are of limited importance. 
4. Overexpression: Although expressed in healthy tissue, these antigens are greatly 
upregulated in tumour tissue.  Low expression in non-tumour sites means that there 
may not be a great risk of autoimmune damage to these tissues, but the threshold is 
not easy to determine.  An example is alpha-foetoprotein. 
5. Viral: A number of tumours are strongly associated with viruses and viral proteins 
may be expressed by these tumours, but also potentially non-transformed virally 
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infected tissues.  Human papilloma virus (HPV) and Epstein-Barr Virus (EBV) are 
linked to tumours and/or lymphomas. 
(Boon and van der Bruggen, 1996, Houghton et al., 2001, Old, 2003, Parmiani et al., 2007, 
Rosenberg, 1999, Van den Eynde and van der Bruggen, 1997, Van Der Bruggen et al., 2002) 
Comprehensive lists of described peptides from tumour antigens can be found at 
www.cancerimmunity.org (with the exception of viral antigen peptides). 
Immune system cells can also be alerted to tumour by expression of NKG2D ligands such as 
MICA and MICB or the minor histocompatibility antigen H60.  Intrinsic processes in the 
tumour can lead to uric acid production and expression of toll-like receptor ligands, such as 
heat shock proteins.  These both serve to generate a proinflammatory reaction through the 
innate system. 
1.5.3 Cancer Testis Antigens 
The family of tumour antigens termed Cancer Testis Antigens (CTAgs) are a group of shared 
tumour specific antigens characterised by expression on germline cells and tumour cells 
only.  The first CTAg was identified by Pierre van der Bruggen in 1991 (van der Bruggen et al., 
1991), using a melanoma cell line MZ2-MEL that could be killed by autologous CTLs.  This 
antigen was named MAGE-1, which was subsequently renamed MAGE-A1.  A similar strategy 
was adopted by colleague Thierry Boon which resulted in the identification of MAGE-A3, 
followed by BAGE and GAGE gene families (Boel et al., 1995, Gaugler et al., 1996, Van den 
Eynde et al., 1995).  By studying the mRNA expression of these genes in various tissues, it 
became apparent that expression was restricted to testes, an immunologically protected 
site, and tumour cells.  This seemed to make these antigens ideal targets for immunotherapy 
because as long as an effective immune response can be mounted against them, there is no 
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apparent risk of healthy tissue damage.  Since then, around 100 CTAg gene families have 
been identified.  Details can be found at www.cta.lncc.br.  The development of a serological 
technique for cloning tumour antigens that elicit a high titre IgG response has helped 
research in this field considerably and is known as SEREX (serological analysis of recombinant 
cDNA expression libraries) (Sahin et al., 1998).  Some antigens are expressed in the testis but 
also in other immune-protected tissues such as the placenta or retina, and have been shown 
to be expressed by tumours.  One such antigen was identified in renal cell carcinoma and 
was termed RAGE-1 (Gaugler et al., 1996).  Although not strictly defined as a CTAg, it has 
been included in this study and grouped as a CTAg throughout this report. 
There is incomplete data regarding protein expression for many CTAgs, but those that have 
been studied have found heterogeneous expression within tumours as some cells may 
express multiple antigens, whilst others have no CTAg expression.  In some tumours, only a 
small proportion (fewer than 1%) of cells in the tumour mass express CTAgs, but strong 
expression is seen in those cells that are positive for this gene expression (Gedye et al., 
2009).  There has been speculation that these expression patterns could indicate that the 
CTAg expressing cells could be cancer stem cells (Old, 2007).  It is also unclear whether many 
CTAg genes are regulated post-transcription, which means that despite gene expression, 
there may not be any detectable protein.  This has important implications for their potential 
immunogenicity which would affect their possible role in immunosurveillance or as an 
immunotherapeutic target (Caballero and Chen, 2009). 
The function of these genes, when either normally or aberrantly expressed, is not well 
understood.  Both MAGE and GAGE families have been shown to confer some resistance to 
apoptosis (Cilensek et al., 2002, Yang et al., 2007) and there have been various suggestions 
of other anti-apoptotic, cell survival and proliferative functions.  With these functions, along 
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with sites of normal expression in the testis and placenta, it is possible to speculate that 
CTAgs are involved in gametogenesis and placentation.  It may be that during 
tumourigenesis, these functions are initiated without appropriate regulation and expression 
of differentiation genes (Old, 2007). 
The limited tissue expression of CTAgs should prevent immune tolerance developing in 
healthy individuals, but it is not clear to what extent these proteins are immunogenic when 
expressed by tumour cells.  It is certainly true that humoral and T cell responses can be 
detected ex vivo in human cancer patients, but it is not necessarily apparent as to whether 
the responses are controlling the disease to any degree, or if they are merely following the 
disease progress but unable to contain it.  It may be that early on there is some immune 
control through CTAg responses but as the tumour develops evasion mechanisms, all or part 
of the response is hampered by development of tolerance.  For example, humoral responses 
have been demonstrated in multiple myeloma (Atanackovic et al., 2007), and T cell 
responses have also been detected in multiple myeloma patients (Goodyear et al., 2005, 
Goodyear et al., 2008).  In the latter study, CD4+ effector memory phenotype CTAg-specific T 
cells were mainly seen in patients diagnosed with monoclonal gammopathy of uncertain 
significance (MGUS), which can be a pre-myeloma condition.  These T cells were cloned and 
could lyse tumour target cells.  However, CTAg responses in patients with advanced multiple 
myeloma were predominantly CD8+ with an effector memory RA phenotype, with limited 
ability to destroy tumour cells during in vitro assays. This suggests that as the disease 
progresses, the immune response is altered, potentially becoming impaired.  
However, it may be that if immunity to CTAgs can be boosted, particularly whilst there is still 
an effective immune response, or if tolerance has been broken by stem cell transplantation, 
then CTAgs could be useful immunotherapy targets.  There have been numerous vaccine 
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trials, particularly in melanoma patients using MAGE-A3 or NY-ESO-1.  Around 20% of 
patients vaccinated with either MAGE-A3 peptide recombinant virus, or peptide pulsed DCs 
showed tumour regressions.  Although this is not extremely high, it is approximately 20 
times higher than reported for spontaneous melanoma regression (Lonchay et al., 2004).  
There have been phase II and III trials of recombinant MAGE-A3 protein vaccines in 
melanoma and non-small cell carcinoma patients which have shown increases in overall 
survival (reviewed (Caballero and Chen, 2009)). 
It is possible that a vaccine strategy, perhaps alongside a tolerance breaking intervention, 
could prove beneficial.  In a study using NY-ESO-1 recombinant protein vaccine along with 
CTLA-4 blockade, 8 of 15 patients had a clinical response of which 5 had NY-ESO-1 antibodies 
as opposed to the 7 non-responders who had no detectable NY-ESO-1 anibodies (Yuan et al., 
2008).  Following stem cell transplantation, previously tolerised T cells would have been 
eradicated, and it is unlikely that donors would have CTAg-specific Tregs, so initiating a 
CTAg-specific immune response could lead to improved survival. 
1.5.4 Tumour evasion and escape 
Genomic instability in tumours can produce a wide variety of mutations, and it follows that 
those that confer a favourable advantage to the tumour by preventing destruction by the 
immune system will be passed on through further divisions.  The interplay of these 
evolutionary processes with the selective pressure brought to bear by the immune system 
can result in the tumour being edited sufficiently to evade and escape the immune defences. 
Just as the immune system has a variety of methods to detect and kill malignant cells, the 
tumour can develop various mechanisms of evasion.  Defects in antigen processing pathways 
and downregulation of MHC molecules can protect the tumour (Algarra et al., 2000, 
Marincola et al., 2000).  It was found that tumours of melanoma patients in vaccine trials 
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with gp100 and MART-1 tumour antigen peptides, lost expression of the target antigens or 
underwent a complete loss of the MHC molecules on which the antigens were presented.  
This suggests that the tumours evolved to resist the therapeutically manipulated immune 
attack (Jager et al., 1997, Khong et al., 2004). 
Defects in the IFN-γ receptor signalling pathway confer resistance to IFN-γ in human lung 
adenocarcinoma cells (Kaplan et al., 1998).  Rather than develop resistance to a certain 
cytokine, some tumours secrete immunosuppressive cytokines such as IL-10 or TGF-β (Khong 
and Restifo, 2002) and one study found that secretion of soluble MICA/B led to 
downregulation of NKG2D on T cells and NK cells (Groh et al., 2002). 
Tumour cells can also hijack the regulatory side of the immune system to aid escape.  
Accumulations of Tregs have been seen in tumour sites which may have been induced by 
TGF-β secretion by neoplastic cells.  Evidence has shown that some tumours can act on 
certain DC subsets to induce a regulatory phenotype in CD4+ CD25hi T cells (Ghiringhelli et 
al., 2005). 
Despite elaborate immune defence mechanisms, tumour cells can still evolve sufficiently to 
evade detection, or subvert tolerogenic mechanisms to survive and proliferate (as described 
above). 
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1.6 Acute Myeloid Leukaemia 
Acute myeloid leukaemia (AML) is a clonal proliferative disorder caused by genetic 
mutations within haematopoietic progenitor cells, and leads to a failure of differentiation 
and the accumulation of leukaemic blast cells in the bone marrow, peripheral blood and 
organs.  Typically, the leukaemic blasts in AML are myeloid or monocytic progenitors, but 
erythroid and megakaryocytic forms of AML also occur.  The result of this is severely 
attenuated blood production, impaired immunity and sometimes organ failure which, if 
untreated, is likely to lead to death within a few months.  
AML is the most common adult acute leukaemia with nearly 2000 cases diagnosed per year.  
Patients have a median age at diagnosis of 70.  AML can occur de novo or be preceded by 
myelodyspolasia or myeloproliferative disorders and there may be evidence of these pre-
leukaemic conditions at diagnosis.  A double-hit model was proposed that suggested 
mutations leading to constituitive expression of RAS (cell surface receptor) or FLT-3 and C-
KIT (tyrosine kinases), in combination with overexpression of HOX genes, would increase 
proliferation and block differentiation respectively.  Either of these mutations singly would 
lead to a myeloproliferative disorder, but together would cause AML (Frohling et al., 2002). 
However, it is possible that several mutations are necessary to initiate AML. 
1.6.1 Diagnosis of AML 
In the UK, AML is categorised under the World Health Organisation (WHO) system which has 
four major groups, and incorporates cytogenetic data and levels of accumulated blast cells in 
the bone marrow.  AML is suspected if there are 20% blast cells in the marrow, and these 
should be shown to be myeloid in origin.  At least 20% should stain positive for common 
myeloid differentiation markers such as CD33 or CD13.  Other critical myeloid markers 
include cytoplasmic myeloperoxidase.  Acute promyelocytic leukaemia is a distinct form of 
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leukaemia which is treated with all-trans retinoic acid (ATRA) and athracycline 
chemotherapy, or arsenic, with a relatively good prognosis.  Forms of AML with good 
prognosis such as core-binding factor AML with t(8;21) and inv16 usually respond well to 
chemotherapy alone.  Genetic abnormalities with poor prognosis in AML include monosomy 
5, monosomy 7 and complex cytogenetics, and these patients are unlikely to have a good 
prognosis even with transplantation.  The presence of FLt-3 abnormalities also carries a poor 
prognosis. 
1.6.2 Immune evasion by AML 
The bone marrow microenvironment is very permissive to cancer cell homing, survival and 
proliferation due to having high concentrations of growth factors required for 
haematopoiesis.   Solid tumour metastases often home to, and thrive in the bone marrow, 
and this niche has been implicated in resistance to chemotherapy in leukaemic patients.  The 
CXCR4/CXCL12 axis has been show to promote tumour blast survival by preventing 
apoptosis.  Chronic myeloid leukaemia patients have been treated very successfully with 
imatinib, but complete eradication of disease in the bone marrow is not achieved due to 
CXCR4/CXCL12 interactions (Vianello et al., 2010).  There are numerous other interactions 
with the microenvironment such as blast cell integrins interacting with stromal ligands such 
as VCAM-1 to facilitate survival.  Overexpression of blast cell receptors allows diseased tissue 
to out-compete non-diseased marrow, further disrupting normal haematopoietic function 
and reducing immune capacity.  Direct cellular interactions and secretion of soluble factors 
serve to impair the immune response to the tumour (Buggins et al., 2001). For example, 
blast cell production of indoleamine 2,3-dioxygenase can promote Foxp3 expression in T 
cells and potentially convert local effector cells to an immunosuppressive phenotype (Curti 
et al., 2007). 
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1.6.3 Treatment of AML 
Treatment of AML consists of several courses of chemotherapy which aim to induce 
remission within the first 1 or 2 courses, followed by consolidation chemotherapy.  There are 
increasing attempts to have tailored treatments, often with novel experimental agents, 
according to the genetic subgroup and risk category of AML in the current AML17 trial in the 
UK.  Standard induction chemotherapy consists of a combination of an anthracycline, such as 
danurubicin or idarubicin with cytosine arabinocide (Ara C).  A monoclonal antibody such as 
gentuzumab ozogomycin, which targets CD33, can be used, but its optimal usage in AML is 
still being explored.  Patients are typically in hospital with myelosuppression for several 
weeks following each course of chemotherapy before neutrophil and platelet recovery 
occur.  
However, the majority of patients relapse, and salvage chemotherapy only leads to second 
remission in 50% of cases, often only for a few months (Craddock et al., 2005).  The 
prognosis of AML depends critically on the age and performance status of the patient, and 
on the genetic subtype of AML. 
Elderly patients often have AML with genetic abnormalities that confer unfavourable 
prognosis, and long-term survivors are rare.  
Where a HLA-matched donor is available, allogeneic stem cell transplantation may be the 
most favourable option. This is discussed further in section 1.8. 
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1.7 Multiple Myeloma 
Multiple myeloma (MM) is a plasma cell tumour with approximately 3000 new cases per 
year in the UK and the median age at diagnosis is 65.  It is characterised by accumulations of 
malignant monoclonal plasma cells in the bone marrow leading to anaemia, renal 
impairment, bone destruction, hypercalcaemia and severe immune dysfunction, with 
associated susceptibility to infection.  A premalignant condition called monoclonal 
gammopathy of uncertain significance (MGUS) can exist in asymptomatic individuals and in a 
minority of cases transforms to active myeloma requiring treatment.  For the majority of 
patients, treatment leads to a plateau phase of variable duration.  Relapse inevitably occurs 
requiring further treatment, but the disease usually becomes resistant. 
A characteristic feature of the disease is unrestrained production by the malignant plasma 
cells of monoclonal immunoglobulin, a paraprotein which is secreted into the blood.  This 
abnormal protein can be measured and identified by electrophoresis.  Around 30-50% of 
patients have excessive concentrations of immunoglobulin light chain which can pass 
through the kidney and be secreted in urine.  A Bence-Jones protein test of the patient’s 
urine sample can be carried out to identify these light chains to aid diagnosis and disease 
monitoring.  More recently, new tests have been devised to measure the free light chain in 
serum, which may ultimately replace the Bence-Jones urine test (Pratt, 2008).  
1.7.1 Immune evasion by myeloma cells 
Myeloma cells in the bone marrow, like the malignant AML cells, have a complex interaction 
with the microenvironment which is crucial for maintenance and progression of the disease, 
and contributes to immune disruption.  Myeloma cells produce a variety of 
immunomodulatory cytokines including IL-10 and TGF-β, which act on local T cells and DCs, 
driving the local immune microenvironment towards an immunosuppressive state (Pratt et 
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al., 2007).  The tumour cells do express MHC molecules and co-stimulatory markers CD80 
and CD86 although expression is generally low and may be restricted to a limited number of 
malignant plasma cells (Yi et al., 1997). 
1.7.2 Treatment of myeloma 
Myeloma patients are given bisphosphonate which inhibits excessive osteoclast bone 
reabsorption and limit bone damage.  In the last decade, three novel agents, thalidomide, 
bortezomib and lenalidomide have greatly improved the treatment options for multiple 
myeloma, translating into significant improvements in survival.  Before these agents, 
melphalan and prednisolone were given in combination to older patients, whilst younger 
patients received other combinations such as vincristine and doxorubicin/Adriamycin™ 
(VAD), with or without cyclophosphomide (C-VAD), along with steroids methylprednisolone 
or dexamethasone. 
The challenge is now to find optimal use of these three novel agents, both together and also 
with the more established drugs.  It is likely that many other novel agents will be developed, 
such as more immunomodulatory drugs, proteasome inhibitors, HDAC inhibitors and heat 
shock protein inhibitors.  Currently the gold standard initial treatment in the UK is 
cyclophosphamide, thalidomide and dexamethasone (CTD), which is being compared to 
cyclophosphamide, lenalidomide and dexamethasone (CRD) in the UK Myeloma XI trial. 
For those patients who are young and fit enough, stem cell transplantation is still considered 
to be the best option.  Autologous stem cell transplantation is commonly used for myeloma 
patients whereby stem cells are collected after an initial few months of treatment to reduce 
the tumour load and returned to the patient following conditioning therapy.  If a HLA-
matched donor is available, and the patient is determined to be likely to withstand 
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treatment-related toxicity, then allogeneic stem cell transplantation can be considered.  This 
study is focusses on allogeneic transplantation which is discussed further in section 1.8. 
 
1.8 Allogeneic stem cell transplantation 
The principle of stem cell transplantation (SCT) is to ablate the patient’s immune system with 
chemotherapeutic agents and/or irradiation and then harvest haematopoietic stem cells 
from a HLA-matched donor for infusion into the patient.  The stem cells will then home to 
the bone marrow and begin to repopulate the depleted immune system through 
homeostatic mechanisms.  Stem cells can be harvested from the patient, frozen and 
reintroduced following conditioning (autologous (autograft)) or from a healthy, HLA matched 
donor (allogeneic (allograft)). 
1.8.1 Stem cell donors 
Donors are selected on the basis of how closely they are matched to the patient’s HLA 
typing. HLA-mismatches give to a greater risk of graft-versus-host disease, leading to 
potentially fatal tissue damage to the patient.  The first choice would be a fully matched 
sibling, but if this is not available, then searching bone marrow registries such as the 
Anthony Nolan Trust, may yield a matched unrelated donor (MUD).  In some cases, a 
partially matched parent or child can be used, which is known as a haploidentical transplant 
and is more commonly used for paediatric patients.  However no patients in this study had 
haploidentical donors. Another potential source of stem cells is cord blood, which can be 
used where a HLA-identical donor is not available.  There is a considerably lower risk of 
GvHD which allows less stringent HLA-matching (Rocha et al., 2001, Wagner et al., 1996).  
but there is an increased risk of early mortality due to infection resulting from delayed 
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reconstitution (Rubinstein et al., 1998).  However, there were no cord blood transplants in 
this study. 
Traditionally, stem cells were extracted directly from the bone marrow cavity, although this 
practice has largely been replaced by administration of G-CSF to the donor which has the 
effect of mobilising the stem cells into the peripheral blood allowing them to be harvested.  
The choice of procedure is usually made by the donor.  After collection, the stem cells can be 
cryopreserved and stored until infusion into the patient. 
1.8.2 Transplant conditioning 
In the vast majority of cases of patients with acute leukaemia, conventional chemotherapy 
has been used to achieve remission prior to commencing transplant conditioning.  The 
patient is admitted to a bone marrow transplant centre and remains an in-patient 
throughout the procedure, and for several weeks into the post-transplantation period. 
Myeloablative conditioning consists of cyclophosphomide along with either total body 
irradiation (TBI) (CyTBI) or administration of busulphan (Bu/Cy).  These transplants are the 
most effective anti-leukaemic therapies currently in use, with long-term disease free survival 
(DFS) in the region of 60-70% for patients transplanted in first complete remission (CR) for 
acute myeloid leukaemia, with relapse rates up to 30% lower than for patients treated with 
conventional chemotherapy (Craddock, 2008).  However, the intense nature of the 
conditioning regimens means that it is not a viable treatment option for older or more infirm 
patients. 
In order to expand the range of eligible patients for allogeneic-SCT, reduced intensity 
conditioning (RIC) regimens were developed (Childs et al., 1999, Corradini et al., 2002, Giralt 
et al., 1997, Kottaridis et al., 2000, McSweeney et al., 2001, Slavin et al., 1998).  RIC 
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transplants use less chemotherapy than fully myeloablative transplants and have more 
immunosupporession.  RIC conditioning leads to a mixed chimeric state in the bone marrow, 
often needing donor lymphocyte infusions (DLI) to achieve full donor chimerism.  The 
strategy relies on an immunological graft-versus-leukaemia/tumour effect rather than 
intensive tumour reducing chemotherapy.  RIC transplants have a lower mortality (around 
15-20%) and long term DFS can be achieved in patients for 20-30% of patients in their fifth 
and sixth decades.  It is unclear which subgroups of AML patients are most likely to benefit 
from RIC transplantation and it is even less clear in myeloma patients where GvHD linked to 
graft-versus-myeloma presents a major hurdle to allogeneic transplantation in myeloma.  
Typically, TBI is not used, although sometimes reduced dose irradiation is utilised.  A typical 
combination of chemotherapy agents is fludarabine, melphalan and campath. 
Patients are kept in a protected environment, with a low-microbial diet due to their very 
high-risk of infection as a result of immune system depletion.  Prophylactic antimicrobial 
drugs such as ciprofloxacin, fluconazole, septrin and acyclovir are administered, and 
cyclosporine is given to reduce the risk of early onset GvHD.  This is usually maintained at a 
constant dose for some time into the post-transplant period, before being reduced over time 
until it can be completely withdrawn.  The length of time before tapering is based on a 
clinical assessment of risk, as is how sharply the dose is reduced.  If, during the tapering 
period, the patient begins to show signs of GvHD, then the physician may increase the dose 
again.  This staged withdrawal is carefully managed to minimise GvHD risk whilst allowing 
sufficient immunity to infections without compromising GvL. 
The composition of the conditioning regimens has implications, not just for depleting the 
immune system, but also for the dynamics of reconstitution.  Campath is a monoclonal 
antibody directed against CD52 on the surface of many myeloid, lymphoid and some CD34+ 
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cells of the bone marrow, leading to antibody mediated cell death.  It can be delivered in 
vivo as part of the patient’s conditioning or administered to the stem cells in vitro for a T-
deplete graft prior to infusion.  The antibody persists in the patient at cytotoxic levels for 
considerably longer after in vivo delivery which delays T cell reconstitution (Morris et al., 
2003).  Reduced dosage of campath during conditioning improves reconstitution but carries 
an increased risk of GvHD (Chakraverty et al., 2010).  Conversely it is well-known that there 
is a higher risk of relapse with greater T cell depletion. 
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Figure 1.8.2.1 Types of allogeneic transplantation 
Myeloablative conditioning (A) destroys the patient immune system and tumour cells with 
high dose chemotherapy and total body irradiation.  Following infusion of stem cells 
harvested from the HLA-matched donor, homeostatic mechanisms cause an accelerated 
reconstitution to restore the immune system to normal levels.  For patients who would not 
withstand the harsh conditioning regimens, a reduced intensity conditioning (RIC) protocol 
can be followed (B) whereby the immune system is depleted with less toxic chemotherapy, 
usually without irradiation.  Following infusion of the donor stem cells, there is a period of 
mixed chimerism (shaded area, C) before the newly transplanted system ‘out-competes’ the 
damaged patient cells. 
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1.8.3 Graft-versus-Leukaemia 
The presence of a functioning adaptive immune system is crucial to the success of the 
transplantation procedure.  As described in the previous section, cyclosporine is given 
prophylactically to prevent GvHD, and by reducing the dose within the first 20 days following 
transplantation, relapse rates can be reduced by up to 30% (Bacigalupo et al., 1991, 
Bacigalupo et al., 2000).  This suggests a link between T cell activity and relapse prevention.  
Occurrence of GvHD is associated with a decreased risk of relapse (Horowitz et al, 1990) and 
as GvHD is thought to be T cell mediated, it would follow that GvL has a T cell component.  
Further evidence came from experiments demonstrating that further input of T cells 
following transplantation  enhances the GvL effect and prevents relapse (Kolb et al, 1990).  
However, despite the obvious benefit of a GvL effect, GvHD is a serious cause or morbidity 
and mortality.  Therefore, in order to optimise stem cell transplantation as a therapy, 
strategies to enhance GvL whilst preventing GvHD must be developed.  
If targets of GvL can be elucidated, then there is the possiblilty of immunotherapeutic 
targeting to enhance the anti-tumour effect.  Despite careful matching of HLA types 
between donor and patient, disparities between polymorphic genes in the donor and 
recipient can lead to immunogenic minor histocompatibility antigens (mHAgs) (Goulmy et 
al., 1976).  If expression of these antigens is restricted to the haematopoietic system, then 
they can be targeted to induce anti-leukaemia immunity.  For example, HA-1 can elicit an 
immune reaction from the donor immune system with a single amino acid difference (den 
Haan et al., 1998).  This minor difference affects the stability of MHC presentation and 
immunogenicity (Nicholls et al., 2009, Spierings et al., 2009).  The difference of one amino 
acid substituted for another can alter the efficiency of TAP-transportation and lead to 
increased immunogenicity, as is the case with HA-8 (Brickner et al, 2001).  HA-1 and HA-2 
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specific T cells were isolated from three relapsed allograft patients following DLI.  There 
followed a complete remission of the disease and chimerism of the patients was restored to 
100% (Marijt et al., 2003).  This demonstrates the potential of tumour-specific immunity.  
Other examples of haematopoietic system restricted mHAgs are HA-2, HB-1 and LRH-1 
(reviewed (Goulmy, 2006)). 
The tumour cells can also become visible to the donor immune system through the aberrant 
or overexpression of tumour associated antigens (TAA).  These may have been expressed 
prior to transplantation but not induced a strong anti-tumour response due to tolerance 
developing.  However, the transplanted donor immune system will not be tolerised to these 
antigens.  The number of tumour cells will have been diminished by the conditioning 
treatment.  Therefore, the opportunity arises to eradicate residual tumour cells which may 
occur naturally, but the response could be strengthened by targeted immunotherapy. 
A number of studies have shown that Wilm’s tumour antigen (WT-1) is overexpressed in 
acute leukaemias and has the potential to elicit robust T cell responses in patients (Oka et 
al., 2000, Rezvani et al., 2005).  Vaccine trials using WT-1 in combination with PR-1 to treat 
myeloid leukaemia patients showed reduced tumour load suggesting a vaccine induced anti-
tumour effect (Rezvani et al., 2008).  CD8 memory T cell responses have been shown to 
PRAME-1 in acute lymphoblastic leukaemia (ALL), acute and chronic myeloid leukaemia 
(CML) patients (Rezvani et al., 2009). MUC-1, another TAA, has been shown to be expressed 
in both AML and MM (Brossart et al., 2001), with a positive-correlation between expression 
and reduced risk of relapse (Kapp et al., 2009).  Peptides from these antigens could be 
utilised as part of a vaccine strategy. 
Although these overexpressed antigens have been shown to be well tolerated, with little 
toxicity in the vaccine trials, the nature of their tissue expression means the possibility of 
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inducing GvHD cannot be ignored.  Therefore, the possibility of using CTAgs for 
immunotherapy post transplantation should be considered as there is no expression in 
healthy tissues, making it unlikely that GvHD reactions would be initiated.  Several CTAgs 
have been shown to be expressed in MM such as MAGE, LAGE and NY-ESO (Pellat-
Deceunynck et al., 2000, van Baren et al., 1999, van Rhee et al., 2005).  T cell responses to 
CTAg proteins are found in MM patients (Goodyear et al., 2005, Goodyear et al., 2008) 
indicating the immunogenic potential in the post-transplantation setting.  A number of 
CTAgs including RAGE-1, MAGE-C1, MGEA-6, GAGE-3, and some MAGE-A family members 
were shown to have RNA expression in AML (Guinn et al., 2005).  If CTAg genes are being 
expressed in AML patients, then it is possible that they could elicit T cell immunity which 
could constitute a component of the GvL effect. 
1.8.4 Graft-versus-host disease 
Graft-versus-host disease (GvHD) is an important clinical complication following allo-SCT and 
is a significant cause of morbidity and mortality.  As mentioned above, the condition is 
closely linked to the protective GvL effect, with a large T cell contribution.  Tissue targets are 
not well understood, although certain mHAgs have been related to GvHD.  For example HY 
antigen, which is expressed in male tissue, can be the target of a T cell response if the donor 
was female, as functional CD8+ HY-specific T cells have been detected in women who have 
had a male pregnancy (James et al., 2003, Piper et al., 2007b, Verdijk et al., 2004).  However, 
there are likely to be a very wide range of potential tissue target antigens, so there is a need 
to understand the mechanisms of pathogenesis in order to modulate the harmful effects of 
GvHD without compromising GvL.  Current treatments can be broadly immunosuppressive, 
or pan-T cell inhibiting which carry a risk of relapse due to suppressing anti-tumour 
immunity. 
Chapter 1: Introduction 
46 
 
GvHD is classified into acute and chronic disease, with the acute form occurring within the 
first 100 days following transplantation.  Acute GvHD tends to be directed against skin, liver 
and gut tissues, whereas chronic GvHD has broader effects, resembling autoimmune 
conditions such as systemic sclerosis.  The pathophysiology of acute GvHD has been 
described as a three-step process (figure 1.8.4.1) beginning with damage to host tissue 
which may lead to proinflammatory responses from these cells, or lipopolysaccharides (LPS) 
being released into the bloodstream, and result in the release of inflammatory cytokines 
such as IL-1, TNF-α and IFN-γ.  MHC molecules and co-stimulatory molecules are upregulated 
on activated APCs. During the next stage, the donor immune cells respond to the APCs by 
proliferating and secreting further inflammatory cytokines and chemokines, including IFN-γ 
and IL-2.  In the third stage, or effector phase, there is tissue damage caused by activated T 
cells and NK cells, which also secrete further cytokines.  Chemoattractant chemokines such 
as CCL2, CCL3, CXCL2, CXCL9-11 CCL17 and CCL27 recruit further effector cells to the site 
(reviewed (Ferrara et al., 2009)). 
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Figure 1.8.4.1 Three stage pathophysiology of GvHD 
Tissue trauma during conditioning leads to the release of bacterial lipopolysaccharide (LPS) 
into the circulation, triggering macrophages to secrete IL-1 and TNF-α which upregulate 
MHC on host tissues, facilitating mHAg recognition.  Stage 2 is characterised by activation of 
donor T cells which differentiate into Th1 cells in the presence of IL-12.  The boxed area 
shows the proposed role of Th17 cells in the pathophysiology of GvHD, beginning with the 
differentiation in the presence of IL-6 and TGF-β.  IL2 and IFN-γ secreted by Th1 cells leads to 
further T cell expansion and activation of NK cells, both of which damage host tissues 
through perforin and granzyme and Fas ligand in stage three.  The action of IL-17A on host 
tissues induces IL-8 production which has chemoattractant effects, leading to the 
recruitment of further T cells. 
(Adapted from (Hill and Ferrara, 2000))  
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Skin involvement is the most common manifestation of acute GvHD, and patients develop a 
pruritic, macropapular rash.  Gut GvHD leads to diarrhoea, possibly with bleeding as a result 
of mucosal ulceration.  Severity of the disease is classified by a staging system from grade I 
to grade IV.  Higher grade disease is associated with a poor prognosis with long term survival 
for grade III being around 25%, down to 5% for grade IV (reviewed (Ferrara et al., 2009)). 
The role of T cells in GvHD has been the target of extensive investigation.  As indicated 
previously, depletion of T cells has a preventative effect in GvHD.  However, disease is 
reduced in patients who have either a CD4+ or CD8+ T cell depleted graft, suggesting that 
there is involvement of both subsets, although the fact that there is some disease indicates 
that either subset may independently cause some level of GvHD (Champlin et al., 1990, 
Gallardo et al., 1997).  Polarisation of T cell subsets is of great interest, and early 
experiments suggested that acute GvHD reactions were predominantly of a Th1 nature, and 
chronic GvHD was mediated by Th2 cells (Allen et al., 1993, De Wit et al., 1993).  However, 
this model is too simple, particularly in the light of discoveries that the T cell repertoire is 
more dynamic that the Th1/Th2 paradigm.  In studies using mice deficient in the Th2 
associated cytokine IL4, decreased GvHD was observed, whereas in mice lacking the Th1 
associated cytokine IFN-γ a more severe pathology was induced (Murphy et al., 1998, Yang 
et al., 1998).  It is most likely that there is a complex interaction between innate immune 
cells, natural killer (NK) cells Th1, Th2, Th17 and Treg subsets.  
There is conflicting data concerning the role of Tregs in GvHD.  It would seem logical that the 
occurrence of GvHD would be associated with a decrease in Tregs.  This has been shown in 
one study of acute GvHD patients which showed a decreased frequency of Tregs as disease 
severity increased (Magenau et al., 2010).  However two studies of Tregs in chronic GvHD 
found opposing trends.  One study showed that Tregs were increased in GvHD, although the 
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lymph node homing marker CD62L was decreased on these cells (Clark et al., 2004).  The 
other study stated that Tregs were increased (Zorn et al., 2005).  It is difficult to compare 
these studies directly as Clark et al looked at absolute numbers of cells that were CD4+ 
CD25hi whereas Zorn et al examined frequencies of Tregs, and used Foxp3 expression to 
characterise the cells.  However, such inconsistencies are unsurprising in the context of 
recent findings concerning the phenotypic flexibility of T cell subsets, and the complex 
nature of the regulatory immune system.   It is interesting to note that the CD4+ CD25hi 
CD62L- population described by Clark et al were also shown to be CD45RO+ as opposed to 
CD45RA expressing.  Hoffmann et al published that homogeneous T cell lines with a 
regulatory phenotype could only be generated from a CD4+ CD25hi CD62L+ CD45RA+ 
population.  This may indicate that some functional plasticity is involved (Hoffmann et al., 
2006).  As the inflammatory disease progresses, cells which had previously had an effector 
phenotype, may have become regulatory.  
With this in mind, it is perhaps unsurprising that the limited literature on the role of Th17 
cells in GvHD is not consistent.  Mouse studies have shown that in one case the absence of 
IL-17A augments Th1 differentiation leading to increased GvHD (Yi et al., 2008), but in 
another IL-17A does contribute directly to GvHD, albeit without influencing overall survival 
(Kappel et al., 2009).  A third study found that lethal GvHD was mediated by Th17 cells with 
severe pulmonary and cutaneous manifestations (Carlson et al., 2009).  Other evidence 
points to GvHD potentially being mediated by different T cell subsets synergistically, 
independently or altered differentiation.  In mouse models, allogeneic Th17 cells were 
shown to cause GvHD independently, although not in a syngeneic setting, which suggested 
an antigen dependent mechanism.  In the same system, Th1 cells could independently cause 
GvHD.  However, polarised Th17 cells did not maintain their phenotype and began to 
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produce large amounts of IFN-γ.  Furthermore, blocking differentiation into a Th17 
phenotype did not affect GvHD development (Iclozan et al., 2010).  This indicates that Th17 
cells can contribute to, but are not necessary for GvHD. 
Understanding of T cell homing mechanisms in GvHD may yield ways to disrupt the disease.  
Studies have shown that a number of chemokines including CCL2, CCL3, CCL4, CCL5, CXCL2, 
CXCL9, CXCL10, CXCL11, CCL17 and CCL27 are overexpressed in affected tissues, and a higher 
frequency of CXCR3 and CCR5 expressing T cells causing in GvHD sites (Duffner et al., 2003, 
Wysocki et al., 2005b).  CCR5 expressing Tregs have also shown to modulate GvHD in disease 
sites (Wysocki et al., 2005a).  Acute skin GvHD patients have elevated CXCL10 and recruit 
CXCR3 expressing T cells to disease sites (Piper et al., 2007a).  Further characterisation of T 
cell trafficking chemokines and receptors in both acute and chronic GvHD may well provide 
insights into mechanisms that could be targeted for therapeutic intervention. 
1.8.5 Separating GvL and GvHD 
There are a number of potential strategies for enhancing the GvL effect whilst 
simultaneously diminishing GvHD.  Better reconstitution can be achieved in patients who 
have received a T-cell depleted graft by subsequent donor lymphocyte infusion (DLI).  This is 
carried out after the first few weeks in order to avoid the highly inflammatory environment 
in this period, when there is increased activation of DCs and MHC class II is upregulated on  
epithelial cells (Li et al., 2006).  Mouse models showed that delayed DLI in mHAg 
mismatched animals enhanced GvL without increasing GvHD (Klingebiel et al., 2008), 
although GvHD is increased if the DLI is given to lymphopenic recipients as compared to non-
lymphopenic mice (Miller et al., 2007).  Unfortunately in human systems, this approach has 
had inconsistent results with regards to separation of GvL and GvHD, particularly in acute 
leukaemia and myeloma (Kolb et al., 2004).  DLI is often successfully used to treat relapse in 
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allograft patients with less rapidly growing tumours such as chronic myeloid leukaemia 
(Dazzi et al., 2000), but this approach has been less successful in AML, partly because the 
blast-reduction chemotherapy required can promote a proinflammatory environment, 
leading to increased risk of GvHD post-DLI (Edinger, 2008). 
Selection and expansion of regulatory T cells for reinfusion has been shown to suppress 
GvHD (Taylor et al., 2002) but not at the expense of the GvL effect (in murine models) 
(Edinger et al., 2003).  Caution should be exercised with this approach due to the potential 
plasticity of the reinfused cells, as a conversion to pro-inflammatory effector cells may 
exacerbate GvHD.  It has been reported that murine transplant recipients treated by 
extracorporeal photopheresis, where leukocytes are treated ex vivo with 8-
methyloxypsoralen and exposed to UVA radiation, have increased frequencies of Tregs and 
reduced GvHD incidence (Gatza et al., 2008). 
The immune environment could be manipulated by therapeutically targeting APC 
populations.  Selective depletion of CD11b+ donor DCs or addition of CD11b- donor DCs can 
enhance GvL without a corresponding increase of GvHD in murine studies (Li and Waller, 
2004).  Certain subsets of DCs which express indoleamine 2,3-dioxygenase (IDO), which is an 
immunomodulatory  enzyme, are thought to be tolerogenic by suppressing effector 
responses and expanding Tregs (Chen et al., 2008).  It has been proposed that expansion of 
‘regulatory DCs’ may prevent GvHD without diminishing GvL (Li et al., 2009).  However, this 
has only been shown in preclinical models and is yet to be demonstrated in human 
transplant recipients. 
A potential strategy to limit GvHD is to use cytokine blockades such as anti-TNF therapy in 
order to modulate the cytokine-mediated proinflammatory environment.  Elevated plasma 
levels of this cytokine have been associated with increased severity of GvHD and higher 
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mortality (Choi et al., 2008).  Soluble TNF-α suppression in a murine allograft model resulted 
in decreased GvHD without compromising GvL (Borsotti et al., 2007), although consistent 
administration of a TNF-α antibody, infliximab, over three weeks resulted in an increased 
frequency of severe infectious complications (Hamadani et al., 2008).  Another study showed 
that this strategy was effective for reducing GvHD without inhibiting GvL, but also reported 
infectious complications (Couriel et al., 2004).  It may be that a certain dose could be 
beneficial as a component of a combined strategy. However, these studies underline the fact 
that caution must be exercised when using immunosuppressive strategies to combat GvHD, 
so that necessary immune function is not excessively compromised.  
By further understanding the mechanisms of both GvL and GvHD, it may be possible to 
achieve the goal of augmenting anti-tumour immunology whilst simultaneously diminishing 
GvHD pathogenesis in order to improve the overall survival and quality of life for allo-SCT 
patients, and potentially make this a viable treatment option for a greater number of people. 
The aims of this project were two-fold. One was to investigate the presence of CTAg 
immunity following allo-SCT in order to determine the potential of these genes to be 
exploited for immunotherapy.  The other was to attempt to elucidate the roles of T cell 
subsets in the pathogenesis of GvHD, and whether there were any patterns that could be 
utilised or interrupted to treat or prevent GvHD. 
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2.1 Patients 
2.1.1 GvL Study Patients 
41 patients with a primary diagnosis of AML or MM who were undergoing an allogeneic 
stem cell transplant were studied.  Written informed consent was obtained prior to joining 
the study and appropriate ethical approval was obtained (South Birmingham Regional Ethics 
Committee).  35 patients had a diagnosis of AML with the remaining 6 undergoing treatment 
for MM.  20 patients received a myeloablative conditioning regimen consisting of 
cyclophosphamide (60mg/kg x 2 days) and 14.4 Gy total body irradiation (TBI), and 21 
received a reduced intensity conditioning (RIC) regimen incorporating fludarabine (25mg/m2 
x 5 days), campath (140mg/m2) and melphalan (10mg x 5 days) (table 4.1.1).  
2.1.2 GvHD Study Patients 
Patients who were undergoing allogeneic stem cell transplantation for treatment of various 
haematological malignancies at University Hospital Birmingham NHS Trust and Heartlands 
and Solihull NHS Trust were recruited into the study.  Written informed consent was 
obtained prior to joining the study and appropriate ethical approval was obtained (South 
Birmingham Regional Ethics Committee).  Peripheral blood samples from 55 patients were 
studied.  The patients were divided into three cohorts which consisted of patients who had 
had acute GvHD (n=18), chronic GvHD (n=15) or no GvHD (n=22).  Samples were analysed 
during GvHD and before or after GvHD episodes.  The PBMC samples were split and then 
either stained with antibodies to Foxp3 in order to quantify Tregs, or a combination of IFN-γ 
and IL-17A antibodies to measure frequencies of Th1 and Th17 cells respectively.  This co-
staining allowed identification of the Th17-1 subset which secretes both IFN-γ and IL-17A.  
We also used antibodies to investigate the expression of chemokines CCR6, CXCR3 and CCR4 
in relation to Th1 and Th17 subsets. 
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2.1.3 Isolation of PBMCs from patient whole blood samples 
Heparinised peripheral blood samples of 42ml were taken pre-transplantation and then at 
several time points in the post transplant period.  A further sample was taken into a tube 
without anticoagulant.  This was left to clot at room temperature or at 37oC, before being 
centrifuged at 2200rpm for 5 minutes and a 2ml serum sample removed for storage at -80oC.  
Bone marrow samples were obtained at the time of routine clinical monitoring and 
mononuclear cells (MC) were isolated from all samples by density gradient centrifugation 
using Lymphoprep (Nycomed, Oslo, Norway).  The whole blood was diluted in an equal 
volume of RPMI 1640 (Invitrogen, Paisley, UK) prior to being layered onto lymphoprep and 
centrifuged at 1994 rpm for 30 minutes, brake off.  A 2ml sample of the plasma was 
removed and frozen at -20oC.  The lymphocyte layer was removed by transfer pipette to a 
sterile tube containing 20ml RPMI 1640 (Invitrogen).  Further washes were carried out by 
centrifuging at 1500rpm for ten minutes, then 1200rpm and finally 1000rpm with the 
supernatant being discarded each time and the pellet resuspended in 20ml RPMI.  During 
and after the final wash, the resuspension media was RPMI supplemented with 10% Human 
Serum (HS) (TCS Biosciences, Buckinghamshire, UK) or Foetal Calf Serum (FCS) (PAA, 
Somerset, UK), penicillin/streptomycin (Invitrogen) and L-Glutamine (Invitrogen). 
All IFN-γ capture assays were carried out using freshly isolated peripheral blood (PBMC) or 
bone marrow (BMMC) samples. Foxp3 staining and intracellular cytokine staining 
experiments were carried out on cryopreserved PBMC samples. 
2.1.4 Cell freezing and thawing 
Cells were centrifuged for 5 minutes at 1200 rpm  and the supernatant was removed.  The 
pellet was resuspended in the residual supernatant by gently flicking the tube and was then 
placed on ice for 10 minutes.  1 ml freezing media, consisting of FCS (PAA) containing 10% 
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dimethyl sulphoxide (DMSO) (Sigma) was added dropwise for each vial to be frozen and then 
transferred to chilled cryovials.  The vials were placed in a freezing container which allowed 
the cells to be surrounded by, but kept separate from isopropanol, for controlled 
temperature reduction of 1oC per minute.  The container was placed in a -80oC freezer and 
after 24 hours the cells were removed to -180oC storage in a liquid nitrogen freezer. 
To thaw the cryopreserved cells, the vials were removed from liquid nitrogen storage and 
placed in a waterbath at 37oC and monitored closely until the cryovial contents were in 
liquid phase.  The cells were immediately transferred to 10 ml culture medium consisting of 
RPMI (Sigma) with 10% FCS (PAA), supplemented with penicillin/streptomycin/L-glutamine, 
and washed by centrifuging at 1200 rpm before resuspension in an appropriate volume of 
culture medium. 
2.1.5 Generation of B95.8 lymphoblastoid cell lines (LCL) 
PBMCs were isolated from whole blood as described in 2.1.3.  Cells were resuspended in 
B95.8 tissue culture supernatant (prepared in house) at 1x107 cells per ml and incubated for 
one hour at 37oC/5% CO2, with gentle agitation every 15 minutes.  
The cells were then washed twice by adding 10ml LCL culture medium (RPMI 1640, 10% FCS, 
pen/strep, L-glutamine) and centrifuging for 5 minutes at 1200rpm.  After the final wash, the 
cells were resuspended in 2ml LCL medium supplemented with 2µg/ml cyclosporine (CSA) 
(Sandoz, Surrey, UK) and incubated in 2 wells of a 48 well culture plate, at 37oC/5% CO2.  
After 7 days, half of the media was replaced with CSA supplemented LCL medium.  Cultures 
were monitored for the presence of clumps of cells and expanded into 24 well plates and 
then T25 tissue culture flasks, where appropriate.  The media continued to be replaced with 
CSA supplemented medium when yellow for 14-21 days, after which time CSA was no longer 
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added.  Cells continued to be grown in T25 or T75 flasks and medium was changed twice per 
week, and the cultures were split weekly to prevent overgrowth.  
2.2 Detection of CTAg-specific T cells by IFN-γ Cytokine Secretion Assay 
A panel of 20 peptides (Alta Biosciences, Birmingham, UK) from ten CTAg gene families was 
chosen on the basis of having been previously identified as T cell epitopes (as detailed on the 
website of the Academy of Cancer Immunity) and also shown to have RNA expression in AML 
and/or MM (Guinn et al., 2005, van Baren et al., 1999).  The peptides, their HLA restriction 
and gene derivation are detailed in table 4.1.2 (Chapter 4).  Peptide-specific T cells were 
identified from PBMCs using interferon-gamma cytokine secretion detection and enrichment 
assay kit (CSA) (Miltenyi Biotec®, Bergisch Gladbach, Germany)) according to manufacturer’s 
instructions.  Freshly isolated PBMC were seeded into wells of tissue culture plates (Iwaki) in 
RPMI 1640 media (Invitrogen) supplemented with 10% human serum (H+D Supplies) and L-
glutamine (Invitrogen) at a cell density of 1x107/ml and left overnight without stimulation at 
37oC in 5% CO2.  Peptides were then added either individually or in pools of not more than 6 
at a final concentration of 10μg/ml.  An equivalent volume of DMSO (Sigma, UK) was added 
to a negative control well which was then used to determine gate positioning for FACS 
analysis, as shown in figure 1.  Staphylococcal enterotoxin B (SEB) (Sigma, UK) was used as a 
positive control at a concentration of 1μg/ml.  Following a three hour stimulation period, the 
cells were labelled for five minutes with IFN-γ catch reagent and incubated with continuous 
rotation for 45 minutes at 37oC.  The cells were then labelled with IFN-γ detection reagent 
conjugated to PE fluorochrome, followed by anti-PE magnetic beads.  Magnetic selection 
was carried out either manually using MS columns (Miltenyi Biotech, Bergisch Gladbach, 
Germany) for double positive selection, or using the equivalent “posseld” selection 
programme on an autoMACs (Miltenyi Biotech, Bergisch Gladbach, Germany).  Pre- and 
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post-selection samples were labelled with CD4-FITC, CD8-PC5 monoclonal antibodies 
(Beckman Coulter, High Wycombe, UK) and propidium iodide (1 μg/ml, Sigma, UK) to 
exclude dead cells.  Flow cytometric analysis was carried out using either Beckman Coulter 
XL-2 flow cytometer (Beckman Coulter, High Wycombe, UK) with WinMDI software for 
analysis (Scripps Institute, La Jolla, USA) or a BD LSRII with FACS DIVA analysis software (BD 
Biosciences).  The percentage of antigen-specific T cells in the CD4+ or CD8+ pool, was 
calculated using the number of cytokine secreting cells in either the positively selected 
fraction or pre-selected sample gated on CD4+ or CD8+ cells within the PBMCs.  Any IFN-γ 
secreting cells detected in the unstimulated negative control were considered to be 
background and subtracted from the frequency of cells producing IFN-γ following peptide 
stimulation. 
2.3 Foxp3 staining 
PBMCs were washed three times with cold phosphate-buffered saline (PBS) and stained with 
surface antibodies and a dead cell exclusion dye.  The antibodies were CD127 FITC 
(eBioscience, Hatfield, UK), CD25 PC5 (Beckman Coulter, High Wycombe), CD4 PC7 
(eBioscience), CD8 Pacific Blue (eBioscience), CD45RA AF700 (Biolegend, San Diego, USA) 
and CD3 APC-Cy7 (Biolegend).  A LIVE/DEAD Fixable Dead Cell Stain kit (Invitrogen, Paisley, 
UK) was used to exclude dead cells. 
The PBMCs were then fixed and permeabilised using the Foxp3 staining buffer kit 
(eBioscience) according to manufacturer’s instructions.  The sample was split and stained 
either with Foxp3 PE antibody (eBioscience) or Rat IgG1 PE Isotype control antibody.  
Samples were analysed on a BD LSRII (BD Biosciences, Oxford, UK). 
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2.4 Intracellular cytokine staining for Th1/Th17 
The portion of PBMC sample not used for Foxp3 quantification was stained with surface 
antibodies to CXCR3 (CD183) PE (BD Biosciences), CCR4 PC7 (BD Pharmingen, Oxford, UK), 
CD8 AmCyan (BD Biosciences), CCR6 APC (R&D Systems, Abingdon, UK), CD3 APC-Cy7 
(Biolegend).  The sample was resuspended in RPMI (Invitrogen or Sigma-Aldrich, Gillingham, 
UK) containing 10% foetal calf serum (PAA) and then split.  One part was stimulated for 6 
hours at 37oC 5% CO2 with 25ng/ml PMA and 400ng/ml ionomycin (Sigma-Aldrich) and the 
other left unstimulated, both having monensin added at 1.25μg/ml within 1 hour of 
incubation.  After 6 hours the tubes were transferred to a refrigerator and left overnight at 
4oC.  The cells were washed three times with, and resuspended in, cold PBS before staining 
with LIVE/DEAD fixable dead cell staining kit (Invitrogen).  The samples were then fixed for 
30 minutes using 4% paraformaldehyde (Sigma-Aldrich) before washing with MACS buffer 
(PBS, 0.5% Bovine Serum Albumin (BSA) (Invitrogen), 2mM EDTA (Sigma)) and permeabilised  
for 5 minutes at room temperature, in the dark, with 0.5% saponin (Sigma-Aldrich).  Some 
cells were removed for isotype control staining with anti-mouse IgG1 Pacific Blue or AF700 
and then the samples were stained with IL-17A Pacific Blue (Biolegend) and IFN-γ AF700 
(Biolegend) antibodies.  Samples were washed with MACS buffer and then analysed on an 
LSRII (BD Biosciences) flow cytometer.  Our CD4+ population was identified by gating on 
CD3+ CD8- cells within the lymphocyte gate, due to potential down-regulation of CD4 on the 
surface following stimulation.  Statistical tests were carried out with Prism 5 (Graphpad 
Software, San Diego, USA), using a paired t-test (for two time point or group comparisons) or 
a Mann-Whitney test (more than two time point comparisons), and Spearman’s non-
parametric test was used to determine correlations. 
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2.5 Luminex analysis of serum cytokines 
Concentrations of cytokines and chemokines present in the serum of patients were 
measured by using a 25-plex luminex kit (Panomics, Milan, Italy) according to manufacturer’s 
instructions.  Serum samples were stored at -80oC and were thawed at the time of carrying 
out the assay.  The panel of cytokines and chemokines measured is shown in table 5.4.1 
(Chapter 5).  
A 96 well filter plate was prepared by adding 150µl reading buffer and incubating for 5 
minutes at room temperature.  The buffer was removed through the filter by using a vacuum 
filter pump designed for extraction of liquids through the plate filter.  50µl of antibody beads 
were added to each well and excess buffer was removed by filtration.  The beads were then 
washed with 150µl wash buffer, removed by filtration and blotting the base of the plate.  
25µl assay buffer was added per well, followed by 25µl of samples and standards to 
appropriate wells.  The plate was sealed and wrapped in foil, then incubated for one hour at 
room temperature on a plate shaker (500rpm).  
Buffer was removed by vacuum filtration and the plate was washed three times with wash 
buffer.  25µl mixed detection antibodies were added to each well and the plate was sealed 
to incubate for 30 minutes at room temperature on a plate shaker (500rpm).  Buffer was 
then removed by vacuum filtration and the plate was washed three times with washing 
buffer. 
Streptavidin-PE was added at 50µl per well and the plate was sealed for a further incubation 
on a plate shaker (500rpm) for 30 minutes at room temperature.  Solution was removed by 
vacuum filtration and the plate was washed three times.  120µl/well reading buffer was 
added and the plate resealed and incubated for 5 minutes on the plate shaker.  The plate 
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was then read on a luminex reader. Statistical tests were carried out with Prism 5 (Graphpad 
Software, San Diego, USA), using a paired t-test (for two time point or group comparisons) 
2.6 Interferon-γ ELISA 
This assay was used to test specificity of T cell clones by establishing recognition of peptide 
loaded target cells.  In most cases, peptide-loaded LCLs were used as target cells.  LCLs were 
resuspended in a minimal volume of RPMI 1640 with peptide added at to a concentration of 
10µg/ml and incubated for one hour at 37oC.  Negative control LCLs had an equivalent 
volume of DMSO added instead of peptide.  The targets were then washed and resuspended 
at 3x105cells/ml in T cell line medium (TCL) (RPMI 1640, 10% HS, pen/strep, L-glutamine).  
100µl of LCL suspension was added to wells of a 96 well U-bottomed tissue culture plate 
(Iwaki, Japan).  T cell clones were suspended at 1x104 cells/ml in TCL medium, and 100µl 
added to the targets.  Control wells of T cells only, targets only and LCLs that had either not 
been loaded with peptide or loaded with an irrelevant peptide, were also set up.  The plates 
centrifuged at 1000rpm for 5 minutes, then incubated for 12-18 hours at 37oC/5% CO2, and 
centrifuged again.  150µl supernatant was removed and the concentrations of IFN-γ were 
established. 
A Maxisorp™ plate (Thermo Scientific Nunc, Leicestershire, UK) was coated with 0.75µg/ml 
anti-human IFN-γ antibody (Endogen) in 50µl coating buffer (0.1M Na2HP04 (pH9)), sealed 
and kept at 4oC overnight.  The antibody was then removed and the plate blotted onto 
tissue.  200µl blocking buffer (PBS, 1% BSA, 0.05% Tween 20 (Sigma-Aldrich)) was added per 
well and the plate left for 2 hours at room temperature.  Following the incubation, the plate 
was washed three times with washing buffer (PBS, 0.05% Tween 20) and 50µl test 
supernatants, along with standards (2000pg to 15pg IFN-γ in doubling dilutions) were added.  
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The plate was then washed 4 times with 200µl/well washing buffer prior to 50µl/well 
biotinylated anti-human IFN-γ antibody (Endogen) (0.75µg/ml in blocking buffer) being 
added for one hour at room temperature.  The plate was then washed 4 times and 50µl/well 
Extravidin-Peroxidase (Sigma-Aldrich) (diluted 1/1000 in blocking buffer) was added for 30 
minutes at room temperature.  After 8 more washes, 100µl/well TMB (Tebu Bio, 
Cambridgeshire, UK) was added and the plate was left for up to 20 minutes at room 
temperature in the dark.  The reaction was stopped by the addition of 100µl 0.5M sulphuric 
acid and the plate was read at 450nm on an absorbance plate reader. 
2.7 Chromium-release Cytotoxicity Assay 
This assay was utilised to assess the cytotoxic killing ability of the T cell clones by measuring 
the percentage of target cells lysed following co-culture.  Peptide-loaded LCLs were used as 
target cells and were prepared in the manner described in section 2.6.  After peptide 
loading, the LCLs were incubated with 100µCi Na251CrO4 for one hour at 37oC/5% CO2 and 
agitated every 15 minutes before being washed with T cell line (TCL) medium (RPMI 1640, 
10% HS, pen/strep, L-glutamine). 
Targets and clones were resuspended in TCL medium to give effector to target ratios 30:1, 
10:1 or 5:1 in a total volume of 200µl per well during co-culture.  Target only wells were set 
up for spontaneous lysis (200 µl TCL medium) and maximum lysis (100µl TCL medium and 
100µl 1% SDS) measurements.  The plates were centrifuged at 1000rpm for 5 minutes and 
then incubated for 4-6 hours for CD8+ T cell clones or 12-16 hours for CD4+ T cell clones.  
Following the incubation period, 100µl supernatant was harvested and measured using a 
Topcounter gamma-radiation counter (Hewlett-Packard), which calculated the percentage of 
target lysis according to the following formula: 
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  % specific lysis = sample release – spontaneous release 
              maximum release – spontaneous release 
 
Positive values were considered to be those above a 20% threshold. 
2.8 T cell cloning 
T cell responses were cloned using this method for further characterisation and functional 
assays.  The T cell culture (TCC) medium used throughout was RPMI 1640, 5% HS, 5% FCS, 
pen/strep, L-glutamine.  
Feeder cells consisting of allogeneic LCLs and overnight PHA-activated buffy coats from three 
donors were irradiated (40Gy).  The feeder cells were washed 4 times in TCC medium and 
resuspended at 1x105 LCL and 1x106 per ml.  The mixture was supplemented with 20U/ml IL-
2 (Chiron), IL-4 (Peprotech) (10ng/ml), IL-7 (Peprotech) (10ng/ml), IL-15 (Peprotech) 
(8ng/ml), IL-21 (Peprotech) (8ng/ml) and PHA (Sigma) (10µ/ml).  Final concentrations were 
half of these amounts.  100µl of this mixture was added to wells of 96 well U bottomed 
tissue culture plates (Iwaki).  
T cells for cloning were washed and aliquoted into different volumes of TCC medium to give 
concentrations of 0.3 cells, 1 cell, 3 cells and 10 cells per 100µl, and added to wells of feeder 
cells to give a total volume of 200µl per well.  The plates were then wrapped in foil and 
incubated at 37oC/5%CO2.  On day 7, 100µl of media was replaced with TCC containing IL-2 
(20U/ml) to give a final concentration of 10U/ml. 
From day 14, the plates were monitored for clonal outgrowths.  If growth was observed, the 
contents of the well were transferred to a well in a 48 well tissue culture plate containing 1 
ml of feeder cell/cytokine mix as described earlier.  Half of the media in the wells was 
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replaced twice weekly with TCC medium supplemented with either IL-2 alone, or with IL-2, 
IL-7, IL-15 and IL-21 at the concentrations described earlier.  Every two weeks, irradiated 
feeder cells were also added to the wells at the same cell concentrations as the original 
cloning mix.  Clones were tested for function and specificity at least 7 days after the most 
recent addition of feeder cells. 
2.9 T cell clone rapid expansion protocol 
This method was used to expand the numbers of T cell clones in a short time in order to 
provide the Regional Genetics Laboratory with enough cells to extract sufficient DNA for 
their standard chimerism analysis. 
The media used throughout was RPMI 1640 (Invitrogen) with 5% HS (TCS Biosciences), 5% 
FCS (PAA), pen/strep (Invitrogen), 2mM L-Glutamine (Invitrogen), 25µM β-Mercaptoethanol 
(Invitrogen), 12.5mM HEPES (Invitrogen).  To a T25 tissue culture flask (Iwaki) containing 
25ml of this media, 1x105 clone was added, along with 5x106 40Gy irradiated LCLs, 2.5x107 
40Gy-irradiated allogeneic buffy (from three donors) and 30ng/ml OKT3 monoclonal 
antibody.  The flask was incubated at 37oC/5% CO2. 
On the second day, IL-2 (Chiron) was added to a final concentration of 50U/ml.  The mixture 
was centrifuged at 1200rpm for 5 minutes on day 4, and then the pellet resuspended in 25 
ml culture medium with 50U/ml IL-2.  On day 8, half of the media was replaced with fresh 
culture medium containing 100U/ml IL-2 (to give a final concentration of 50U/ml).  This step 
was repeated on day 11 and on day 14 the cells were harvested and sent for DNA analysis. 
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2.10 CFSE Proliferation Assay 
Cells were washed three times in 10ml phosphate buffered saline (PBS) by centrifuging at 
1200rpm for five minutes and resuspending in 10ml PBS for each wash.  After the third wash 
the cells were counted and resuspended at a concentration of 2x107 cells/ml.  Meanwhile, 
CFSE (Invitrogen) was diluted from the stock solution of 10mM (in DMSO) to 2µM, before 
being added an equal volume to the cell suspension, giving a final CFSE concentration of 
1µM.  The cells were vortexed gently and incubated in a 37oC water bath for 10 minutes, 
with occasional agitation.  After the incubation period, culture medium (RPMI 1640, 10% 
Human Serum, penicillin/streptomycin, L-Glutamine), pre-warmed to 37oC was added at an 
equal volume to the cell/CFSE suspension in order to stop the reaction.  A further three 
washes were carried out as described before in 10ml PBS and the cells were resuspended at 
an appropriate concentration for further experiments. 
 2.11 Immunohistochemistry 
Slides with paraffin-embedded bone marrow trephine samples were obtained from the 
Pathology Department of the Queen Elizabeth Hospital, Birmingham.  Slides were incubated 
in a dry oven at 60oC for 20 minutes before being transferred to preheated W/Cap (pH8) in a 
coplin jar being heated to 98oC in a waterbath.  After 30 minutes the jar was removed from 
the waterbath and left to cool for 20 minutes at room temperature, then washed under a 
running cold tap for 5 minutes.  The jar was filled with 0.3% H2O2 in methanol for 10 minutes 
and washed again under a cold tap for 5 minutes. 
The slides were then laid out on a staining rack and 10µg/ml MAGE antibody (Invitrogen) or 
IgG2a isotype antibodies were added and left for one hour at room temperature.  The slides 
were washed by stirring in TBS buffer for 30 minutes before being returned to the staining 
rack. 
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Two drops from a dropper bottle of envision solution (Dako: Chemate/Envision kit) were 
added to each slide and incubated under cover for 30 minutes at room temperature.  The 
slides were then washed again for thirty minutes by stirring in TBS buffer and returned to 
the staining rack.  DAB (Dako) was added for 5 minutes and washed off with water, followed 
by addition of Mayer’s haematoxylin solution which was washed off after 30 seconds.  The 
slides were washed under a cold tap for 2 minutes, then under a hot tap for one minute 
before a further wash for 1 minute in cold water. 
A liquid mounting solution was then added to the area of the slide where the sample was 
located and a glass coverslip was placed carefully on the slide.  The sample was then 
examined under a light microscope and the level of staining assessed. 
2.12 CD137 Assay 
Cryopreserved PBMCs were thawed, washed in RPMI 1640 (Invitrogen) and resuspended at 
1x107 cells/ml in T cell culture medium (RPMI 1640, 10% human serum, 0.5% 
penicillin/streptomycin, 0.5% L-glutamine).  Cells were incubated with 10 µg/ml CTAg 
peptide(s) for 24 hours (37oC, 5% CO2).  Equivalent volumes of DMSO (Sigma) were added to 
negative control wells and 1 µg/ml SEB was used for positive controls.  Each well was 
harvested, washed in MACS buffer (PBS, 0.5% Bovine Serum Albumin (BSA) (Invitrogen), 
2mM EDTA (Sigma)) then stained with anti-CD137-PE (BD Biosciences), along with CD3-APC-
Cy7(BD Biosciences) and CD8-AmCyan (BD Biosciences) to identify T cells.  CD14-ECD 
(Beckman Coulter), CD19-ECD (Beckman Coulter), CD56-PC7 (BD Biosciences) and 1µg/ml 
propidium iodide (Sigma) were also added to exclude other cell populations and dead cells.  
Responding cells could either be assessed directly by flow cytometry or enriched using PE-
microbeads (Miltenyi Biotech). 
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2.13 Peptide-stimulated T cell line 
Freshly isolated PBMC were resuspended in 1 ml serum-free RPMI 1640 media (Invitrogen) 
and 30µM peptide was added.  The cells were incubated for 1 hour and then T cell line (TCL) 
media (RPMI 1640 with 10% Human Serum (TCS Biosciences)), supplemented with 25 ng/ml 
IL-7 (Peprotech) and 2 ng/ml (Peprotech), was added at a volume to achieve a cell 
concentration of 3x106 cells/ml.  Each 1 ml of cell suspension was transferred to one well of 
a 24 well cell culture plate.  On day three, a further 1 ml of TCL media was added containing 
IL-2 (Chiron) to a concentration of 20 U/ml.  Every three days, 1 ml of media was removed to 
be replaced with another 1 ml of TCL media with 40 U/ml IL-2 (for a final concentration of 20 
U/ml).  Cells were harvested after 10-14 days. 
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        Chapter 3: Identifying Alloreactive T cells by CFSE Proliferation Assay  
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3.1 Introduction 
An important contribution to the success of allogeneic stem cell transplantation is the 
development of GvL.  The association between the occurrence of GvHD and a decrease in 
the likelihood of relapse (Horowitz et al., 1990) suggests that some form of GvL is also 
developing.  However, GvHD continues to be a major cause of morbidity and mortality.  
Clinical strategies to prevent or treat GvHD are often immunosuppressive and have the 
disadvantage of potentially undermining GvL.  Both GvL and GvHD are T cell mediated and as 
targets of GvHD are extremely varied and not well characterised, broadly 
immunosuppressive treatments are used.  Many patients receive prophylactic cyclosporine 
following transplantation, and a clinical decision is made to reduce the dose over time until it 
can safely be withdrawn.  During this tapering period, if the patient shows signs of 
developing GvHD-like symptoms, the dose is again increased.  Alternatively, patients may be 
treated with courses of steroids such as prednisolone. 
It would be advantageous to be able to distinguish between pathogenic T cells that cause 
GvHD and those providing beneficial GvL.  Both of these processes are thought to be caused 
by alloreactive T cells which develop from the donor immune system that has been 
transplanted into the patient.  The identity of tumour targets that elicit a GvL reaction are 
poorly characterised currently.  However, if alloreactive T cells that cause GvL can be 
identified in patients, it may be possible to establish their specificity or isolate them for 
immunotherapy.  T cells that have the capacity to respond to the patient’s tumour could be 
cloned and expanded, perhaps while the patient is receiving immunosuppressive GvHD 
treatment, and then reintroduced to the patient, leading to a more robust GvL response. 
Alloreactive cells could be identified by culturing T cells isolated from the patient following 
transplantation, with irradiated samples taken before transplant conditioning.  Those cells 
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that proliferate are potentially alloreactive.  An identical parallel experiment that uses donor 
cells instead of the pre-transplant sample should not induce proliferation if the patient’s 
immune system is fully donor - this can be established by chimerism analysis.  Therefore, the 
level of background, non-alloreactive proliferation can be established.  Labelling the T cells 
from the post-transplant sample with a dye such as CFSE allows the proliferating cells to be 
identified through progressive loss of the dye during cell division (Lyons, 2000, Lyons and 
Parish, 1994).  The CFSE-dim population can then be sorted to allow cloning of potentially 
alloreactive cells.   Previous studies have used this fluorescence based method to identify 
rare antigen-specific CD4 cells (Mannering et al., 2003), and alloreactive T cells in murine 
studies (Pachnio et al., 2006, Suchin et al., 2001).  This chapter seeks to establish whether 
this approach could be used in a human setting. 
3.2 Use of CFSE to identify alloreactive cells 
5, 6-carboxylfluorescein diacetate succinimidyl ester (CFSE) is initially non-fluorescent and is 
converted to the fluorescent anionic form by intracellular esterases.  When CFSE labelled 
cells undergo division, the dye is distributed equally between the daughter cells (Weston and 
Parish, 1990).  Therefore, cells that have proliferated have a lower concentration of CFSE and 
can be differentiated from the non-dividing population by FACS, due to having less-bright 
staining.  An example of CFSE staining is shown in figure 3.2.1.  A detailed method for CFSE 
staining is given in Chapter 2 (2.10). 
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Figure 3.2.1 Example of FACS staining of CFSE labelled CD4+ T cells 
Dividing populations of T cells can be seen, segregated by dotted lines as a histogram and by 
dot plot, where progressive loss of CFSE denotes increased numbers of divisions.  Cells which 
have undergone the most numbers of divisions are shown in area A and undivided cells are 
in B.  CD4+ T cells are above the quadrant in the dot plot.  Those below may be CD8+. 
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The method used for stimulating alloreactive T cell proliferation is to co-culture CFSE-
labelled PBMCs with irradiated pre-transplant samples or donor samples.  This would be 
ideally done with tumour samples from the patient, but due to lack of availability of these, a 
pre-transplant sample of peripheral blood was used with the expectation that there would 
be some tumour present.  There was not a practical and reliable method to test each sample 
for the quantity of tumour.  However, there should have been a degree of tolerance to non-
tumour specific antigens and any reactivity to these would be indicated by proliferation in 
the patient’s post- transplant sample when co-cultured with the donor sample.  T cells 
specific for mHAgs may also be detected.  
3.3 Optimisation of CFSE proliferation assay as a method for detecting alloreactive 
cells 
One of the challenges of this study was the limited availability of clinical material, 
particularly the pre-transplant samples.  Therefore it was necessary to ensure the method 
was optimised and tested on healthy donor samples before applying the technique to clinical 
material.  
3.3.1 Titration of CFSE 
An important consideration when choosing an assay to identify, sort and ultimately clone 
Ag-specific T cells is whether the cells will be viable at the end of the experiment.  A concern 
for this assay was the potential toxicity of the CFSE dye.  Higher concentrations can cause 
cell death, inhibit cellular proliferation and alter the expression of surface markers 
(Last'ovicka et al., 2009).  Therefore it was necessary to establish the lowest concentration 
that would allow dividing cells to be differentiated from the non-proliferating population.  
PBMCs from a healthy donor were labelled with reducing concentrations of CFSE (4µM, 
2.5µM and 1µM) and stimulated either by co-culture with irradiated autologous or 
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allogeneic cells, or with Tetanus Toxoid.  After seven days in culture at 37oC 5% CO2, the cells 
were stained with CD4 ECD or CD8 PC5 and analysed by flow cytometry (Coulter XL).  Data is 
shown in figure 3.3.1.1 as dot plots, with percentages of proliferating and non-proliferating 
CD4+ or CD8+ T cells shown.  
Following stimulation with Tetanus Toxoid, both CD4+ and CD8+ T cells exhibit greater 
proliferation at 1µM than 2.5 or 4µM CFSE labelling.  Where 4µM CFSE was used, 9.4% 
proliferation of CD4+ T cells was observed, but 10.9% after labelling with 1µM (figure 
3.3.1.1A).  10.19% of CD8+ T cells proliferated after labelling with 1µM CFSE, but only 4.2% 
proliferated in response to the same stimulus when labelled with 4µM CFSE (figure 3.3.1.1B).  
This may be due to toxicity at the higher concentrations or perhaps the mechanism for 
recognition of the Toxoid is impaired.  After allogeneic stimulation there is a slight reduction 
in the percentage of proliferating cells between the maximum and minimum concentration 
of CFSE used for labelling.  This reduction was only 1.4%, from 9.9% at 4µM to 8.5% at 1µM 
only for CD4+ T cells (figure 3.3.1.1A) and 0.5% from 8.6% to 8.1% for CD8+ T cells (figure 
3.3.1.1B).  When 2.5µM CFSE was used for labelling, the frequency of dividing CD8+ T cells 
was considerably lower than where 1 or 4µM was used.  The reason for this is unclear, but 
may simply be a technical problem during that assay.  Overall, the conclusion drawn was that 
the lowest concentration would be most suitable for the assay when considering the 
potential toxicity of CFSE. 
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Figure 3.3.1.1 Titration of CFSE 
Dot plots showing proliferation of CD4+ (A) and CD8+ (B) (y-axis) T cells after seven days in 
culture, following stimulation with irradiated autologous PBMCs, allogeneic PBMCs or 
tetanus toxoid (TT).  Proliferating T cells were measured by labelling with CFSE (x-axis) 
titrated from 4mM to 1mM (top to bottom, decreasing concentration).  Percentages shown 
are dividing (upper left quadrant) or non-dividing (upper right quadrant) CD4+ or CD8+ T 
cells as proportions of the total lymphocyte gate.  Proliferating T cells were isolated from 
peripheral blood of healthy donors, as were irradiated target cells used for stimulation.  
Autologous stimulation was by cells from the same donor, and the allogeneic stimuli cells 
were from a different, HLA-mismatched donor. 
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3.3.2 Proliferation over time 
A time course experiment was set up using healthy donor cells to determine the optimum 
co-culture time that allowed sufficient proliferation to occur.  PBMCs were isolated from the 
blood of four donors and an aliquot of each was irradiated to use as autologous stimuli.  The 
remaining PBMCs were labelled with CFSE and stained with antibodies against CD4 and CD8. 
Cells from each donor were plated into 24 well plates and co-cultured with irradiated 
autologous or allogeneic cells, or left unstimulated.  Samples were analysed on a Coulter XL 
flow cytometer at days 7, 10 and 14.  The percentages of dividing cells are shown in figure 
3.3.2.1 for each condition, as means for all donors.  Proliferation occurred in response to 
allogeneic stimulus between days 7 and 10, and stabilised up to day 14 in the CD4+ 
population.  There was a decrease in the number of CD8+ T cells that had proliferated 
following day 10 which may be due to cell death.  Therefore the optimum time to harvest co-
culture assays to determine proliferation was around day 10 (figure 3.3.2.1). 
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Figure 3.3.2.1 Proliferation over time 
Mean percentages of proliferating CFSElow CD4 (A) or CD8 (B) cells from four healthy donors 
are shown with standard deviation (y-axis), when cultured for up to 14 days with irradiated 
allogeneic PBMC from a HLA-mismatched healthy donor (green line), autologous PBMC (red 
line) or no stimulation (blue line).  Cells were harvested at days 7, 10 and 14, stained with 
CD4 and CD8 antibodies, then the percentages of proliferating cells were established by flow 
cytometry. 
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3.3.3 Supplementation of culture medium with cytokines  
In order to assist the growth of proliferating cells and reduce the risk of cell death, the 
culture medium could be supplemented with cytokines.  However, this would carry a risk of 
driving non-specific proliferation.  Experiments were carried out similar to those in described 
in 3.3.2 but with IL-2 supplemented at different concentrations.  Figure 3.3.3.1A shows that 
in healthy donors there was little difference in proliferation when 20U/ml IL-2 was added, in 
comparison to those wells without IL-2 addition.  Where IL-2 was supplemented at 500U/ml 
there was a slight decrease in proliferation following allogeneic stimulation.  It is not clear 
why this would be, but high levels of IL-2 have been associated with maintenance of a 
suppressive environment (Antony et al., 2006, Fontenot et al., 2005).  The data shown is a 
representative example of several similar experiments. 
Figure 3.3.3.1B shows proliferation when CFSE-labelled patient PBMCs were co-cultured with 
irradiated autologous (donor) or allogeneic (pre-transplant) cells in the presence of varying 
concentrations of IL-2.  Whilst the presence of high concentrations of IL-2 seems to favour 
allogeneic CD8 proliferation, there is a slight increase in autologous cell division.  However, 
there is a marked increase in autologous CD4 proliferation, to similar levels as with 
allogeneic targets.  This result does suggest that addition of IL-2 can promote non-specific 
proliferation. 
The proliferation inducing effects of supplementing the standard culture medium with IL-7 
and IL-15 are demonstrated in figure 3.3.3.2.  Healthy donor CFSE-labelled PBMCs were 
cultured alone, or co-cultured with irradiated allogeneic cells.  These experiments were 
carried out using either standard T cell culture medium (RPMI with 10% Human Serum, 1% 
penicillin/streptomycin, 1% L-glutamine) or the same media supplemented with IL-7 
(25ng/ml) and IL-15 (2ng/ml).  Whilst considerable increases in allogeneic proliferation were 
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observed in the presence of additional IL-7 and IL-15, it should be noted that in the absence 
of allogeneic stimuli, increases were still nearly five-fold (CD4) and ten-fold (CD8), suggesting 
that higher concentrations of these cytokines lead to considerable non-specific proliferation. 
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Figure 3.3.3.1 Effect of adding IL-2 to cultures 
CFSE labelled PBMCs from a healthy donor (A) were cultured in media only (blue line), or co-
cultured with irradiated autologous (pink line) or allogeneic (orange line) PBMC in the 
presence of varying concentrations of IL-2 (x-axis).  Similarly, PBMCs isolated from a stem 
cell transplant patient (B) and CFSE labelled were co-cultured with irradiated autologous 
PBMC (from the HLA-matched donor, pink line) or allogeneic PBMC (isolated from the 
patient prior to transplant conditioning, orange line).   The frequency of proliferating CD4+ T 
cells (left column) or CD8+ T cells (right column) was determined by the percentages of 
CFSElow cells (y-axis).  
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Figure 3.3.3.2 Proliferative effects of supplementing media with IL-7 and IL-15 
CFSE labelled PBMC from a healthy donor were cultured in media only, or co-cultured with 
irradiated allogeneic PBMC with or without IL-7 and IL-15 (y-axis).  The frequency of 
proliferating CD4+ T cells (left column) or CD8+ T cells (right column) was determined by the 
percentages of CFSElow cells (upper left quadrants) compared to percentages of undivided, 
CFSEhi T cells (upper right quadrants), shown as percentages of the entire lymphocyte 
population. 
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3.4 Detection and cloning of alloreactive T cells 
Having optimised the culture conditions for the assay, it was necessary to test the principle 
further in healthy donor samples and then investigate whether this method shown 
successfully in a mouse model could be applied to human allograft patients. 
3.4.1 Alloreactive T cell detection in healthy donor and transplant patients 
PBMCs were isolated from the blood of healthy donors and split into fractions that were 
either irradiated or labelled with CFSE, a sample of which were analysed for staining by flow 
cytometry on day 1.  Cells from the irradiated fraction were either used in autologous co-
culture or as allogeneic stimulation for labelled T cells from other donors.  Co-cultures were 
set up as described earlier.  Cells harvested after 10 days and stained for CD4 and CD8 for 
analysis on a Coulter XL flow cytometer.  Example dot plots are shown in figure 3.4.1.1A.  
The proportions of proliferating cells were recorded for both autologous and allogeneic 
cultures for each donor and are shown in figure 3.4.1.2.A.  In almost all cases, there was 
greater proliferation in the allogeneic cultures, although to differing degrees.  The 
differences may be attributable to levels of HLA mismatch between donors.  Complete HLA-
typing data was not available for all donors. 
Peripheral blood samples were donated by allograft patients when attending the bone 
marrow transplant patient clinics.  PBMCs were isolated from these fresh samples and 
stained with CFSE.  Samples of the CFSE-labelled cells were assessed for CFSE-staining levels 
by flow cytometry on day 1. 
 Cryopreserved PBMCs isolated from blood samples that had previously been taken from 
either the HLA-matched donor (autologous), or the patient prior to beginning transplant 
conditioning (allogeneic), were thawed and irradiated.  Tumour samples collected at the 
time of diagnosis were used for allogeneic stimulation instead of the pre-transplant PBMCs, 
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where available.  Co-culture assays were set-up as before and cells harvested after 10 days 
before being stained with anti-CD4 ECD and anti-CD8 PC5 for analysis using a Coulter XL flow 
cytometer.  Sample dot plots are shown in figure 3.4.1.1B.  A summary of autologous and 
allogeneic proliferation of cells from all patients is shown in figure 3.4.1.2B.  If the 
autologous proliferation is seen as ‘background’, then there was little evidence of specific 
proliferation in the allogeneic wells.  That the high levels and incidence of allogeneic 
response seen in the healthy donors was not seen in the patients in not surprising due to the 
patient and donor pairs being HLA-matched.  Other reasons for the lack of responses could 
be that the pre-transplant PBMC samples are an inadequate source of allo-antigen, or that 
the post-transplant PBMCs from the patients were in poor condition due to in-vivo 
immunosuppression. 
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  CFSE 
Figure 3.4.1.1 Measurement of proliferation by CFSE-labelling 
Example dot plots are shown from CFSE proliferation assays to determine the frequencies of 
proliferating CD4 or CD8 (y axis) T cells following autologous or allogeneic stimulation with  
irradiated PBMC.  Healthy donor T cells (A) were stimulated with PBMC from the same donor 
(auto) or from a different healthy donor (allo).  Stem cell transplant patient (B) T cells were 
stimulated with PBMC from the HLA-matched stem cell donor (auto) or PBMC isolated from 
the patient before transplant conditioning.  The frequencies of proliferating T cells were 
determined by CFSElow cells (x-axis) and are shown in the upper left quadrants as 
percentages of Total lymphocytes, and the percentages of non-dividing T cells in the upper 
right quadrants. 
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Figure 3.4.1.2 Comparison of proliferation induced by co-culture with autologous or allogeneic cells 
The percentages of dividing CD4+ (left) and CD8+ (right) T cells measured by CFSE loss 
following co-culture with allogeneic or autologous cells for all healthy donors (A) and 
allograft patients (B) are shown.  Freshly isolated PBMCs from patients were co-cultured 
with irradiated PBMC from their HLA-matched donor (autologous) or PBMC isolated from 
the patient prior to transplant conditioning, or tumour (allogeneic) (x-axis). 
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3.4.2 Generation of alloreactive T cell clones 
Despite a lack of clear allo-specific proliferation, there were instances of proliferation above 
background in the allogeneic cultures and attempts were made to isolate alloreactive T cells 
by FACS and generate clones by limiting dilution.  The frequencies of dividing cells are shown 
in table 3.4.2.1.  In some cases, such as patient TS142PM, the autologous response was 
higher than from allogeneic stimulation.  However, some samples had robust responses to 
allogeneic stimuli above background, for example KaM153PM at 17 weeks post-
transplantation had 1.32% alloreactive T cells (table & figure 3.4.2.1).  T cell clones were 
grown from two patients, KaM153PM and KS114PM. 
The sorted cells were cloned by limiting dilution as per the method outlined in Chapter 2 
(section 2.8).  Unfortunately the clones generated from KaM153PM were lost due to a 
contaminated feeder cell product.  Clones from KS114PM were tested for specificity against 
a tumour sample taken from the patient at diagnosis, and also against PBMCs from the 
donor, in order to demonstrate whether these clones were alloreactive and tumour-specific.  
Results of IFN-γ ELISA recognition assays and 51Cr-release killing assays are presented in 
figure 3.4.2.2.   Donor LCLs were used as autologous targets as there was no other donor 
material available, and it is acknowledged that there was the risk of response to EBV 
proteins.  However, in the 51Cr release assay there was no lysis of donor LCLs, suggesting that 
this was unlikely to be a problem.    Some lysis of tumour was evident for all clones, but only 
four breached the threshold of 20% to be considered positive results.  IFN-γ ELISA data was 
available for three of these and for two clones, concentrations were more than double for 
reactions to tumour cells than to donor LCLs (which were similar low concentrations to the 
negative control).  However, the concentrations against the tumour were between 400 and 
600 pg/ml suggesting only weak responses.  Three clones were strongly positive for IFN-γ 
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production against tumour over background levels.  Unfortunately killing assay data was only 
available for one of these and lysis was considerably below the threshold.  From the data 
available, clone 1E12 had the best correlation between IFN-γ production and killing ability.  
However, some CD4+ T cell subsets do have robust cytokine responses, but are not 
necessarily cytotoxic. 
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Patient Time point (weeks 
post-transplant) 
% CD3 (above 
background) 
% CD4 (above 
background) 
% CD8 (above 
background) 
KS114PM 114 (21 post-DLI)  0.39 0.17 
KS114PM 120 (27 post-DLI)  4.48* 0.49 
RJ140PM 45 0.25   
TB142PM 43 0   
KaM153PM 17 1.32   
KaM153PM 26  0.21 0.03 
 
Table 3.4.2.1 Alloreactive T cell frequencies from cell sorting experiments 
CFSE-labelled patient PBMC samples were co-cultured with irradiated autologous PBMC 
(from HLA-matched stem cell donor) or allogeneic PBMC (isolated from patient blood prior 
to transplant conditioning).  After 11 days, the cells were harvested and stained either for 
CD4/CD8 or for CD3 alone and the CFSElow CD3+/CD4+CD8+ T cells were FACS separated for 
T cell cloning by limiting dilution.  The percentages of proliferating cells are shown in the 
table for each sorting experiment.  The frequencies shown were calculated by subtracting 
any proliferation following autologous stimulation from the percentage of dividing cells after 
allogeneic stimulation.  The time post-transplant is shown in weeks along with the portion of 
that time following donor lymphocyte infusion (DLI) (if applicable).  The figure for 
proliferating CD4+ T cells at 120 weeks post-transplant from patient KS114PM (*) is elevated 
due to gating complications.  However, a clear population was observed.  
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Figure 3.4.2.1 Sample dot plots from cell sorter showing proliferation in response to pre-transplant patient PBMC 
A CFSE-labelled PBMC sample from patient KaM153PM was co-cultured with irradiated 
autologous PBMC (from the patient’s HLA-matched stem cell donor, left) or allogeneic PBMC 
(isolated from patient blood prior to transplant conditioning, right).  After 11 days, the cells 
were harvested and stained for CD3 and the CFSElow CD3+ T cells were FACS separated for T 
cell cloning by limiting dilution.  As 0.11% T cells proliferated during autologous cell co-
culture, as compared to 1.43% during allogeneic cell stimulation, then 1.32% of dividing T 
cells were considered to be responding to allogeneic stimulation, and therefore were 
allogeneic. 
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Figure 3.4.2.2 Investigation into functions of T cells cloned from KS114PM 
T cell clones from patient KS114PM were tested by IFN-γ ELISA (A) for reactivity against, and 
ability to kill (B) patient tumour cells and LCLs derived from the HLA-matched transplant 
donor.  Killing ability was assessed by specific lysis of target cells in a 51Cr release assay.  
There was no lysis of donor LCLs, and killing above a threshold of 20% was considered 
positive (red line). 
Both ELISA and 51Cr data was available for clones to the left of the dotted line and are shown 
in the same columns.  For clones to the right of the dotted line, results are available for only 
one assay. 
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3.5 Discussion 
The data from this study confirmed that CFSE could be used to detect proliferating T cells in 
co-culture assays and higher levels of cell division clearly occurred in an allogeneic culture 
when using mismatched healthy donor cells.  The attempts to translate the findings of 
previous mouse studies that alloreactive T cells could be detected by this method following 
stem cell transplantation into a human clinical scenario proved somewhat less conclusive.  It 
is to be expected that the effect would be far more subtle in the transplant setting as having 
a high degree of histocompatibility between donor and patient is designed to prevent large 
donor responses to patient tissues, which would lead to GvHD.  Therefore, the idea of this 
study was to try to detect those cells that would respond to tumour.  As such, tumour 
reactive T cells are likely to be at low frequency it may well be that this method is not 
sufficiently sensitive, and that even low levels of background proliferation may prevent 
detection of tumour specific T cells.  Very few clones isolated from a patient in this study 
exhibited killing ability and/or cytokine release in response to tumour.  Only two of around 
20 clones tested, produced IFN-γ to more than double background levels and also killed 
above threshold.  One of these clones was the most effective at lysing tumour cells. 
There are a number of potential reasons for the apparent inconsistency between cytokine 
production and killing ability.  Clones often lose killing function whilst retaining the ability to 
produce cytokines.  This is particularly true of CD8+ cells.  Cell sorting was carried out by 
selecting CD3+ CFSElo cells and whether the cloned cells were CD4+ or CD8+ was not 
established due to very low numbers of clones.  This could also be a technical problem with 
the method as CD4+ T cells require a longer incubation with target cells in a 51Cr assay.  It 
could also be a result of a very disturbed immune environment from which the cells were 
taken, which can vary immensely between patients.  Therefore, the original cells used to 
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generate the clones could have been functionally deficient in some ways.  It cannot be ruled 
out that the effects of CFSE itself could have led to impaired functionality of the clones.  It 
has been shown that the dye is toxic to cells at higher concentrations (Last'ovicka et al., 
2009), and despite titration experiments carried out to minimise this risk, it is impossible to 
rule out the possibility that certain functions were impaired due to the presence of CFSE. 
These factors may also contribute to very low frequencies of alloresponsive cells, which may 
be present at levels too low to be reliably detected by this method.  The fact that the mouse 
studies had far greater responses is not surprising as in some cases the donor mice were 
vaccinated to have alloreactive T cells, which was necessary to demonstrate the principle.  
Perhaps if human donors were vaccinated against tumour, then patients would have more 
easily detectable frequencies of alloreactive, tumour-specific T cells.  However there are 
enormous ethical problems associated with this concept.  Another major factor is that the 
mice used have a ‘clean’ immunological background, so the system doesn’t take into account 
the decades of immunological challenges that shape a human immune system. 
There are many clinical variables that cannot easily be accounted for in stem cell transplant 
patients.  The type of conditioning has a profound effect on reconstitution, which could lead 
to patients having cells with impaired proliferative potential.  For example, campath (anti-
CD52 monoclonal antibody), which is routinely used in non-myeloablative transplants has 
been shown to delay T cell reconstitution (Morris et al., 2003).  Both patients from whom 
clones were generated in this study had myeloablative transplant conditioning with TBI and 
cyclophosphomide.  Prophylactic cyclosporine (CsA) therapy was administered to all patients 
in this study, but the length of time for this treatment was assessed clinically on a case by 
case basis.  In routine protocols for prophylactic immunosuppressive therapy, cyclosporine is 
given from the time of infusion and the patient is monitored.  When it is deemed 
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appropriate, the dose of CSA is reduced over time until complete withdrawal.  If there are 
signs of GvHD during this ‘tapering’ period, then the dose may be increased again.  However, 
immunosuppressive treatment could have impaired the ability of the T cells to proliferate in 
assays.  Similarly, if patients were being specifically treated for GvHD at the time of sample 
collection, then it is possible they would have circulating steroids in the blood.  As these 
assays were carried out on freshly collected samples, it was not always known if the patient 
was receiving an immunosuppressive therapy at the time of setting up the assay.  Where 
patients were receiving highly suppressive drugs, such as intravenous prednisolone, samples 
were not used for proliferation assays. 
Whilst it was encouraging to have isolated a clone that could recognise and kill tumour cells, 
the low number of patients in whom alloreactive T cells could be detected was 
disappointing.  Another major drawback to this study was that in order to screen patients, 
and then expand and test any clones, large amounts of pre-transplant and donor cells are 
required.  Detection could possibly be enhanced by repeated stimulation with allogeneic 
cells as in some tumour antigen studies.  For example, in a recent WT1 vaccine study, T cells 
were restimulated three times with peptide (Krug et al., 2010).  This would require larger 
quantities of pre-transplant material and donor cells.  The ideal source of allo-antigen would 
be tumour, but this needs to be collected at diagnosis, and not all patients would go on to 
receive a stem cell transplant (SCT).  Those that do may well be managed for some years 
before transplantation.  It was decided that under those circumstances, this aspect of the 
study should be discontinued and work should be refocused on studying a more specific 
approach to detecting anti-leukaemic T cells. 
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4.1 Introduction 
The successful outcome of allogeneic SCT as treatment for haematological malignancies is 
enhanced by GvL immune response (Collins et al., 1997, Horowitz et al., 1990, Kolb et al., 
1995, Porter et al., 1999).  Understanding the cellular targets of this response may facilitate 
development of therapeutic approaches to increase the efficacy of this treatment.  A major 
complication for allograft patients is GvHD which is a major cause of morbidity and mortality 
(Billingham, 1959, Lee et al., 2002).  Characterisation of GvL may allow development of 
therapies to boost immunity against leukaemic cells without affecting the patient tissues 
frequently damaged by GvHD.  Although GvL effects have been demonstrated in allograft 
patients, including in those treated for myeloma and AML (Bensinger et al., 1996), 
identification of specific targets is important to develop effective T cell mediated 
immunotherapy. 
Studies have demonstrated target potential of a number of antigens overexpressed by 
tumours such as Wilms Tumour 1 (WT1) and PRAME, although expression is not tumour 
exclusive which could lead to potential side-effects (Ikeda et al., 1997, Inoue et al., 1994, 
Kapp et al., 2009, Menssen et al., 1995, Miwa et al., 1992, van Baren et al., 1998).  There is 
also interest in other potential GvL targets, for example minor histocompatibility antigens 
(mHAgs) such as HA-1 which has been shown to be expressed by AML (Faber et al., 1995, 
Mutis et al., 1999). 
One group of tumour antigens that has potential for anti-tumour immunotherapy is the 
cancer/testis antigen (CTAg) genes.  These genes are only expressed in immune privileged 
germline cells (and retina in the case of RAGE-1) in healthy individuals, but are frequently 
expressed by tumours (Boon and van der Bruggen, 1996, Gaugler et al., 1996, Old, 2007, 
Simpson et al., 2005, Stevenson et al., 2007).  Such highly restricted tissue distribution marks 
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them as potentially suitable vaccine targets for GvL with reduced risk of GvHD.  There have 
been numerous studies demonstrating an effective anti-tumour T cell response directed 
against these antigens (Dhodapkar et al., 2003, Jungbluth et al., 2005, Lim et al., 2001, 
Meklat et al., 2007, Pellat-Deceunynck et al., 2000, Taylor et al., 2005, van Baren et al., 1999, 
van Rhee et al., 2005) and our laboratory has previously demonstrated CTAg-specific T cell 
responses in myeloma and MGUS patients (Goodyear et al., 2005, Goodyear et al., 2008).  It 
has also been shown that RNA expression of some of these CTAg gene families such as 
MAGE, BAGE, RAGE-1, LAGE, NY-ESO-1 can be detected in AML patients (Guinn et al., 2005).  
This opens the possibility of enhancing anti-tumour immunity post-allograft to reduce the 
risk of relapse for these patients.  Vaccine trials in metastatic melanoma have demonstrated 
tumour regression in up to 20% of patients, without toxic effects (Baumgaertner et al., 2006, 
Coulie and van der Bruggen, 2003, Jager et al., 2006, Lonchay et al., 2004).  Given the gene 
expression of CTAg genes in AML, it was important to address the question of whether an 
effective T cell response could be induced to the proteins. To date, no CTAg-specific T cell 
responses have been reported post-transplantation in AML patients, with only one report in 
a patient with relapsed myeloma (Atanackovic et al., 2007). 
In this study 45 patients (table 4.1.1) were screened immediately prior to, and at various 
time points post-transplantation, for T cell responses to a panel of 25 peptides derived from 
10 CTAg families (table 4.1.2) using the IFN-γ cytokine secretion assay in order to determine 
whether CTAgs could be potential GvL targets. 
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Patient Characteristics  
Patient age (years): median (range) 48 (22-64) 
Gender, number (%) 
          Male 
          Female  
 
22 (49) 
23 (51) 
Underlying disease, number (%) 
          AML 
          MM 
 
38 (84.5) 
7 (15.5) 
Transplant type, number (%) 
          Myeloablative 
                    Sibling  
                    Unrelated donor 
          Non-myeloablative  
                    Sibling 
                    Unrelated donor 
 
 
14 (31.1) 
8 (17.7) 
 
10 (22.2) 
13 (28.8) 
HLA-types of patients, number (%) 
          A1 
          A2 
          A3 
          A24 
          B7 
          B18  
          B44 
          Cw7 
          Cw16 
 
20 (44.4) 
26 (57.7) 
11 (24.4) 
4 (8.8) 
16 (35.5) 
2 (4.4) 
17 (37.7) 
30 (66.6) 
4 (8.8) 
Diseased state, number (%) 
          Relapsed 
          Non-relapsed 
 
8 (17.7) 
37 (82.3) 
 
Table 4.1.1 Characteristics of patients screened for CTAg responses 
The table shows details of the ages, sex, transplant conditioning, disease status, donor, HLA-
type and relapsed disease in the cohort studied for responses to CTAgs. 
  
Chapter 4: Detection of CTAg-specific T cells post allograft 
98 
 
GENE POSITION PEPTIDE HLA-
Restriction 
Population 
frequency (%)  
Reference 
BAGE      
 8-10 AARAVFLAL Cw16 7 (Boel et al., 1995) 
LAGE-1      
 Alt-ORF MLMAQEALAFL A2 44 (Aarnoudse et al., 1999) 
MAGE-
A1 
     
 161-169 EADPTGHSY A1 26 (Traversari et al., 1992) 
 96-104 SLFRAVITK A3 22 (Chaux et al., 1999a) 
 135-143 NYKHCFPEI A24 19 (Fujie et al., 1999) 
 289-298 RVRFFFPSL B7 17 (Luiten and van der 
Bruggen, 2000) 
 114-127 LLKYRAREPVTKAE DR13 19 (Chaux et al., 1999b) 
MAGE-
A2 
     
 157-166 YLQLVFGIEV A2 44 (Kawashima et al., 1998) 
 156-164 EYLQLVFGI A24 20 (Tahara et al., 1999) 
 212-220 EGDCAPEEK Cw7 41 (Breckpot et al., 2004) 
MAGE-
A3 
     
 168-176 EVDPIGHLY A1 26 (Gaugler et al., 1994) 
 112-120 KVAELVHFL A2 44 (Kawashima et al., 1998) 
 97-105 TFPDLESEF A24 19 (Oiso et al., 1999) 
 195 - 203 IMPKAGLLI A24 19 (Consogno et al., 2003) 
 167-176 MEVDPIGHLY B18 6 (Bilsborough et al., 2002) 
   B44 21  
 243-258 KKLLTQHFVQENYLEY DP4 75 (Schultz et al., 2000) 
   DQ6 63  
 149-160 VIFSKASSSLQL DR4 24 (Kobayashi et al., 2001) 
   DR7 25  
 191-205 GDNQIMPKAGLLIIV DR11 25 (Consogno et al., 2003) 
 281-295 TSYVKVLHHMVKISG DR11 25 (Manici et al., 1999) 
 114-127 LLKYRAREPVTKAE DR13 19 (Chaux et al., 1999b) 
MAGE-
A4 
     
 230-239 GVYDGREHTV A2 44 (Duffour et al., 1999) 
MAGE-
C2 
     
 191-200 LLFGLALIEV A2 44 (Ma et al., 2004) 
 336-344 ALKDVEERV A2 44 (Ma et al., 2004) 
NY-ESO-
1 
     
 157-165 SLLMWITQC A2 44 (Jager et al., 1998) 
RAGE-1      
 352-360 LKLSGVVRL A2 44 (Oehlrich et al., 2005) 
 32-40 PLPPARNGGL A2 44 (Oehlrich et al., 2005) 
 11-20 SPSSNRIRNT B7 17 (Gaugler et al., 1996) 
SAGE      
 715-723 LYATVIHDI A24 20 (Miyahara et al., 2005) 
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Table 4.1.2 CTAg peptides used in study 
Peptide sequences are shown along with the protein names they are derived from and their 
location within that protein. The columns on the right of the table show the HLA restrictions 
and the prevalence of those HLA types in the Caucasian population. 
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4.2 Optimisation of T cell assays 
Many assays used for identifying T cell responses rely on detection of an upregulated surface 
marker or measurement of soluble factors, for example, cytokine production.  T cells 
upregulate CD137 upon activation and therefore antibodies to this marker can be used to 
detect cells responding to a stimulus by flow cytometry (Wolfl et al., 2007).  Similarly, CD154 
can be used to detect recently activated CD4+ cells (Chattopadhyay et al., 2006).  
Traditional standard assays such as ELISA or ELISPOT, rely on detection of cytokines such as 
interferon-γ (IFN-γ), secreted in response to a specific stimulus (see chapter 2).  The 
disadvantages of these techniques include being unable to further utilise the cells afterwards 
and the inability to study surface markers in order to characterise the phenotype of the 
responding cells.  The latter problem can be overcome by use of intracellular cytokine 
staining which allows surface marker detection by antibodies (see chapters 2 and 5).  
However, due to the ‘fix and permeabalisation’ steps, the cells are killed during the assay 
which makes it impractical for further culture and functional studies.  
An assay that uses a surface bound antibody to ‘capture’ secreted cytokine, therefore 
maintaining the integrity and viability of the cell, was developed by J Campbell (Campbell, 
2003).  A second, fluorochrome-conjugated antibody is used to detect the cell by flow 
cytometry and magnetic beads can be used for enrichment.  The detailed method was 
outlined in Chapter 2 and a schematic diagram is shown in figure 4.2.1.  An example of the 
flow cytometric readout is shown in figure 4.2.2.  This assay is known as the IFN-γ Cytokine 
Secretion Assay (or IFN-γ Capture). 
The detection sensitivity can be enhanced to 0.0001% on the basis of the number of cells in 
the post-selection fraction, although this tends to underestimate the true frequency due to 
cell loss during selection.  For example, if 6x106 PBMCs were stimulated with CTAg peptide 
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and 17.9% were CD8+, then from these 1 075 800 CD8+ T cells, if 14 were PE-labelled in the 
positively-selected fraction it would indicate that by this method at least 0.013% ((14/1 075 
800)x100) of the CD8+ T cell pool was CTAg-specific. 
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Figure 4.2.1 The IFN-γ cytokine secretion assay (IFN-γ Capture) 
Following peptide stimulation the T cell produces IFN-γ.  A bi-specific antibody is bound to 
CD45 on the T cell surface.  The other specificity is IFN-γ which ‘captures’ the secreted 
cytokine at the cell surface (A).  A second IFN-γ specific, fluorochrome conjugated antibody 
also binds the captured cytokine (B).  The cells can then be enriched magnetically by the use 
of fluorochrome specific magnetic beads (C) and the number of IFN-γ secreting cells can be 
enumerated using flow cytometry (D).  
  
T cell
IFN-γ
Peptide 
stimulation
A
D
C
B
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Figure 4.2.2 Example flow cytometric dot plots from  IFN-γ capture assay 
Background IFN-γ production (x-axis) by CD8+ T cells (y-axis) was established by the negative 
control where an equivalent volume of DMSO was added instead of peptide (A and C).  This 
was subtracted from any response following peptide stimulation (B and D).  In many cases, 
pre-enrichment frequencies were used to measure responses (A and B) but a magnetic 
enrichment step was included to increase the sensitivity of detection where the unsorted 
frequency was low, or in order to isolate CTAg-specific T cells for cloning purposes (C and D). 
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C D
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IFN-γ
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4.2.1 Detection of viral-specific T cell responses using IFN-γ cytokine secretion assay 
The suitability of the IFN-γ capture assay was assessed by enumerating the frequency of T 
cells specific for known viral peptides in the blood of healthy lab donors.  In order to test 
reproducibility, PBMCs were resuspended at a concentration of 1x107 cells/ml in RPMI 
supplemented with 10% Human Serum and 0.5ml volumes were aliquoted into wells of a 48 
well tissue culture plate.  Three wells were stimulated using a viral peptide at a final 
concentration of 2μg/ml and an equivalent volume of DMSO was added to a negative 
control well.  The assays were analysed on a Coulter XL Flow cytometer.  Two healthy donors 
were screened with one peptide each, on two separate occasions, seven days apart.  EBV 
peptides, CLG and GLC (table 4.2.1.1), were selected because colleagues had previously 
shown low frequency T cell responses to one of those peptides in these donors, which would 
be most comparable to the predicted low level tumour responses.  Figure 4.2.1.1A shows the 
mean response frequencies after any background was subtracted.  Representative plots of 
pre- and post-enrichment FACS plots are shown for one donor at one time point in figure 
4.2.1.1B.  The assay was extremely reproducible between wells.  Differences between 
responses at different times in the same donor were intra-assay fluctuations which were 
expected. 
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Peptide Antigen HLA restriction Virus Reference 
FPKTTNGCSQA IE-1221-231 B55 CMV (Khan et al., 2007) 
AGILARNLVPMVATV pp65489-507 DRB5 CMV (Li Pira et al., 2005) 
NLVPMVATV pp65495-503 A2 CMV (Wills et al., 1996) 
GLCTLVAML BMLF-1259-267 A2 EBV (Steven et al., 1997) 
CLGGLLTMV LMP2173-181 A2 EBV (Rickinson and Moss, 
1997) 
NPKFENIAEGLRALL EBNA-1475-489 DR11 EBV (Leen et al., 2001) 
HRCQAIRKK EBNA-3B149-157 B27 EBV (Lautscham et al., 
2001) 
 
Table 4.2.1.1 Viral peptides used for control and optimisation assays 
Amino acid sequences of CMV and EBV peptides used for optimisation experiments to 
measure patient or healthy donor responses, the gene they were derived from and the 
position therein.  These peptides were referred to by a code derived from the first three 
letters of the amino acid sequence (underlined).  HLA restrictions are shown for each 
peptide and the virus they were derived from. 
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 Figure 4.2.1.1 Viral responses can be detected reproducibly by IFN-γ capture 
In order to assess the IFN-γ capture assay for reproducibility, healthy donors with known 
viral responses were screened in triplicate and repeated after seven days.  The mean 
responses (with standard deviation), after any background was subtracted are shown for 
two donors (A).  Week 1 responses are in blue and week 2 in red.  Darker coloured bars 
represent pre-enrichment frequencies and the post-enrichment as lighter bars, and the 
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frequencies on the y-axis.  Sample dot plots showing an assay in triplicate (B) show CD8+ T 
cells (y-axis) and the frequencies that secreted IFN-γ (a-axis) in response to peptide or 
DMSO.  Pre-enrichment plots (left) and enriched plots (right) are shown. Frequencies shown 
are percentages of the whole lymphocyte population. Low frequency responses to those 
peptides, in the selected donors, had previously been detected using ELIspot assays by 
colleagues.  
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4.2.2 Optimisation of sample processing prior to screening 
One limitation of using the IFN-γ CSA for screening patients for T cell responses is that it 
does not work well when using cryopreserved PBMCs.  The number of samples that can be 
screened at any one time is limited by the labour intensive and time consuming nature of 
the assay.  As most samples were obtained from a single, weekly clinic, it was sometimes 
difficult to screen all eligible patients.  Therefore to establish whether delaying the assay 
would have any effect on the results, an experiment was set up to compare the results of an 
assay being carried out immediately on PBMC isolated at the time of blood collection with 
another carried out 24 hours after PBMC isolation.  The effect of immediate isolation of 
lymphocytes or leaving the sample as whole blood for 24 hours was also assessed.  A 
summary of the experimental design is shown in table 4.2.2.1 and the frequencies of CD4+ 
and CD8+ T cells responding to the viral peptides are shown in figure 4.2.2.1.  EBV peptide 
NPK was used to stimulate CD4+ T cells and peptide HRC to stimulate CD8+ T cells.  The 
frequency of responding CD4+ T cells in the non-enriched fraction increased from 0.02% to 
0.04% in experiment B when the cells had been incubated without stimulus for an extra 24 
hours, and a smaller increase to 0.03% was seen when the blood was left whole for 24 hours.  
These increases were exaggerated following enrichment.  No increase in background was 
seen and these increased responses were not apparent with CD8+ T cells which showed a 
small decrease from 0.05% to 0.04%.  No conclusions can be drawn from this experiment 
without further investigation as to the reason for the increased CD4+ effect, although it is 
interesting to note that there was no background increase in the unstimulated well.  It may 
be that some suppressive factor is involved which decreases with time when in culture or 
lymphocyte isolation is delayed, or it could simply be due to variability between assays.  The 
majority of the screening of this study was against MHC class I restricted peptides and this 
experiment did not show a major decrease in frequency, although some increase in 
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background CD8+ IFN-γ from 0% to 0.01% was seen.  When the background is subtracted, 
the frequency of antigen-specific response decreases from 0.05% to 0.03%.  The purpose of 
this experiment was to establish whether the assay could be delayed and what the preferred 
method of storage was for the cells.  The results suggest that although a delay is not optimal, 
it would be possible to detect responses two days after the blood was taken although the 
threshold of detection could be compromised.  The CD4+ T cell data indicated that the blood 
should be left whole and lymphocyte isolation should be performed immediately prior to the 
assay.  This also opened up the possibility of obtaining samples from more distant locations, 
although very low frequency responses may not be detected. 
A further experiment was carried out to investigate the effects of short-term culture on viral 
response detection by IFN-γ capture.  The response to an CMV peptide FPK becomes 
undetectable after five days of culture at 37oC in 5% CO2 (figure 4.2.2.2).  It is possible that 
without stimulation or adequate cytokines the T cells became anergic or died.  
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Day 1 Day 2 Day 3 
Blood taken     
75% lymphoprep - assays (A) 
& (B) set up 
Assay (A) run Assay (B) run 
25% left whole 25% lymphoprep (assay (C) 
set up) 
Assay (C) run 
 
Table 4.2.2.1 Design of experiment to determine the effect of delaying the assay on detection of antigen-specific T cells 
On day 1 a blood sample was obtained from a healthy donor with a known EBV peptide 
response.  The sample was split and PBMCs were isolated immediately from 75% of the 
sample (fraction 1).  The remaining 25% was kept overnight at 4OC prior to PBMC isolation 
(fraction 2).  Isolated lymphocytes from fraction A were plated out at 5x106 into wells of a 
48w plate.  Assay A was carried out on Day 2 using wells of PBMCs from fraction 1 and the 
remaining wells were kept at 37OC 5% CO2 for a further 24 hours before Assay B was carried 
out.  On Day 2, PBMCs were isolated from fraction 2 of the blood sample and plated out in a 
similar fashion to fraction 1.  The lymphocytes were incubated at 37OC 5% CO2 and then used 
for Assay C on Day 3. 
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Figure 4.2.2.1 The effect of delaying the assay on detection of antigen-specific T cells 
T cell responses to EBV peptides in a healthy donor, screened by IFN-γ capture carried out at 
different times following blood sample collection according to the schedule detailed in table 
4.2.2.1.  On the x-axis, D1 corresponds to Experiment A, D2 corresponds to Experiment B and 
+24h represents Experiment C.  Frequencies of T cells producing IFN-γ in response to 
stimulation by peptide is shown.  Pre- and post-enrichment frequencies of CD4+ T cells in 
response to NPK (A and B respectively) are shown and CD8+ T cells in response to HRC (C and 
D). 
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Figure 4.2.2.2 The effect of short-term culture of cells on the detection of viral-specific responses by IFN-γ capture 
PBMCs were isolated from blood sample and the cells resuspended at 1x107 per ml.  The 
cells were divided into wells of a 48 well tissue culture plate with each well containing 5x106 
PBMCs, and incubated at 37oC in 5% CO2.  An IFN-γ capture assay was carried out on half of 
the wells on day one and then the other half on day five in order to establish the frequency 
of peptide-specific T cells (y-axis) that could be detected using this assay, following overnight 
resting and after culture for 5 days.  CMV peptide FPK was used to stimulate the cells to 
detect viral responses.  Appropriate positive and negative controls were used, as described 
in Chapter 2. 
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4.3 Isolation, culture and testing of T cell clones derived from allograft patients 
Strong CD4+ and CD8+ T cell responses were detected in AML allograft patient SS238PM 
when MAGE-A3 peptide GDNQ-batch 1 was included in the screening panel.  Substantial 
numbers of IFN-γ producing T cells could be isolated using magnetic separation and T cell 
clones were derived using the protocol detailed in the methods chapter.  Several batches of 
T cell clones were generated allowing extensive work to carried out on these cells.  However, 
it was ultimately determined that these were not in fact CTAg responses, but probably the 
result of contamination of the GDNQ peptide by a viral peptide.  Nevertheless, this work has 
been included to show the principle of the cloning technique being used to generate T cell 
clones from an allograft patient, and the process by which the probable contaminant was 
determined. 
4.3.1 Frequency and phenotype of responses to peptide GDNQ-Batch1 in patient SS238PM 
High-frequency CD4 and CD8 responses were detected in AML patient SS238PM on a 
number of occasions.  Responses were detected prior to transplant and then at multiple 
times post transplant.  These are shown, along with associated clinical complications, most 
notably two CMV reactivations, up to 62 weeks post-transplantation in figure 4.3.1.1a.  At 25 
weeks a very high frequency CD8+ T cell response was detected and flow cytometry dot 
plots are shown (figure 4.3.1.1b).  Cloning was attempted with 50% of the enriched CD8+ 
fraction and the rest was split into tubes for phenotyping.  Those IFN-γ secreting cells were 
mainly CCR7- CD27- CD28- CD45RO- LFA1+ and CD57+ which suggests that they were highly 
differentiated, not unlike CMV-specific CD8+ T cells (Appay et al., 2002). 
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Figure 4.3.1.1 Time course and phenotype of T cell responses to GDNQ – Batch 1 from patient SS238PM 
GDNQ-specific T cell frequencies were monitored over time in samples from AML patient, 
SS238PM (A).  Time points from pre-transplant to 62 weeks post-transplant are shown, with 
CD8+ responses in the upper graph and CD4+ in the lower.  Clinical events are shown 
beneath the x-axis.  Screening was carried out using IFN-γ capture assay.  Very high 
responses were detected at some time points and an example of staining is shown of one 
such response, seen at 25 weeks (B).  Due to the high numbers of cells in the post sort-
fraction, 50% was used for cloning by limiting dilution, whilst the remaining cells were 
further characterised by antibody staining for CD8 (y-axis), CCR7, CD45RO, CD57, LFA-1, 
CD27 and CD28 expression (x-axis) (C). 
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4.3.2 Culture, expansion and chimerism of T cell clones 
IFN-γ producing T cells from the positively selected fraction were cloned by limiting dilution 
as per the protocol outlined in Chapter 2 (section 2.8) and where cell numbers permitted, 
plated at concentrations of 100, 30, 10, 3, and either 1 or 0.3 cells per well.  Wells that 
showed a clearly enlarged pellet after 21-28 days in culture at 37oC 5% CO2, were transferred 
to a single 48 well plate. Irradiated PHA-stimulated PBMCs and LCLs were used with PHA, to 
boost proliferation and half of the media in the wells was replaced twice per week, 
supplemented with either IL-2 only (20 IU/ml) or along with IL-7 (5ng/ml), IL-15 (2ng/ml), IL-
21 (2ng/ml).  As the clones became confluent, they were split between further wells of a 
48w or 24w plate.  Clonal specificity was measured and is detailed in section 4.3.3. 
It has been reported that functional mHAg-specific T cells can persist in the recipient despite 
rigorous transplant conditioning (Shatry et al., 2007).  It was interesting to note that this 
patient had detectable responses to peptides GVYD and GDNQ both prior to transplant 
conditioning and at 18 weeks following transplantation (figure 4.3.2.1), which raised the 
question as to whether cells specific for either of these peptides had persisted through 
conditioning with proliferative capacity to give rise to detectable responses.  CD4+ 
frequencies were 0.058% pre-conditioning and 0.011% at 18 weeks, and CD8+ frequencies 
were 0.062% and 0.07% respectively.  Two clones (IB8SS & IG9SS) isolated from patient 
SS238PM post-transplantation were expanded using a rapid expansion protocol (see Chapter 
2, section 2.9) and sent to the West Midlands Clinical Regional Genetics Laboratory 
(WMCRGL) to determine whether they were of patient or donor origin.  DNA microsatellite 
analysis was carried out to compare DNA extracted from the T cell clones with stocks of DNA 
taken from the patient prior to transplantation and the stem cell donor that were held by 
the WMCRGL.  In brief, these clinical standard tests were comparisons of 16 highly-
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polymorphic alleles.  A section of results are shown in figure 4.3.2.2.  Position, height and 
area of the peaks are compared between samples.  One such set of peaks has been 
highlighted in the figure, demonstrating a difference in position between the patient’s pre-
transplant DNA and that of the donor’s DNA.  The origin of the clones can be determined by 
matching the peaks from clonal DNA to the patient or donor DNA.  The highlighted peaks 
show that both clones match the donor DNA rather than the patient.  This pattern was 
repeated for other polymorphisms and the laboratory report confirms that these clones 
were derived from donor haematopoietic stem cells, so therefore likely to have been 
generated post-transplantation.  It is unlikely that the healthy donor would have a CTAg-
specific T cell response, although this needed to be confirmed by obtaining a sample from 
the donor and screening for such responses.  Therefore, these results suggest that the 
response was generated post-transplant. 
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Figure 4.3.2.1 Responses to GVYD/GDNQ pools pre- and post-transplantation 
CD4+ and CD8+ T cell (x-axis) responses to pooled peptides GVYD and GDNQ were detected 
by IFN-γ capture (y-axis) in patient SS238PM, both prior to transplant conditioning (A) and 
then again at 18 weeks following transplant (B).  
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Figure 4.3.2.2 Chimerism analysis to determine origin of clones from SS238PM 
GDNQ-Batch 1-specific T cell clones IB8SS & IG9SS derived from SS238PM were sent to West 
Midlands Clinical Regional Genetics Laboratory to establish whether they had originated 
from cells of patient or donor lineage.  Microsatellite analysis was performed to compare 16 
highly polymorphic alleles in DNA samples taken from the patient pre-transplantation (A), 
from the donor (B) and from two clones isolated from the patient post-transplantation 
specific for GDNQ peptide (C and D).  Position, height and area of peaks were compared 
between samples.  One set of peaks showing similarities between the clones and the donor 
DNA sample has been highlighted.  The figure shows a representative set of peaks and data 
for all polymorphisms is shown in Appendix A. 
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4.3.3 Characterisation of specificity and functionality of T cell clones 
CD4+ and CD8+ T cell clones were generated from the positively selected fraction following 
stimulation with GDNQ-batch 1 peptide, at various time points.  It was necessary to establish 
specificity and whether the clones had ability to kill target cells.  Initial peptide screening was 
carried out by IFN-γ ELISA, following the protocol outlined in Materials and Methods (section 
2.6).  In order to screen large numbers of clones, 50µl of resuspended clone was taken and 
split into 4 wells of a 96 well U bottomed plate.  Two wells were stimulated with peptide and 
an equal quantity of DMSO was added to the remaining two wells.  Figure 4.3.3.1A shows 
levels of IFN-γ production from samples of clones generated at 19 weeks post-
transplantation.  The functional ability of these clones to kill target cells was assessed using a 
chromium release assay (as described in Materials and Methods Chapter 2, section 2.7).  
Briefly, partially HLA-matched LCLs were loaded with either peptide or an equivalent volume 
of DMSO, and then labelled with 51Cr.  The labelled LCLs were then co-cultured with the T 
cell clones for 4 hours (or overnight) at 37oC 5% CO2 and supernatants were harvested to be 
read on a gamma counter along with those from spontaneous (minimum) and induced 
(maximum) lysis wells.  The machine calculates a percentage of target cells lysed based on 
comparison with minimum and maximum values.  A positive result was considered to be 
over a threshold of 20% when any background from the negative control (DMSO only) wells 
was subtracted.  Examples of the levels of lysis of targets by the clones are shown in figure 
4.3.3.1B.  It can be clearly seen that all of the clones shown retained good killing ability, with 
levels around 50%, at seven weeks following the initial cloning, compared with no killing of 
the negative control cells, indicating that all lysis was peptide dependent.  
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Figure 4.3.3.1 Screening for T cell clone peptide specificity and cytotoxicity 
T cell clones were generated at 19 weeks post-transplantation by stimulation of PBMCs 
isolated from patient SS238PM with GDNQ-batch1 peptide.  Specificities of proliferating 
clones were tested using IFN-γ ELISA (A).  Negative control wells had an equivalent volume of 
DMSO added.  Concentration of IFN-γ in pg/ml is shown on the y-axis.   Clone 1 is clearly not 
specific for GDNQ-batch 1 and clone 12 is unlikely to be specific.  All other clones are 
considered to be specific for the peptide and could be selected for further characterisation.  
Some of the selected clones were used in a chromium release assay to assess cytolytic 
function (B).  Percentage of target cells lysed following co-culture with partially HLA-matched 
0
200
400
600
800
1000
1200
1 2 3 4 5 6 7 8 9 10 11 12
IF
N
-g
 p
g/
m
l
GDNQ
DMSO
0
10
20
30
40
50
60
1B6 2D10 1A12 1B11 1F12
%
 L
ys
is
Clone
A2 GDNQ Loaded LCL
A2 LCL
A 
B 
Chapter 4: Detection of CTAg-specific T cells post allograft 
122 
 
LCLs which had either been loaded with GDNQ-batch 1 peptide (red bars) or had an 
equivalent incubation with DMSO as a negative control (blue bars) is shown.  Levels of lysis 
over 20% were considered to be a result of peptide specific recognition and killing.  
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Although the ability of the clones to kill and recognise peptide had been established it was 
important to try and show that the clones could recognise endogenously processed antigen.  
The myeloma cell line, U266, has partial HLA-matching with the patient, and T cell clones 
from SS238PM can recognise peptide when presented by this cell line.  As U266 has 
previously been shown to express MAGE-A3 (Pellat-Deceunynck et al., 2000), an IFN-γ ELISA 
was performed to compare U266 recognition by CD8+ T cell clones, with and without loading 
of GDNQ-batch 1 peptide.  A negative control of mismatched LCL loaded with peptide was 
used to establish the levels of background spontaneous release.  Figure 4.3.3.2 shows that 
the clones strongly responded to peptide loaded U266, and no IFN-γ was produced in 
response to the mismatched LCL.  Low concentrations of IFN-γ were detected in the 
supernatant of the clones that had been co-cultured with U266 alone.  Whilst it would not 
be surprising if the response to naturally occurring antigen is lower than to a peptide loaded 
target, the low level of cytokine produced against U266 alone make it difficult to say with 
any degree of certainty, that this was a result of the T cells recognising and responding to 
MAGE-A3 expressed by the cell line.  
In order to establish the functional avidity of the peptides, a peptide titration experiment 
was carried out to demonstrate the minimum concentration of peptide recognised by three 
CD4+ T cell clones (figure 4.3.3.3).  Target LCLs were loaded with peptide at 10-fold 
decreasing concentrations and T cell clone recognition was measured by IFN-γ ELISA. 
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Figure 4.3.3.2 CD8+ T cell clone recognition of myeloma cell line U266 with or without peptide 
CD8+ T cell clones isolated from patient SS238PM were co-cultured with the MAGE-A3 
expressing myeloma cell line, U266 and response was measured by IFN-γ production.  U266 
targets were loaded with GDNQ-Batch1 peptide or incubated with an equivalent volume of 
DMSO in order to establish whether the clones were able to recognise naturally expressed 
MAGE-A3 or required surface peptide.  Spontaneous IFN-γ production was tested by co-
culture of clones with a HLA-mismatched LCL loaded with GDNQ-Batch1 peptide. 
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 Figure 4.3.3.3 Titration of GDNQ-batch 1 peptide concentration in order to establish avidity of T cell clones 
The recognition of decreasing concentrations of GDNQ-Batch 1 peptide by T cell clones with 
an IFN-γ ELISA readout is shown.  Target cells for antigen presentation were partially HLA-
matched LCLs loaded with 10-fold diminishing concentrations of peptide.  The dotted lines 
denote the concentrations of peptide that sensitized for half-maximal IFN-γ release for each 
of the three clones tested and the values were between 10-7M to 10-10M. 
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4.3.4 T cell responses to overlapping 9mer peptides derived from GDNQ 15mer sequence 
Another batch of clones was generated at 42 weeks post transplantation, again following 
stimulation by GDNQ-batch 1 peptide.  Similarly to previous occasions, very strong CD8+ T 
cell response was generated and cells from the magnetically enriched fraction were 
expanded by established cloning techniques.  As the peptide used was a 15 amino acid 
peptide which had previously been shown to elicit CD4+ T cell responses (Consogno et al., 
2003), it was somewhat surprising to find that such strong CD8+ T cell responses were 
generated.  It was necessary to establish which part of the sequence GDNQIMPKAGLLIIV was 
causing the CD8+ response.  A literature search did not yield any previously described 
shorter peptides suitable for class I presentation from that sequence.  A batch of overlapping 
9mer peptides (named E1-7) was synthesised by Alta Bioscience covering the 15mer 
sequence.  Reactivity of a previously characterised CD8+ T cell clone against these peptides 
was tested by ELISA and compared with GDNQ-batch 1.  Stimulation with peptides E2 and E3 
led to similar amounts of IFN-γ production as when GDNQ-batch 1 was the stimulus.  A lower 
amount of IFN-γ was produced against E4 but was considerably higher than background, so 
this peptide was used alongside E2 and E3 in future experiments, but E1, E5, E6 and E7 did 
not elicit a response (figure 4.3.4.1).  
Peptides E2, E3 and E4 were used along with the full length GDNQ-batch 1 peptide and a 
previously acquired 11mer, also from the GDNQ sequence, to stimulate SS238PM PBMCs ex 
vivo for an IFN-γ capture assay.  The sequences and results are summarised in Table 4.3.4.1.  
As it would not be expected to observe a CD4+ response to the shorter peptides, it was not 
surprising that CD4+ frequencies are considerably lower.  Indeed, the detection of IFN-γ 
producing CD4+ T cells in the absence of longer peptide may have been due to the large 
amount of IFN-γ secreted by the CD8+ T cells binding to antibodies on the CD4+ T cells.  It 
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may also be due to other cytokines produced by the responding CD8+ cells inducing IFN-γ 
production by CD4+ cells, by way of bystander activation.  However, the higher frequency of 
CD4+ T cells secreting IFN-γ in the presence of the full length peptide fits with expected 
results.  One curious observation was that there was absolutely no T cell response to the 
11mer peptide, which was surprising as it spanned all three shorter sequences which had 
generated large CD8+ responses.  The suspected reason for this result is discussed later. 
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Figure 4.3.4.1 CD8+ T cell clone responses to overlapping 9mer peptides derived from GDNQ 
In order to determine the amino acid sequence within the 15mer peptide that was 
recognised by the CD8+ T cells, a T cell clone which had previously been shown to recognise 
GDNQ-Batch1 was used to assess reactivity to overlapping 9mer peptides that span the 
sequence of GDNQ.  Peptides were loaded onto T2 cells and specificity was measured by 
IFN-γ ELISA (y-axis).  Responses to peptide loaded T2s is shown by the blue bars and to 
unloaded T2 controls indicated by the red bars.  
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Peptide Sequence CD8+ response CD4 response 
Full               G D N Q I M P K A G L L I I V 7.35% 8.54% 
11mer                   D N Q I M P K A G L L 0% 0% 
E2                   D N Q I M P K A G 8.23% 1.33% 
E3                       N Q I M P K A G L 8.16% 1.55% 
E4    Q I M P K A G L L 8.65% 0.88% 
 
Table 4.3.4.1 Ex vivo T cell responses to overlapping peptides and GDNQ-batch 1 
Shorter peptides were made from the sequence of GDNQ in order to establish which part of 
the sequence was responsible for eliciting CD8+ T cell responses.  The amino acid sequences 
of four shorter peptides is shown along with both CD8+ and CD4+ pre-sort frequencies from 
ex vivo IFN-γ capture screen of patient SS238PM.  Peptides E2, E3 and E4 had previously 
been shown to be the only 9mer peptides recognised by CD8+ T cell clones (figure 4.3.4.1).  
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4.3.5 Establishing HLA restriction of CD8+ T cell clones 
Having established that shorter peptides contained within GDNQ could be responsible for 
eliciting CD8+ T cell responses, the next step was to further characterise the peptides.  Firstly 
it was important to establish which HLA restriction these peptides had.  Comparison of the 
HLA-typing of the patient and cell lines or LCLs that had previously been successfully used to 
present the GDNQ-batch 1 peptide showed that the only consistent Class I alleles were A2 
and Cw7.  CD8+ T cell clones were tested by ELISA, using myeloma cell line U266 (A2+ve, 
Cw7+ve) and two LCLs from other donors, AS222PM (A2+ve, Cw7-ve) and HD-NK (A2-ve, 
Cw7+ve).  Figure 4.3.5.1 clearly shows that the peptides can only be recognised when 
presented through HLA-A2, and that in the A2-ve LCL, there is no recognition.  It was 
concluded that CD8+ recognition of peptides within the sequence of GDNQ was HLA-A2 
restricted.  It was noticeable that higher concentrations of IFN-γ were produced in response 
to U266 presented peptides than when presented by AS222PM LCLs.  This may have been 
due to the LCLs naturally having lower MHC expression, or the potential reactivity to 
naturally expressed MAGE-A3 on U266 could have led to a greater response. 
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Figure 4.3.5.1 HLA-restriction of CD8+ responses to GDNQ derived peptides 
IFN-γ responses to GDNQ and the shorter 9mer peptides derived from that sequence by 
clones from SS238PM were measured by ELISA, using target cells with differing HLA types in 
order to establish how the recognition was restricted.  Responses to target cells which were 
double positive for both A2 and Cw7 are shown in A, along with by A2+ve and Cw7-ve LCLs 
(B) and A2-ve and Cw7+ve LCLs (C).   No IFN-γ secretion was observed in the absence of HLA-
A2. 
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4.3.6 Reactivity of clones to MAGE-A3 transfected cell lines 
MAGE-A3 transfected LCLs DESA-M3+ and VACH-M3+ (along with empty vector controls - 
DESA-EBV and VACH-EBV) were kindly provided by Pierre van der Bruggen (Ludwig Institute 
for Cancer Research, Belgium).  An in-house generated LCL, KS114PMd, was also transfected 
with MAGE-A3 by the van der Bruggen group.  These cell lines were used as target cells to 
test the ability of the T cell clones to recognise endogenously processed antigen as a more 
physiologically relevant model than peptide loaded targets. 
The reactivity of CD4+ clones against a range of transfected and non-transfected targets, 
with and without peptide, is shown in figure 4.3.6.1.  The potential MHC Class II restriction 
required for GDNQ recognition was uncertain.  Although it has been reported that the 
restriction is HLA-DR11 (see table 4.1.2), the patient is DR11-ve, therefore any recognition 
must have a different restriction.  In this experiment, clones did not respond to DESA, 
regardless of whether the peptide was present.  Only background levels of IFN-γ, close to or 
below 500 pg/ml, were produced by two clones and around 1500 pg/ml for clone T6E3, in 
response to all targets including the negative control.  Although these were considerably 
higher than the negative controls for the VACH cell line, it may be due to alloreactivity, and 
unrelated to the antigen of interest.  More intriguing results were seen when VACH was used 
as the target cell line.  Higher levels of IFN-γ were produced to the transfected cell line, with 
or without peptide, and only to the non-transfected line where peptide was present.  
Therefore, this raised the possibility that the clones could in fact recognise GDNQ-batch 1 
peptide and endogenously expressed MAGE-A3 protein.  
CD8+ T cell clones were also screened by ELISA to ascertain whether they could recognise 
MAGE-A3 transfected cell lines.  It was noteworthy that despite large responses, relatively 
few CD8+ clones grew out following GDNQ stimulation in the IFN-γ capture assay, and none 
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from E2, E3 or E4 9mer responses.  As previously shown, these clones recognised U266 with 
GDNQ-batch 1 but here there was no recognition of this MAGE-A3 expressing cell line 
without peptide.  There was no evidence of recognition of the HLA-A2+ve LCL KS114PMd 
with or without peptide, or whether it had been transfected with MAGE-A3 or not.  Any IFN-
γ produced in response to U266 without peptide was in a similar range, or below levels 
where the negative control LCL, KS228PM, was the target cell.  The donor from whom this 
particular LCL was generated shares no common HLA type with the patient SS238PM.  It was 
unclear why the clones produced extremely high levels of IFN-γ in response to U266 with 
GDNQ -batch 1 but not to the HLA matched LCL.  It is possible that although the patient 
SS238PM, cell line U266 and donor KS114PMd are all HLA-A2+ve, the patient and donor may 
have a different subtype.  These clones do not back up the earlier observation that CD8+ 
clones could recognise U266 without peptide (see figure 4.3.3.2).  It may be that these 
clones have a different affinity. 
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Figure 4.3.6.1 CD4+ T cell clone responses to MAGE-A3 transfected cell lines 
In order to investigate whether clones could recognise endogenously produced antigen, 
three CD4+ clones which had been generated from patient SS238PM after stimulation with 
GDNQ-batch 1 were screened for reactivity against MAGE-A3 transfected LCLs by IFN-γ 
ELISA.  Concentration of IFN-γ is shown on the y-axis and target cells are on the x-axis.  
Target cells were non-autologous LCLs, DESA and VACH, which had been transfected with 
MAGE-A3. Non-transfected DESA and VACH LCLs were used as negative controls.  The 
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capacity for antigen presentation by the target cells to the T cell clones was confirmed by 
peptide loading target cells with GDNQ-Batch1.  IFN-γ production in response to unloaded 
targets was compared between transfected and non-transfected target cells to establish 
whether the clones could recognise endogenous MAGE-A3 antigen.  
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Figure 4.3.6.2 CD8+ T cell clone responses to transfected LCLs and MAGE-A3 expressing tumour cell lines 
ELISA screening was used to test specificity of CD8+ T cell clones isolated from patient 
SS238PM following stimulation with GDNQ-batch1 in IFN-γ capture assays.  Clones 1B2 and 
1E5 (A and B) were isolated at 42 weeks following transplantation and the remaining clones 
(B only) were isolated at 46 weeks.  Target cells were myeloma cell line U266, HLA-
mismatched LCL KS228 and partially HLA-matched LCL KS114, either transfected or non-
transfected.  Peptide-loaded targets were used to confirm the capacity for antigen 
presentation to the T cell clones. 
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4.3.7 Responses to different batches of GDNQ peptide 
New batches of some peptides were made to replenish diminished stocks and the new 
GDNQ peptide was used for further characterisation experiments.  However, when this new 
peptide was used, no reactivity of previously characterised clones was observed.  In the light 
of these observations, clones were tested for response to both batches of peptide by ELISA.  
Whilst the previous results were replicated when using the old, batch 1 peptide, there was 
no difference between the new batch 2 peptide and the DMSO controls (figure 4.3.7.1).  
Therefore, there was no response to the new batch of GDNQ peptide.  From this, it was 
suspected that either the new batch had been incorrectly synthesised, or that the old batch 
was somehow contaminated with another peptide.  
The two batches of peptide were also compared for their ability to stimulate ex vivo 
responses using IFN-γ capture assay.  Unsurprisingly, although GDNQ-batch 1 still led to high 
frequencies of CD4+ and CD8+ T cell responses, GDNQ-batch 2 did not lead to any response 
(figure 4.3.7.2).  Further batches of GDNQ were synthesised and tested, none of which could 
elicit any response. 
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Figure 4.3.7.1 Comparison of responses to new and old batches of GDNQ peptide 
CD4+ and CD8+ T cell clones were screened by IFN-γ ELISA for responses to the original 
GDNQ-batch 1 peptide and newly synthesised GDNQ-batch 2 which had been loaded onto 
partially HLA-matched VACH LCLs.  MAGE-A3 transfected and non-transfected lines were 
used and cell lines incubated with an equivalent volume of DMSO were negative controls for 
peptide recognition.  A representative CD4+ clone is shown.  Responses to GDNQ-batch 1 
were in excess of 2000 or 1500 pg/ml against MAGE-A3 transfected and non-transfected 
LCLs respectively.  However, when GDNQ-batch 2 was presented by the same target LCLs the 
values were similar to the negative control where no peptide was present.  
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Figure 4.3.7.2 IFN-γ capture assays comparing old and new batches of GDNQ peptide 
Ex vivo responses to batch 1 and batch 2 GDNQ peptides were compared by IFN-γ capture 
assay.  PBMCs freshly isolated from patient SS238PM were incubated with either batch of 
peptide.  Pre-enrichment frequencies (A) and the number of magnetically enriched cells (B) 
are compared.  Blue bars represent responses to GDNQ-batch 1 and the frequency/number 
of IFN-γ secreting cells following incubation with GDNQ-batch 2 would be in red, but no 
response was seen GDNQ-batch2 
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4.3.8 SS238PM patient and donor responses to CMV derived peptides 
As in-house tests on the GDNQ-batch 2 by mass spectrometry and the manufacturer’s data 
both suggested that the peptide had been correctly synthesised, attention was given to the 
possible source and identity of any contaminant.  Suspicion fell upon peptides derived from 
cytomegalovirus (CMV) as they are heavily used in the immediate environment of where 
GDNQ-batch 1 had been handled initially.  
Around this time, a blood sample was obtained from the HLA-matched, but unrelated stem 
cell donor for SS238PM.  Whilst establishing whether similar responses to GDNQ-batch 1 and 
E2-4 could be detected in the donor, a HLA-A2 restricted CMV peptide seen as a likely 
candidate for the contaminant was screened.  CD8+ responses were generated by this 
peptide, NLV (see table 4.2.1.1).  Responses to the CMV peptide were up to four times 
higher than to the GDNQ-batch 1 and E2-4 peptides (figure 4.3.8.1), although if it were this 
peptide causing the contamination, it would be present in much lower concentrations than 
where the pure CMV peptide was added.  Other CMV peptides tested did not elicit 
responses (data not shown). 
Further literature searches revealed that a previously described 15mer CMV peptide AGIL, 
contained the entire NLV sequence (see table 4.2.1.1).  This had also been used in the 
vicinity of GDNQ-batch 1 and would account for the observed CD4+ and CD8+ responses.  As 
a number of CD4+ T cell clones were growing that had been generated from, and had shown 
to be reactive to GDNQ-batch 1, they were tested for reactivity to this CMV peptide and also 
to a third batch of GDNQ.  This batch had been made in case the second batch had somehow 
been incorrect.  The data in figure 4.3.8.2 clearly shows that these clones respond to AGIL 
peptide, and there is no response to the new, higher-purity GDNQ peptide.  As two new 
batches of GDNQ peptide had not caused any reactivity either ex vivo, or by T cell clones, it 
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seemed likely that the original GDNQ-batch 1 had been contaminated with CMV peptide 
AGIL, and peptides E2-E4 were either also contaminated with this peptide, or possibly with 
the shorter NLV peptide.  This would explain the curious result described earlier (see figure 
4.3.4.1) where there was no response to an 11mer peptide which spanned all sequences of 
E2-E4. 
Interestingly, the clones still responded to the MAGE-A3 transfected DESA cell line.  An IFN-γ 
capture assay was set up with transfected and non-transfected DESA cells being used to 
stimulate PBMCs rather than peptides.  T cells produced IFN-γ in response to both cell lines, 
but the frequency was higher in response to the transfected cell line (figure 4.3.8.3A).  It 
would be as expected to find responses to both because it is likely that the patient would 
have T cells specific for EBV proteins which are expressed by LCLs.  It was encouraging to see 
a higher response to the transfected line.  The enriched fractions were cloned by limiting 
dilution and then tested for specificity (figure 4.3.8.3B).  It was interesting to note that the 
clones from VACH-M3 responding T cells appeared to have different patterns of recognition 
to those from cloned from VACH-EBV responses.  The non-transfected LCL generated clones 
recognised LCLs irrespective of peptide, which indicates they were responding to EBV 
protein.  However, the VACH-M3 generated clones responded to the transfected cell line, 
and also the LCL target cells only when AGIL peptide was present, but not GDNQ (batch 3).  It 
is not surprising that they would recognise the MAGE-A3 transfected line, but it seems that 
GDNQ is not the peptide responsible for this recognition.  However, it is puzzling that they 
also seem to respond to AGIL peptide.  It can also be observed that although the VACH-EBV 
generated clones recognise the non-transfected LCL, there was a lower concentration of 
cytokine produced in response to the transfected cell line.  The reason for this is unclear. 
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Figure 4.3.8.1 SS238PM stem cell donor responses measured by IFN-γ capture 
Freshly isolated PBMCs from the stem cell donor for S238PM were screened for CD8+ T cells 
specific for GDNQ-batch 1 and E2-4, along with CMV peptide NLV, by IFN-γ capture.  The 
CMV peptide was included as it was suspected that this was the contaminant in the MAGE-
A3 peptides.  Pre-sort frequencies (A) and the number of magnetically enriched IFN-γ 
secreting cells (B) are shown (both y-axis). 
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Figure 4.3.8.2 CD4+ T cell clone responses to pure GDNQ-batch 3 and CMV peptide AGIL 
CD4+ T cell clones generated by IFN-γ capture following stimulation with GDNQ-Batch1 were 
stimulated by a newly synthesised GDNQ peptide, and CMV peptide AGIL, which was 
thought to be the contaminant in earlier batches of GDNQ.  VACH LCL which had previously 
been shown to present GDNQ-Batch1 peptide (figure 4.3.6.1), and a partially HLA-matched 
LCL (KS114) were loaded with peptide, or incubated with an equivalent volume of DMSO and 
used to stimulate T cells.  MAGE-A3 transfected variants (VACH-M3 and KS114-M3) were 
similarly loaded for T cell stimulation.  Data from two representative clones (A and B) are 
shown. 
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 Figure 4.3.8.3 Ex vivo responses and T cell clones generated by stimulation with MAGE-A3 transfected & non-transfected cell lines 
VACH-M3 and VACH-EBV were used to stimulate PBMCs from patient SS238PM and the 
frequencies of responding T cells were measured by IFN-γ capture (A).  Pre-enrichment 
frequencies (pre-sort) and the numbers of IFN-γ secreting cells following magnetic selection 
(post-sort) are shown.  CD4 responses are on the left and CD8 on the right.  T cell clones 
were generated from both enriched fractions and reactivity against transfected and non-
transfected VACH and KS114PMd cell lines, either with peptides AGIL, GDNQ-batch 3 or 
DMSO
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DMSO was tested by IFN-γ ELISA (B).  The four clones on the left of the graph were 
generated from VACH-M3 stimulation and the four on the right, from VACH-EBV stimulation.  
Representative clones from each group shown. 
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4.3.9 Investigation of clone responses to MAGE-A3 
In an attempt to gauge whether the clones generated from SS238PM did in fact respond to 
any part of MAGE-A3, they were tested by IFN-γ ELISA, first against overlapping peptides 
spanning the whole length of the protein, and then against the whole protein.  The 
overlapping 15mer peptides began at every fifth amino acid and were arranged in pools of 
two peptides per well.  A previously characterised clone was used to screen the pools and 
higher levels of cytokine production would indicate any response (figure 4.3.9.1A).  
However, no obvious response was seen, with only one possibility being peptide 61.  The 
large error for this result suggested that it may be an artefact, and indeed, when further 
tests were conducted with that peptide, no response was seen (data not shown). 
Full-length MAGE-A3 protein was kindly supplied by Professor Pierre van der Bruggen and 
was used as a final test for recognition by the clones (figure 4.3.9.1B).  In this IFN-γ ELISA, the 
target cells were the transfected VACH-M3, and non-transfected VACH-EBV loaded either 
with MAGE-A3 whole protein, AGIL peptide or DMSO as a negative control.  As before, there 
were substantial responses to VACH-M3 and VACH-EBV loaded with AGIL. However, there 
was no response to the whole MAGE-A3 protein (labelled VACH-EBV+MAGE-A3).  Therefore, 
it is very unlikely that these clones are specific for MAGE-A3.  It is not clear why they 
responded to the VACH-M3 transfected LCL. 
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Figure 4.3.9.1 T cell clone reactivity to overlapping peptides and full-length MAGE-A3 protein 
In order to investigate whether T cells isolated from patient SS238PM could be specific for a 
peptide within MAGE-A3, previously characterised clones were tested by IFN-γ ELISA for 
recognition of overlapping 9mer peptides spanning the entire length of MAGE-A3, which 
were arranged in pairs (A).  Each pair was tested in duplicate and means are shown with 
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standard error.  Two clones were tested for reactivity to VACH-EBV loaded with full length 
MAGE-A3 protein by IFN-γ ELISA (B).  MAGE-A3 transfected (VACH-M3) and non-transfected 
(VACH-EBV) LCLs were loaded with either full-length MAGE-A3 protein or CMV peptide AGIL, 
which was the suspected contaminating peptide in early batches of GDNQ peptide.  Negative 
control cells were incubated with an equivalent volume of DMSO. 
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4.4 T cell responses to cancer/testis antigens can be detected post transplantation 
The main purpose of this arm of the study was address the question as to whether there was 
a detectable CTAg-specific T cell response in allograft patients who were being treated for 
acute myeloid leukaemia (AML) or multiple myeloma (MM).  The presence of these 
responses may well contribute to a wider graft-versus-leukaemia effect, which, given the 
highly restricted nature of expression of these antigens, may be a component that could be 
therapeutically enhanced to improve transplant outcome without GvHD complications. 
4.4.1 Cancer testis antigen-specific CD8+ T cell responses can be detected in patients 
following stem cell transplantation 
The interferon-gamma cytokine secretion assay was used to identify CTAg-specific T cell 
responses in response to a panel of 20 immunodominant peptides derived from 10 CTAg 
genes (see table 4.1.2).  Peptides were selected on the basis that they were derived from 
proteins for which RNA expression had previously been demonstrated in AML and/or MM, 
and that immunogenicity has been previously documented in patients with solid tumour 
malignancies (Boon and van der Bruggen, 1996).  Peripheral blood lymphocytes were 
isolated from patients at several time points post-transplant and were stimulated with CTAg 
peptides appropriate to the HLA genotype of the patient. 
Overall, CTAg-specific CD8+ T cells were identified post-transplantation in five patients.  The 
frequency of the CTAg-specific CD8+ T cell response was variable and ranged between 
0.0005% and 0.2% of the total CD8+ T cell pool.  The mean frequency of responses was 
0.045%, which equates to approximately 1 in 2000 CD8+ T cells and is comparable to the 
magnitude of many virus-specific immune responses.  Of the 20 patients who received 
reduced intensity conditioning with Campath, four had detectable CD8 responses to CTAg 
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peptides, whilst of the 21 who underwent myeloablative conditioning only one had CTAg-
specific CD8s (figure 4.4.1.1). 
The majority of CTAg-specific immune responses could be detected without the requirement 
for magnetic enrichment, although selection was used to increase the reliable sensitivity of 
the IFN-γ CSA procedure down to 0.0001%.  If a CTAg-specific response was only apparent 
after magnetic selection then the precursor frequency was calculated on the basis of the 
post-selection sample, although this approach tends to underestimate the true value due to 
cell loss during selection.  Responses could be detected serially in some cases and the 
absolute magnitude of the response varied at different time points in the post-transplant 
period.  
Patients were recruited to the study at a range of different time points in the post–
transplant period and the association between CTAg-specific immunity and time post-
transplant is discussed below.  
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Figure 4.4.1.1 Summary of patient samples screened 
The times of all screened samples are shown in weeks post-transplantation (x-axis).  Patients 
1-35 were treated for acute myeloid leukaemia (AML), and 36-41 for multiple myeloma 
(MM) (y-axis).  Assays where no responses were seen are shown as black squares and 
positive responses are shown in as open circles.  Samples screened after 165 weeks post-
transplantation are indicated by number.  A cross (†) denotes time of death of patients who 
died due to relapse, and a letter R shows where patients suffered relapse but were 
successfully treated and have survived.  The patients above the dotted line, with numbers in 
red, received Campath as part of their reduced intensity conditioning.  Patient 15 is shown in 
more detail in figure 4.4.2.1, patient 8 in figure 4.4.2.2, patient 10 in figure 4.4.2.3, patient 
13 in 4.4.3.2 and patient 37 in figure 4.4.3.1.  Where the first assay time point is to the left of 
the y-axis, the patient was screened prior to starting transplant conditioning. 
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4.4.2 CTAg-specific CD8+ T cell responses were observed in two patients with long term 
disease free survival 
RuH189PM 
CTAg-specific CD8+ T cells were detected in two patients within the first year following 
transplantation and both of these had undergone RIC allograft for AML (figure 3).  AML 
patient RuH189PM had a T cell response to RAGE-1 peptide SPSS and also to the peptide 
pool comprising ALKD/EGDC.  These responses were observed at 9 weeks post transplant 
which was the first time point of analysis.  Of note, the patient had suffered from grade IV 
graft-versus-host disease (GvHD) of the skin at 3 weeks post transplant and this had been 
treated with oral prednisolone.  The T cell response to SPSS was present at 5 separate time 
points of analysis until 51 weeks post transplant although the magnitude of the response 
was variable and was undetectable on 4 occasions.  Cyclosporine A (CsA) treatment had 
been discontinued at 27 weeks post-transplantation and this coincided with a transient 
increase in the RAGE-1 specific T cell response (figure 4.4.2.1).  
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Figure 4.4.2.1 Responses to CTAg antigens in patient RuH189PM 
Frequencies of T cells (y-axis) specific for either RAGE-1 peptide SPSS (red) or pools of MAGE 
peptides ALKD and EGDC (blue) were measured by IFN-γ capture in peripheral blood samples 
from AML patient RuH189PM.  The patient was screened at various time points up to 109 
weeks post-transplantation for SPSS responses.  An early incidence of grade IV skin GvHD 
was resolved around seven weeks post-transplantation.  The grey area indicates the period 
during which the patient received prophylactic cyclosporine treatment which was decreased 
over time until complete withdrawal.  
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AML patient JB235PM 
CTAg-specific T cells were detected in patient JB235PM at 17, 23 and 29 weeks post 
transplantation and this also coincided with tapering of CsA therapy, which was finally 
discontinued by 25 weeks.  However, at 20 weeks no response was detected (Figure 4.4.2.2). 
This patient was one of thirteen that were screened prior to starting transplant conditioning, 
although no pre-transplant responses were detected. 
 
Importantly, patients RuH189PM and JB235PM have remained in remission since 
transplantation and now remain disease free at 52 and 37 months post transplant 
respectively.  Overall, there were 14 patients who were screened for CTAg-specific immune 
responses on two or more occasions within the first year post-transplant and who had 
relapse free survival.  As CTAg-specific T cells were observed in two of these, we were able to 
demonstrate immunity to this relatively limited CTAg peptide panel in 14.3% of this group.   
Attempts were made to expand the CTAg-specific T cells from the enriched, peptide-
stimulated fraction by limiting dilution cloning (Chapter 2, section 2.8), in order to further 
characterise the cells.  Unfortunately, no clones grew which may be attributable to the cells 
being more fragile early post-transplantation, and the magnetic selection process may have 
damaged them further. 
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Figure 4.4.2.2 CTAg-specific T cell frequencies in patient JB235PM 
The magnitude of the T cell response (y-axis) to MAGE-A2/3 peptide EGDC over time (x-axis) 
in AML patient JB235PM was measured by IFN-γ capture assay of peripheral blood samples.  
The grey area indicates the time of prophylactic administration of cyclosporine and the 
tapering period before complete withdrawal is shown by the slope.   
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AML patient JT138PM 
Screening began on an additional AML patient (JT138PM) at 92 weeks post transplant and a 
T cell response was observed against peptides ALKD and EADP but not detected thereafter 
(figure 4.4.2.3).  This patient has also remained relapse free during follow up.  
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 Figure 4.4.2.3 CTAg-specific T cell frequencies in patient JT138PM 
Patient JT138PM was screened from 92 weeks post-transplatation for the presence of CTAg-
specific T cells by IFN-γ capture.  CD8+ T cells responding to MAGE peptides ALKD/EADP 
were detected, although the response was near the level of detection of the assay, and 
subsequently, no response was evident.  Prophylactic cyclosporine treatment is shown by 
the grey area, and the tapering of this treatment prior to complete withdrawal is indicated 
by the slope. 
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4.4.3 CTAg-specific T cell responses can also be detected at the time of disease relapse 
MM patient TS125PM 
Previous studies of CTAg-specific immunity in patients with myeloma have revealed that 
CD8+ responses are often observed around the time of disease relapse and probably reflect 
immune response to increased tumor load (Goodyear et al., 2008).  A similar pattern was 
observed in patient TS125PM with a diagnosis of MM who was initially studied at a time 
point over 2 years after SCT with a myeloablative conditioning regimen.  The serum 
paraprotein level had risen at 124 weeks post-transplant and indicated the onset of disease 
relapse.  The first CTAg analysis was undertaken 10 weeks after this point and revealed a 
broad CTAg peptide-specific immune response which included specificity for peptides in 
three different peptide pools and included reactivity against the peptide EGDC.  The patient 
was treated with thalidomide and the next sample was taken at 143 weeks at which time the 
magnitude of the EGDC-specific response had fallen by 60% and responses to other peptide 
pools were not observed.  The patient responded well to thalidomide with a reduction in the 
paraprotein level, and no CTAg-specific immune response could be detected in subsequent 
analyses. (figure 4.4.3.1).  
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Figure 4.4.3.1 CTAg-specific responses in patient TS125PM 
A time course of responses to CTAg peptides and peptide pools (red, grey, blue and green 
lines) measured by IFN-γ capture assay of peripheral blood samples from myeloma patient 
TS125PM is shown along with paraprotein concentration (purple line, right y-axis).  Duration 
of thalidomide treatment of the relapse is shown in green.  Prophylactic cyclosporine 
therapy is indicated by the grey area, with the slope denoting the period during which this 
was tapered prior to complete withdrawal. 
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AML patient NC172PM 
Patient NC172AM with a pre-transplant diagnosis of AML was screened from 38 weeks post-
transplant and responses were seen at 53 weeks to peptides SLFR, EGDC and MEVD.  At 55 
weeks the patient was diagnosed with relapse of AML and died shortly afterwards (figure 
4.4.3.2).  
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Figure 4.4.3.2 Responses to CTAg peptides in patient NC172PM 
CTAg-specific CD8+ responses (y-axis) were measured by IFN-γ capture assay carried out on 
peripheral blood samples from AML patient NC172PM.  Screening commenced at 37 weeks 
post-transplantation and responses were detected on one occasion shortly before diagnosis 
of relapse.  The patient subsequently died as indicated by the cross.  The period of 
prophylactic cyclosporine therapy is indicated by the greyed area and the slope denotes the 
time over which this therapy was tapered prior to complete withdrawal. 
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4.4.4 RAGE-1 specific T cells can be detected at higher frequency within bone marrow 
compared to peripheral blood 
Paired blood and bone marrow samples from patient RuH189PM were obtained at 35 and 51 
weeks post-transplantation.  T cells specific for SPSS were detected by IFN-γ cytokine 
secretion assay and the frequency was found to be up to seven times higher in bone marrow 
compared to PBMC. In peripheral blood, at both 35 and 51 weeks, 0.0006% of CD8+ T cells 
were specific for SPSS, whereas in the bone marrow, the frequencies were 0.0021% at 35 
weeks and 0.0042% at 51 weeks (figure 4.4.4.1).  
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Figure 4.4.4.1 Comparison of CTAg-specific CD8+ frequencies in blood and bone marrow 
Paired blood and bone marrow samples were obtained on two occasions from AML patient 
RuH189PM and screened by IFN-γ capture assay for T cells specific for RAGE-1 peptide SPSS. 
IFN-γ secreting CD8+ T cell frequencies (y-axis) following peptide stimulation are shown in 
peripheral blood (blue bars) and bone marrow (red bars) 35 and 51 weeks.   
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4.4.5 The CTAg-specific CD8+ T cell response post-transplantation is preferentially focussed 
on peptides derived from the MAGE family of proteins 
20 CTAg peptides were used in this study and T cell responses within SCT patients were 
detected against 6 of these.  Interestingly, immunity was focussed on peptides derived from 
the MAGE family of proteins and four patients showed T cell immune responses against 
peptide EGDC (figure 4.4.5.1).  Overall, CD8+ T cell responses were observed against 
peptides derived from the MAGE subfamily proteins A1, A2, A3 and C2, and a strong immune 
response against RAGE-1 was also observed in one patient.  
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Figure 4.4.5.1 Numbers of patients with responses to each peptide 
All peptides used to screen transplant patient responses to selected CTAg proteins (y-axis) 
are shown.  Blue bars indicate number of patients (x-axis) that responded to each peptide, 
either singly or as a component of a pool, when used in an IFN-γ capture assay to stimulate 
PBMCs isolated from blood samples taken from AML or MM patients following 
transplantation. 
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4.4.6 Detection of CTAg-specific T cells using CD137 assay 
Frozen PBMC samples were available for some patients, taken at various times post-
transplantation.  The IFN-γ capture assay does not work with previously frozen cells and as 
colleagues had recently been using up-regulation of CD137 as a measure of antigen 
responsiveness, it was decided to try this assay to test frozen samples for the presence of 
CTAg-specific T cells.  CD137 is transiently up-regulated on T cells following contact with 
antigen and antigen-specific T cells have successfully been identified and sorted using this 
marker (Wehler et al., 2008). 
The method is described fully in Chapter 2 (section 2.14), but in brief: cryopreserved PBMCs 
were thawed, washed and resuspended at 1x107 cells/ml in T cell culture medium (RPMI, 
10% human serum, 0.5% penicillin/streptomycin, 0.5% L-glutamine).  Cells were incubated 
with CTAg peptide for 24 hours (37oC, 5% CO2) and then stained with CD137 antibody, 
conjugated to PE, along with CD3APC-Cy7 and CD8-AmCyan to identify T cells.  CD14-ECD, 
CD19-ECD, CD56-PC7 and PI were also added to exclude other cell populations and dead 
cells.  Responding cells could either be assessed directly by flow cytometry or enriched using 
PE-microbeads.  Example dot plots showing the gating strategy and results for one patient at 
one time-point are shown in figure 4.4.6.1. 
Samples from two patients with IFN-γ responses were screened in this way. PBMCs isolated 
from JB235PM at 5,10,13,29 and 40 weeks, along with those from JT138PM at 6, 13, 20, 25 
and 33 weeks post-transplantation were screened.  In the 10 week sample from JB235PM, 
0.31% of CD8+ T cells fell in the CD137+ region against a background of 0.1%.  However, this 
‘population’ did not enrich (figure 4.4.6.2).  In some IFN-γ capture assays there had been an 
apparent response that did not enrich, and the assay manufacturer said these were unlikely 
to be real responses (J. Campbell - personal communication).  As the same enrichment 
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system was used for this assay, this was not considered a positive response.  No convincing 
responses were observed above background 
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Figure 4.4.6.1 Example of CD137 assay for identification of CTAg specific T cells 
A representative example of a CD137 assay, showing the gating strategy and staining.  
Cryopreserved PBMC isolated from AML patient JB235PM were thawed and stimulated for 
20 hours with MAGE-A2/A3 peptide EGDC.  Antibodies specific for CD137, CD3, CD8, CD14, 
CD19 and CD56 were added.  The lymphocyte population (A) was gated, then CD14+, CD19+ 
and dead (PI+) cells were excluded (B).  NK cells were gated out by excluding the CD3- CD56+ 
population (C). CD137 expressing cells CD8+ T cells can be seen in region P4 (D, left) and 
magnetic beads were used to enrich this population (D, right).  The lack of enriched cells 
casts doubt on the validity of the apparent CD137+ population in the non-enriched fraction.  
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Figure 4.4.6.2 Demonstration of false-positives in non-enriched fraction of a CD137 assay 
Cryopreserved PBMCs were thawed and stimulated overnight with CTAg peptide EGDC 
(lower) or an equivalent volume of DMSO (upper) before being stained with CD137 (x-axis) 
and CD8 (y-axis) specific antibodies.  Magnetic beads were used to enrich the CD137+ 
population (right).  CD8+ CD137+ T cells are shown in the region P4.  The lack of enriched 
cells casts doubt on the validity of the non-enriched fraction. 
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4.4.7 Peptide restimulation cultures 
All screening assays had been conducted ex vivo with peptide incubations of sufficient 
duration to induce specific T cells to respond.  In a further attempt to generate CTAg-specific 
T cell clones, PBMCs from patients RuH189PM and JB235PM were cultured for up to four 
weeks with weekly peptide restimulation.  This approach was not taken with all screening as 
the potential to influence naive T cells to be responsive to the peptide, and any preferential 
expansion of specific cells would have prejudiced the frequencies, preventing establishment 
of the proportion of CTAg immunity in vivo. 
JB235PM 
Fresh PBMCs were isolated from a blood sample taken at 112 weeks post-transplantation.  A 
peptide-TCL line was set up according to the method outlined in Methods (Methods 2.15).  
EGDC peptide was added to a final concentration of 10µg/ml at weekly intervals until four 
weeks had elapsed.  The cells were then harvested and tested for the presence of EGDC-
specific T cells by IFN-γ capture (figure 4.4.7.1).  Despite there being no apparent response 
above background, half of the post-selection fraction was cloned by limiting dilution 
(Methods 2.8) in case there were specific cells present. No T cell clones grew. 
RuH189PM 
Cryopreserved PBMCs taken at 11 weeks post-transplantation were thawed and a T cell line 
was set-up, stimulated with SPSS peptide (as in previous section).  A strong response had 
previously been detected at 9 weeks post-transplant using fresh PBMCs.  Peripheral blood 
had been taken and frozen at 7 weeks, which contained a large number of stem cells, 
possibly resulting from G-CSF treatment.  In order to stimulate the T cell line during culture 
and for IFN-γ capture, these stem cell rich aliquots were thawed and loaded with peptide.  
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To ensure their suitability for peptide loading, MHC class I levels were assessed by flow 
cytometry and judged to be sufficient.  Following IFN-γ capture, no clear response was 
shown.  However, attempts were made to clone the post-selection fraction to see if any SPSS 
specific T cells could be cultured.  A few wells grew and were expanded further before 
testing for specificity by IFN-γ ELISA.  The clones secreted IFN-γ at concentrations of up to 
900pg/ml, with most in the range of 400-700pg/ml.  However, background levels of cytokine 
production in response to negative controls (LCL without peptide and no stimulation) were 
greater than 50% of peptide loaded LCLs so no clones were considered to be specific for 
SPSS (figure 4.4.7.2). 
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Figure 4.4.7.1 AML patient JB235PM T cell line restimulation experiment 
Freshly isolated PBMC from AML patient JB235PM at 112 weeks were cultured for four 
weeks at 37oC 5% CO2, and were stimulated by addition of MAGE-A2/A3 peptide EGDC at 
weekly intervals.  The line was harvested and split, before addition of EGDC peptide (bottom 
row) or an equivalent volume of DMSO to establish background levels of IFN-γ production 
(top row).  The presence of EGDC specific T cells was assessed by IFN-γ capture assay.  
Magnetic beads were used to enrich any IFN-γ secreting population.  Pre-selection dot plots 
are on the left with frequencies of IFN-γ producing cells, and post-selection on the right with 
the number of IFN-γ producing cells marked. 
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 Figure 4.4.7.2 ELISA screen for specificity of clones generated from RuH189PM 
T cell clones were generated from cryopreserved PBMC isolated from AML patient 
RuH189PM at 11 weeks post-transplantation, by weekly stimulation over four weeks with 
SPSS peptide and IFN-γ capture assay with magnetic enrichment.  Specificity of T cell clones 
was assessed by IFN-γ ELISA.  Targets were HLA-matched LCLs loaded with SPSS peptide 
(blue bars) or unloaded as a negative control (red bars), and T cells alone were used as a 
further negative control (yellow bars).  Concentration of IFN-γ is shown on the y-axis in 
pg/ml. 
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4.4.8 Immunohistochemistry 
Having established that there was T cell immunity to MAGE family proteins in certain 
patients, an antibody to MAGE-A was used to investigate expression of these CTAgs in the 
patients’ bone marrow trephines by immunohistochemistry.  Sections of diagnosis biopsy 
were obtained, mounted on slides, from the pathology department of the Queen Elizabeth 
Hospital, Birmingham.  These were stained according to the protocol outlines in Methods 
Section 2.13, using an anti-MAGE antibody (Invitrogen, Paisley, UK).  A positive control of a 
known MAGE expressing tissue was stained alongside each patient.  A sample of one patient 
and a positive control is shown in figure 4.4.8.1.  
The slides were examined under a light microscope and assessed for positive staining.  The 
results were unclear so a second opinion was sought from an expert pathologist at 
Birmingham Heartlands Hospital.  All patient samples were considered negative with little 
evidence of malignant cells. 
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Figure 4.4.8.1Staining for MAGE-A expression by immunohistochemistry 
Slide mounted bone marrow biopsy samples from patients with CTAg responses were 
obtained from the pathology department of the Queen Elizabeth hospital, Birmingham.  The 
samples were stained with an isotype control antibody (A) or an antibody specific for the 
MAGE-A family of CTAg proteins (C).  Testis samples, which naturally express MAGE-A3, were 
also stained with the isotype (B) and MAGE-A antibody (D). 
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4.4.9 CTAg immunity in non-transplanted AML patients 
Thirteen study patients were screened prior to beginning their transplant conditioning (see 
figure 4.4.1.1).  A further seventeen AML patients were recruited from the Clinical 
Haematology department of the Queen Elizabeth Hospital, Birmingham.  Blood samples 
were taken either during attendance at a clinic appointment, or from in-patients when 
lymphocyte counts recovered following chemotherapy.  Samples with extremely high levels 
of blast cells were generally avoided as it was felt that those cells would affect the efficacy of 
the assay.  In some cases, attempts were made to remove these cells by plastic adhesion, or 
magnetic selection with CD34 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany).  
However, these methods proved to have limited effect.  After many adhesion steps, the 
number of tumour cells was still far too high.  The volume of CD34 microbeads required to 
treat such a high cell concentration was prohibitively expensive, and it was found that less 
than 10% of blast cells expressed CD34 so making this approach would have had little 
benefit. 
Screening of the non-transplanted cohort was carried out in the same way as the post-
transplant group.  Only one sample was available from most patients, but in some cases, 
serial analysis of more than one sample was possible.  If the pre-transplant assays are 
grouped with the non-transplanted cohort then the total number screened was 30.  IFN-γ 
secreting T cells were detected in only one of these patients on one occasion to a pool of 5 
CTAg peptides (data not shown).  The patient was duly followed up after further 
chemotherapeutic treatment but no further responses were observed.  It was not possible 
therefore to verify the response and establish which peptide elicited the response in that 
patient. 
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4.5 DISCUSSION 
Allogeneic stem cell transplantation is a widely used procedure for treatment of 
haematological malignancies and other bone marrow disorders which is increasingly being 
considered as a strategy for treatment of solid tumours such as breast cancer (reviewed in 
(Bregni et al., 2004)).  Success of the transplant is thought to require an effective graft versus 
leukaemia (GvL) effect (Collins et al., 1997, Horowitz et al., 1990, Kolb et al., 1995, Porter et 
al., 1999) which also carries the risk of graft versus host disease (GvHD) complications 
(Billingham, 1959, Lee et al., 2002).  Allograft patients have a decreased risk of relapse 
compared to stem cell transplant patients who receive their graft from an identical twin, 
although the latter group are less likely to experience GvHD.  This suggests that both GvHD 
and GvL could be T cell mediated, and the presence of tumour reactive T cells has been 
shown previously (Montagna et al., 1998).  However, the targets of anti-tumour T cells have 
not been well characterised, so identifying these may enable tumour-directed 
immunotherapy to boost anti-tumour immunity without the risk of increasing GvHD.  Cancer 
testis antigens (CTAgs) could be attractive targets for anti-tumour immunotherapy due to 
their highly restricted tissue expression.  In healthy individuals, they are only expressed on 
germline cells which lack MHC molecules and are therefore considered immune privileged 
sites.  45 allograft patients were studied for the presence of CTAg-specific T cells and these 
responses were found in 11.1%.  The frequencies ranged from 0.0005% to 0.2%, with a 
median 0.024% and mean of 0.045%, although the responses were not always detectable.  
In two AML patients (RuH189PM and JB235PM), CTAg-specific T cells could be detected just 
after the cessation of immunosuppressive therapy.  Following immune suppression, a 
general increase in immune activity occurs.  It is possible that if these T cells were present at 
such a low frequency as to be normally below the level of detection of the assay, then such 
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an increase in immune activity could result in a transient expansion of this cell population, 
making detection possible.  In CTAg vaccine trials for metastatic melanoma, tumour 
regression has been demonstrated even though it was not always possible to detect tumour-
specific T cells, leading to the idea that very low numbers of T cells are required for an 
effective anti-tumour response (Boon et al., 2006, Lonchay et al., 2004).  This may explain 
why the T cells were not seen at all time points. 
CTAg-specific T cells were observed in an AML patient (NC172PM) 2 weeks prior to a 
diagnosis of relapsed disease, and in a myeloma patient (TS125PM) shortly after relapse.  It 
may be that the increased presence of tumour in these patients resulted in a higher 
frequency of T cells, which were then detectable.  Patient NC172PM did not survive 
following relapse, but had also suffered a number of complications including graft failure.  
Although the relapsed myeloma patient has remained stable since, definitive conclusions 
cannot be drawn about whether such responses could aid survival or be an indication of 
disease as the patient was treated with thalidomide for the relapse, and it is not known if 
CTAg-specific T cells could have been detected before relapse.  A previous study in 106 
myeloma patients detected humoral responses to CTAgs post-stem cell transplantation, and 
found in one relapsed patient, T cell responses to NY-ESO (Atanackovic et al., 2007).  This 
study has found CD8+ T cells which respond to MAGE-A2 and pools of peptides from MAGE-
A1 and MAGE-C2 in one relapsed myeloma patient.  It may be the case that following 
relapse, where there is an increased number of tumour cells, there could be more antigen 
present to stimulate an immune response. 
Paired blood and bone marrow samples were obtained from one of the responding AML 
patients, and frequencies of CTAg-specific CD8+ T cells were found to be up to seven times 
higher than in peripheral blood.  If there are residual tumour cells present, they are most 
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likely to reside in the bone marrow cavity and therefore within this site, there would be 
more antigen to elicit T cell responses.  
This study, nevertheless, has shown for the first time, T cell responses to CTAgs in AML 
patients following allogeneic stem cell transplantation.  Due to the nature of the screening 
assay, we could only screen for a limited panel of CTAg peptides, which may have resulted in 
underestimating the number of AML patients who could have CTAg-specific T cells.  Reliance 
of IFN-γ secretion to detect responding cells may have led to an incomplete picture of the 
breadth of responses and further underestimation of the frequencies of responses.  Future 
studies would perhaps utilise another marker such as CD137 upregulation which would 
detect cells responding by means other than IFN-γ secretion.  This may be particularly 
important when establishing the role of CD4+ T cells in the GvL response. 
Previous studies have reported different findings when investigating RNA expression of 
CTAgs in AML (Adams et al., 2002, Chambost et al., 2001, Martinez et al., 2007).  This may be 
due to the function of these genes.  It has been hypothesized that CTAgs have a role in 
tumour progression closely related to their reproductive system function.  Their expression 
is transient in spermatogonia and is lost on differentiation into sperm cells.  Similarly it may 
be that cancer stem cells express CTAgs which are lost as cancer cells differentiate (Old, 
2007).  This could explain huge differences between the numbers of myeloma patients who 
have CTAg-specific T cells as shown in previous studies by colleagues (Goodyear et al., 2005, 
Goodyear et al., 2008) and the number of non-transplanted AML patients.  Another study in 
this institute has found that AML cell lines express fewer CTAgs than myeloma cell lines 
(Goodyear et al., 2010).  Therefore, CTAg expression may be more transient in AML due to 
the acute nature of the condition compared to myeloma.  If leukaemic stem cells express 
CTAgs whereas AML blasts are less likely to, then it is tempting to speculate that this is 
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reflected in the observation of higher frequencies of CTAg-specific T cells in the bone 
marrow of AML patients.  Transient expression on selected cells may also account for the 
lack of MAGE antibody staining in the immunohistochemistry study. 
These data raises the possibility that following transplantation, if there are low numbers of 
residual leukaemic stem cells present expressing CTAgs, immune responses can be directed 
against these antigens and contribute to a graft versus leukaemia effect. 
The experience with the contaminated GDNQ peptide shows the importance of keeping an 
open mind about unexpected results, in this instance the implausibly high frequency 
responses that well out of the range of ‘usual’ tumour antigen responses.  It was tempting to 
speculate that it was an extraordinarily good finding, but the frequencies were very much 
higher than reported responses to other tumour antigens, and the thorough investigation 
into the nature of those responses strongly suggested that there was a contamination, which 
when identified was disappointing.  However, it is satisfying that erroneous results were not 
reported. 
Somewhat surprisingly, the majority of T cell responses were specific for peptides derived 
from MAGE proteins.  Although some studies found that MAGE was not expressed in AML 
(Chambost et al., 2001, Meklat et al., 2007), mRNA expression was demonstrated (Adams et 
al., 2002, Martinez et al., 2007).  The fact that MAGE expression is highly restricted to 
germline cells and malignant tissue is likely to dictate that MAGE-specific immune responses 
are manifest as a GvL response rather than GvHD.  
In conclusion, CTAg-specific CD8+ T cells have been demonstrated in patients following 
reduced intensity stem cell transplantation.  The possible association between the early 
detection of such an immune response and prolonged disease remission provides support 
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for the concept that CTAg-specific immunity plays an important role in GvL.  Further studies 
are now indicated to explore the potential for enhancing CTAg-specific immunity in the post-
transplant setting.  
Locally managed clinical trials to investigate the anti-tumour, and GvL enhancing potential of 
treating AML (non-transplanted or transplanted) patients with a demethylating agent, 5-
azacytidine, with a histone deacetylase inhibitor (HDACi) in order to upregulate tumour 
antigens such as CTAgs, is being carried out.  Early monitoring of the non-transplanted 
cohort of patients for responses to CTAg antigens was carried out as part of this study, 
although no responses were seen.  However, monitoring was subsequently taken over by 
the dedicated trial team, and after several rounds of treatment, an increased frequency of 
patients developed CTAg-specific responses (Goodyear et al., 2010).  This provides further 
evidence that CTAgs can elicit immune responses and for the exciting possibility that their 
expression can be pharmacologically enhanced for the benefit of patients. 
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5.1 Introduction 
A recently defined subset of CD4+ T cells, principally characterised by secretion of the 
cytokine IL-17A, has been shown to form part of the normal inflammatory response 
(Harrington et al., 2005, Langrish et al., 2005, Park et al., 2005).  This subset, known as 
Th17 cells, has been implicated in a number of inflammatory conditions (Barczyk et al., 
2003, Kirkham et al., 2006, Krueger et al., 2007, Matusevicius et al., 1999, Molet et al., 
2001, Pene et al., 2008) and there is much interest as to whether manipulating the role of 
the Th17 subset in inflammation could be a viable treatment strategy for such conditions. 
Graft-versus-host disease (GvHD) is a continuing clinical challenge to patients undergoing 
allogeneic stem cell transplantation (SCT) to treat haematological malignancies, and there 
have been attempts to ascertain the potential role of this Th17 lineage in the 
pathogenesis of the disease.  Studies carried out in mouse models have reported 
conflicting findings.  In some models the Th17 subset was found to have a causative role 
in the development of GvHD (Carlson et al., 2009), whereas others have shown that 
continued IL-17A production is not required to sustain GvHD (Kappel et al., 2009).  
Another study proposed that the presence of Th17 cells from the donor in the allograft 
could in fact have a protective effect and lead to suppression of GvHD (Yi et al., 2008).  
There has been recent literature challenging the traditional notion that once a T cell’s 
lineage has been determined, then it is irreversibly committed.  It has been shown that it 
is possible for a Treg to differentiate into Th17 (Koenen et al., 2008) and this raises the 
possibility that it could happen in reverse.  This may be the basis for the presence of Th17 
cells in the allograft leading to reduced GvHD in the previously highlighted mouse model.  
Such a change may well depend on the immune environment within the recipient.  It has 
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been proposed that a key factor in the development of both acute and chronic GvHD is a 
decreased frequency of Tregs (Chen et al., 2007). 
The purpose of this study was to investigate the presence of Th17 lineage cells in human 
allograft patients, to characterise their chemokine profiles and relate the frequencies to 
those of Th1 and Treg cells during and before/after episodes of GvHD. I also investigated 
the serum levels of these cytokines in relation to GvHD. 
 
5.2 Optimisation of Foxp3 and Th17 intracellular staining 
The samples used in this study had been collected from patients attending a bone 
marrow transplant clinic at the Queen Elizabeth Hospital, Birmingham.  Ethical approval 
had been received for the collection of 50ml peripheral blood every two weeks from 
allograft patients.  Lymphocytes were isolated from the fresh samples, on the day of 
collection, according to the protocol outlined in Chapter 2 (see Methods 2.1.3).  The cells 
were cryogenically preserved in a liquid nitrogen storage facility.  Clinical information 
about whether a diagnosis of GvHD had been made was recorded.  This was a 
retrospective study and in many cases only a small number or single samples were 
available.  Therefore, in order to prevent wasting precious samples, the assays were 
tested using cryogenically preserved PBMCs from healthy donors. 
The two intracellular staining protocols used were described in detail in Chapter 2 (see 
2.3 & 2.4).  Foxp3 staining was carried out using a Foxp3 staining and buffer kit 
(eBioscience, Hatfield, UK) and the Th1 / Th17 experiments used an established protocol 
with monensin as a protein transport inhibitor, paraformaldehyde as a fixative and 
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saponin for permeablisation.  The antibody panels are summarised here in table 5.2.  All 
analysis was carried out using a BD LSRII flow cytometer with BD FACS DiVa software (BD 
Biosciences, Oxford, UK).  CD4+ T cells were selected by gating on the CD3+ CD8- 
population in order to avoid results bias resulting from CD4 downregulation following 
activation.  Live/Dead Fixable Red dye (Invitrogen, Paisley, UK) was used to exclude dead 
T cells. 
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FoxP3 Panel Ab Manufacturer Th1&17 Panel Ab Manufacturer 
CD127-FITC eBioscience CXCR3-PE BD Bioscience 
Foxp3-PE eBioscience CCR4-PC7 BD Pharmingen 
CD25-PC5 Beckman Coulter IL-17A-Pacific Blue Biolegend 
CD4-PC7 eBioscience CD8-AmCyan BD Biosciences 
CD8-Pacific Blue eBioscience CCR6-APC R&D Systems 
CD45RA-AF 700 Biolegend IFN-γ AF-700 Biolegend 
CD3-APC-Cy7 Biolegend CD3 APC-Cy7 BD Biosciences 
 
Table 5.2 Antibody panels used for Treg / Th1 / Th17 staining 
Antibody panels used for identification and characterisation of Foxp3+ Tregs (left), or 
Th1 and Th17 cells (right). 
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5.2.1 Testing of assays on healthy donors 
The basic antibody panel and kit used to identify Tregs had already been established in 
this laboratory, but minor modifications were verified with healthy donor PBMCs, prior to 
use with patient samples (figure 5.2.1.1).  The conjugated antibodies used for the Th1 & 
Th17 panels were selected so as to avoid high degrees of spectral overlap.  Antibodies 
were titrated, and then tested in combination to optimise concentrations and build an 
analysis protocol for the LSRII (figure 5.2.1.2).  The Th17 gating strategy was to first select 
the lymphocyte population, then exclude cells stained with the dead cell exclusion 
marker.  A gate was then used to select the population that was CD3+CD8-.  The relative 
proportions of Th17 cells were established by IL-17A secreting cells, and Th1 by those 
producing IFN-γ.  Cells that secrete both cytokines have been described in literature as 
Th17-1 (Dhodapkar et al., 2008) and were double-positive in this staining.  Gating on each 
of those populations allowed the frequencies of chemokine receptors CCR4, CCR6 and 
CXCR3 to be established for each subset.  In some experiments, CCR6-FITC was used in 
place of CCR6-APC. 
The transcription factor Foxp3 is widely accepted to be the gold standard marker used to 
recognise Tregs by antibody staining, and the equivalent transcription factor responsible 
for IL-17A production has been shown to be RORγt (Ivanov et al., 2006).  During the 
course of this study an antibody to this protein became commercially available.  Despite 
the manufacturer’s statement that they had only been able to stain in vitro generated 
Th17 cells, a trial sample was available so it was decided to try the antibody on ex vivo 
samples to see if it could be used to back up IL-17A cytokine staining.  However, it proved 
to be ineffective in this situation (figure 5.2.1.3).  CD4+ IL-17A+ T cells were not positive 
for RORγt when using this antibody. 
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Some protocols suggest that PBMCs should be ‘rested’ in culture medium for a few hours 
or overnight before use in an experiment.  However, this may lead to cells dying or 
becoming anergic.  In order to investigate this, an experiment was carried out to compare 
intracellular cytokine staining for IL-17A and IFN-γ, between a sample rested overnight 
and one used immediately after thawing.  Both samples were aliquots of one donation 
from a healthy donor, and had hitherto been treated identically.  There was an apparent 
decrease in detection of IL-17A secreting cells from 0.6% to 0.4% and the frequency of 
IFN-γ secreting cells was reduced by almost half from 13.4% to 7.6% when cells were 
rested.  The proportion of cells secreting both cytokines was 0.2% without resting, but fell 
to <0.1% when the assay was delayed (figure 5.2.1.4). 
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Figure 5.2.1.1 Gating strategy for identification of Foxp3+ CD4+ T cells by flow cytometry 
Cryopreserved healthy donor PBMCs were thawed and stained using a Foxp3 staining kit 
(eBioscience).  The lymphocyte population was identified on a foward-scatter (FS) / side-
scatter (SS) plot and gated (A).  All subsequent plots were descendents of this gate.  The 
CD3+ CD4+ population was then gated (B) and the percentage of Foxp3+ T cells in the whole 
CD4+ T cell population could be determined (C).  CD25 and CD127 were plots were drawn 
from the CD3+CD4+ population (D) and the frequency of Foxp3+ cells in CD25hi CD127lo (E) 
and CD25lo CD127hi (F) populations could be measured. 
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 Figure 5.2.1.2 IFN-γ and IL-17A staining of healthy donor PBMCs  
Intracellular cytokine staining for IL-17A and IFN-γ was carried out on PMA/Ionomycin 
stimulated, cryopreserved PBMCs from a healthy donor.  The lymphocyte population was 
gated using a forward scatter (FSC) / side scatter (SSC) plot (A) and then dead cells were 
excluded by gating on the population negative for Live/Dead Red stain (B).  All further gating 
was carried out on this population.  CD4+ T cells were selected by gating on CD3+ CD8- cells 
(C).  IFN-γ and IL-17A were plotted against each other and then gates were drawn around 
Th17 (D) or Th1 cells (E) for further characterisation. 
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Figure 5.2.1.3 Commercially available RORγt antibody does not stain IL-17A secreting cells 
Intracellular cytokine staining was carried out on healthy donor PMA/Ionomycin stimulated 
PBMCs, which were stained with CD4-FITC and either RORγt-PE antibody (A) or a 
combination of RORγt-PE and IL-17A-Pacific Blue (B) to investigate whether this 
commercially available RORγt antibody could co-stain IL-17A secreting cells. 
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Figure 5.2.1.4 Effect of ‘resting’ thawed PBMC samples prior to intracellular cytokine staining 
Flow cytometric plots of IL-17A and IFN-γ intracellular cytokine staining (ICS) of gated CD4+ 
(CD3+ CD8-) T cells.  PBMCs were isolated from a healthy donor and cryopreserved.  One 
aliquot was thawed and incubated overnight at 37oC 5% CO2 prior to ICS (A), and another 
was thawed immediately prior to ICS (B).  Both assays were carried out concurrently.  
Frequencies of IL-17A (upper left quadrant), IFN-γ (lower right quadrant) or IL-17A/IFN-γ 
(upper right quadrant) are shown. 
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5.2.2 Testing of compensation beads as a replacement for cell compensation controls 
The BD LSRII flow cytometer has an autocompensation facility for effective compensation of 
large antibody panels.  Some drawbacks to using cells to compensate are that precious cells 
that could be used for analysis are diverted to set-up the equipment, and rare antigens may 
not lead to sufficient fluorescence for accurate compensation.  To overcome these 
problems, compensation beads may be used, which are polystyrene microparticles which are 
designed to have similar fluorescent properties to lymphocytes.  They bind any kappa light 
chain-bearing immunoglobulin.  Therefore, they overcome the problem of low antigen 
expression to provide a sufficiently bright staining control.  The relatively stable binding of 
antibodies to these beads means they could potentially be used on more than one occasion.  
Tests were carried out to determine the stability of these antibody/bead complexes over 
time (figure 5.2.2.1).  The compensation was sufficiently comparable between beads and 
cells and the positions of the peaks for compensation beads did not change over 10 days.  
After 19 days, it was observed that there were shifts in peaks for some fluorochromes, and 
some conjugates had deteriorated.  It was decided that one set of compensation beads 
could be used for multiple experiments for up to one week.  A problem did occur with the 
negative population shifting away from the axis leading to autocompensation errors for 
some fluorochromes.  However, after discussions with the software manufacturers, a gating 
strategy was developed to accurately define the negative population which overcame this. 
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 Figure 5.2.2.1 Compensation bead/antibody complex stability over time 
Comparison of peak fluorescence (x-axis) between compensation beads run fresh and on day 
10 of refridgerated storage, for all fluorochromes used in staining panels. 
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5.3 Determination of T cell subsets in GvHD patients by intracellular cytokine 
staining 
The main purpose of this study was to establish whether there was any relationship between 
frequencies of Tregs, Th1, Th17 T cell frequencies and the occurrence of GvHD.  Three 
cohorts of patients were studied in total: those with acute GvHD, with chronic GvHD or no 
GvHD.  Diagnosis and grading of GvHD was made by clinicians at the Queen Elizabeth 
Hospital.  Retrospective analysis of cryopreserved PBMCs was carried out on samples 
collected during, prior to and/or following GvHD.  T cell subset frequencies in samples taken 
during GvHD were compared with those when there was no active GvHD (before or after).  
Samples from the cohort of patients who had not had any diagnosis of GvHD were selected 
to match time-points of samples screened from GvHD patients.  Control patients had 
undergone similar transplant conditioning regimens. 
The protocols used for staining were described fully in Methods (sections 2.3 and 2.4).  
Samples were thawed and then split to be stained immediately for Foxp3 or for IL-17A and 
IFN-γ staining.  Surface antibody staining was carried out initially and then the Foxp3 staining 
protocol commenced.  The IL-17A/IFN-γ cohort was further split for stimulated and 
unstimulated experiments.  PMA/Ionomycin was added to the stimulated experiment tubes, 
followed by 2ng/ml monensin to all tubes.  Both stimulated and unstimulated tubes were 
incubated for a total of 6 hours at 37oC 5% CO2.  All tubes were then moved to 4oC overnight 
before intracellular cytokine staining. 
Acute GvHD patients’ samples were available before or during GvHD.  Chronic GvHD patients 
were screened: (A) before, during and after GvHD; (B) during and before; or (C) during and 
after GvHD.  Control samples were selected to reflect the time-points from cGvHD patients, 
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and are shown as early, mid or late time-points.  These are arbitrary categories due to the 
varied ranges of time-points of the GvHD cohort patients. 
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5.3.1 Treg frequencies in GvHD and control patients 
Samples were stained using the Foxp3 staining kit (eBioscience, Hatfield, UK) according to 
the manufacturer’s instructions.  The frequency of Foxp3+ve T cells in the CD4 populations 
was established.  Tregs are generally considered to be CD127lo and CD25hi so these markers 
were included as confirmation.  A CD8 antibody was included to determine whether any 
CD8+Foxp3+ve cells could be detected, although none were observed. 
The frequencies for each patient are shown as linked time-points (figure 5.3.1.1A and B).  
This study was primarily interested in how the frequencies changed between time-points 
where the patients were suffering GvHD and those where they were not.  In some cases, 
there were elevated levels of Tregs during GvHD, but in other cases frequencies were stable 
or decreased.  The frequencies of Tregs in samples taken during GvHD episodes are shown 
(figure 5.3.1.1C) alongside controls samples taken at similar times from patients who had not 
suffered GvHD.  Median frequencies of Tregs for samples in each group were 5.9% (acute 
GvHD), 7.5% (acute controls), 6.4% (chronic GvHD) and 4.3% (chronic controls), but there 
were no significant differences between any groups.  
The frequencies of Tregs for all patients in each cohort and all time-points were plotted 
(figure 5.3.1.2) in order to see whether any increases could potentially be due to 
reconstitution.  However, there was no significant relationship between either elevated or 
lowered Treg frequencies, and time post-transplantation.  There was a slight trend towards 
increasing Treg frequencies in control patients, but this was not observed with patients. It 
may be related to GvHD, but that could not be confirmed with this data. 
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Figure 5.3.1.1 Frequencies of Foxp3+ve Tregs in GvHD patients and controls 
Intracellular cytokine staining was used to determine the frequencies of Tregs (y-axis) in 
peripheral blood samples taken from acute GvHD patients and transplant patients who had 
not had GvHD (A) or chronic GvHD and patients who had not suffered GvHD (B).  Samples 
were taken during GvHD episodes and before/after disease.  Different time-points from the 
same patient are linked with an individually coloured line.  The frequencies of Tregs in GvHD 
samples are shown for acute or chronic GvHD patients compared to samples taken at similar 
times post-transplantation from patients who had not suffered GvHD (C).  Lines represent 
median values.  
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 Figure 5.3.1.2 All patient Treg frequencies over time 
All frequencies of Foxp3+ CD4+ T cells (y-axis) at each time-point (x-axis) were plotted for all 
acute GvHD (A), chronic GvHD (B) patients and non-GvHD sufferers (C), irrespective of GvHD 
episodes.  Frequencies from samples taken at the same time-point are shown aligned on the 
graph.   
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5.3.2 Determination of Th1 and Th17 subsets in peripheral blood of GvHD patients 
The same samples used for Foxp3+ T cell enumeration were used to establish the 
frequencies of IFN-γ secreting Th1 cells and IL-17A producing Th17 subsets.  PMA/Ionomycin 
was used to stimulate cytokine production.  The non-specific nature of this stimulus meant 
that the frequencies of all cells present would be revealed rather than preferentially 
stimulating one type.  Stimulated and non-stimulated fractions were used, however it was 
felt that if a cell produces IL-17A in the non-stimulated fraction, then it was still a Th17 
lineage cell so that to subtract frequencies in the unstimulated fractions as background was 
not appropriate.  Therefore, all data presented is based on the frequencies of the stimulated 
fractions.  
The frequencies of Th1 and Th17 subsets in samples taken before/during/after acute GvHD 
episodes (figure 5.3.2.1) or chronic GvHD (figure 5.3.2.2) are shown alongside time-matched 
controls.  Samples taken at different times from the same patient are linked.  Median 
frequencies of T cell subsets in samples during GvHD episodes were compared to median 
frequencies of these subsets in control samples taken from control patients at similar times 
(figure 5.3.2.3).  No significant differences were found between GvHD and control sample 
median frequencies.  A trend towards decreased Th17 frequencies in acute GvHD samples 
was observed, this proved to not be significant (p=0767). 
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Figure 5.3.2.1 Frequencies of Th1, Th17 and Th17-1 cells in acute GvHD patients before during and after disease episodes 
Frequencies of T cell subsets (y-axis) in acute GvHD patients as measured by IFN-γ and IL-17A 
production following PMA/Ionomycin stimulation.  Those cells secreting IL-17A only were 
considered to be Th17 lineage (A), IFN-γ and IL-17A together were Th17-1 (B) and IFN-γ only 
were Th1 (C).  Samples were taken before/during/after GvHD episodes (x-axis).  Different 
time points from the same patient are shown by linked points and each patient is 
represented by a different coloured line.  Control samples were taken at equivalent times 
post-transplantation from patients without GvHD and are shown on the right.  Controls were 
not available for all samples.  
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Figure 5.3.2.2 Frequencies of Th1, Th17 and Th17-1 cells in chronic GvHD patients before, during and after disease episodes 
Frequencies of T cell subsets in chronic GvHD patients as measured by IFN-γ and IL-17A 
production following PMA/Ionomycin stimulation.  Those cells secreting IL-17A only were 
considered to be Th17 lineage (A), IFN-γ and IL-17A together were Th17-1 (B) and IFN-γ only 
were Th1 (C).  Samples were taken before/during/after GvHD episodes (x-axis).  Different 
time points from the same patient are shown by linked points and each patient is 
represented by a different coloured line.  Control samples were taken at equivalent times 
post-transplantation from patients without GvHD and are shown on the right.  Controls were 
not available for ell samples..   
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 Figure 5.3.2.3 Median T cell subset frequencies in GvHD samples and time matched controls 
Frequencies of Th17 (A), Th1 (B) and Treg (C) cells were determined by flow cytometry in SCT 
patients during episodes of acute GvHD (left column) or chronic GvHD (right column) and 
compared to time matched samples from SCT patients without GvHD.  Values for 
frequencies of subsets are shown for each patient and median values are indicated.  
IL-17A acute
Pa
tie
nts
Co
ntr
ols
0.0
0.5
1.0
1.5
2.0
2.5
%
 IL
-1
7A
 s
ec
re
tin
g 
C
D
4+
 T
 c
el
ls IL-17A chronic
Pa
tie
nts
Co
ntr
ols
0.0
0.5
1.0
1.5
2.0
2.5
%
 IL
-1
7A
 s
ec
re
tin
g 
C
D
4+
 T
 c
el
ls
IFN-γ acute
Pa
tie
nts
Co
ntr
ols
0
10
20
30
40
50
%
 IF
N
- γ
 s
ec
re
tin
g 
C
D
4+
 T
 c
el
ls
IFN-γ chronic
Pa
tie
nts
Co
ntr
ols
0
10
20
30
40
50
%
 IF
N
- γ
 s
ec
re
tin
g 
C
D
4+
 T
 c
el
ls
Foxp3 acute
Pa
tie
nts
Co
ntr
ols
0
10
20
30
%
 F
ox
p3
 e
xp
re
ss
in
g 
C
D
4+
 T
 c
el
ls Foxp3 chronic
Pa
tie
nts
Co
ntr
ols
0
10
20
30
%
 F
ox
p3
 e
xp
re
ss
in
g 
C
D
4+
 T
 c
el
ls
A
B
C
Chapter 5: T cell subsets in GvHD 
205 
 
Trends in overall frequencies regardless of GvHD 
As previous figures have shown no clear association between GvHD and frequencies of Th1 
or Th17 cells, every time-point for all patients in each cohort was plotted in order to 
investigate any trends that may be due to general reconstitution.  There was no significant 
relationship between Th1 or Th17 frequencies and time post-transplantation in the acute 
GvHD cohort (figure 5.3.2.4), and Th17 frequencies did not significantly increase with time in 
the chronic GvHD cohort or controls.  However, there was a significant increase in Th1 
frequencies over time in both the chronic GvHD (p=0.0146) and all controls cohorts 
(p=0.0229) (figure 5.3.2.5 & figure 5.3.2.6).  As there was a considerable range of 
frequencies at many time-points, the data was split into groups based on transplant type, to 
establish whether these frequency differences could be related to conditioning regimens.  
There appears to be little difference overall except that the chronic Th1 increase is not 
significant in patients who have undergone reduced intensity transplants, as opposed to the 
myeloablative transplant patients (p=0.0041).  However, this is probably due to a single high 
frequency at 13 weeks in one patient.  Nevertheless, there is a distinct upward trend in that 
cohort.  Campath conditioning has been associated with delayed reconstitution (Morris et 
al., 2003) but that does not appear to be the case in these patients. 
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Figure 5.3.2.4 Frequencies of Th1 and Th17 subsets over time in all acute GvHD patients 
Frequencies of Th17 cells (A-C) and Th1 cells (D-F) in blood samples from acute GvHD 
patients were measured by intracellular cytokine staining.  Th17 levels shown in A are split 
into frequencies for patients who had myeloablative conditioning (B) and reduced intensity 
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conditioning (RIC) (C).  Similarly, Th1 frequencies shown in D are divided into myeloablative 
(E) and reduced intensity (F) transplant conditioning regimens.  T cell subset frequencies are 
shown on the y-axis and the numbers of weeks post transplantation are indicated on the x-
axis. 
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Figure 5.3.2.5 Frequencies of Th1 and Th17 subsets over time in all chronic GvHD patients 
Frequencies of Th17 cells (A-C) and Th1 cells (D-F) in blood samples from chronic GvHD 
patients were measured by intracellular cytokine staining.  Th17 levels shown in A are split 
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into frequencies for patients who had myeloablative conditioning (B) and reduced intensity 
conditioning (RIC) (C).  Similarly, Th1 frequencies shown in D are divided into myeloablative 
(E) and reduced intensity (F) transplant conditioning regimens.  T cell subset frequencies are 
shown on the y-axis and the numbers of weeks post transplantation are indicated on the x-
axis. 
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Figure 5.3.2.6 Frequencies of Th1 and Th17 subsets over time in all control patients 
Frequencies of Th17 cells (A) and Th1 cells (B) in blood samples from stem cell transplant 
patients who had not had GvHD were measured by intracellular cytokine staining.  T cell 
subset frequencies are shown on the y-axis and the numbers of weeks post transplantation 
are indicated on the x-axis. 
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5.3.3 Relationship of T cell subset frequencies to site and grade of GvHD 
GvHD site 
The main sites affected by GvHD are skin, liver and gut but any other tissue may be affected, 
which often includes eyes, mouth, lungs and joints.  The most common sites in this study 
were skin and gut, with many patients affected in both. 
T cell subsets in patients with GvHD of either skin or gut only were compared between 
samples taken during GvHD and those taken before/after disease (figure 5.3.3.1).  Whilst 
there are differences in the changes in frequencies within patients in the same cohort, the 
most common trend is for Th17 and Th1 levels to be reduced in skin GvHD patients, but 
raised in gut GvHD patients.  However, there are insufficient numbers of patients in each 
cohort to draw any definite conclusions.  Patients affected in both sites were excluded from 
this analysis.  Patients were not discriminated on the basis of acute or chronic GvHD.  The 
cohorts consisted of six acute with seven chronic skin GvHD patients, and five acute with two 
chronic gut GvHD patients. 
Severity of GvHD 
Acute GvHD is graded clinically with increasing severity from grade 1 to grade 4.  The 
relationship of GvHD severity on T cell subset frequencies was considered (figure 5.3.3.2) to 
establish whether increased severity could result from increased frequencies of Th17 of Th1 
T cells, or a diminished Treg population.  Of the 18 acute GvHD patients studied, eight had 
grade 0 or I, six had grade II and four had grade III disease.  No definite associations could be 
made as some patients in all categories had increased levels or pro-inflammatory subsets 
whilst in others, frequencies were decreased. 
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Figure 5.3.3.1 Differences of T cell subset frequencies at sites of GvHD 
Frequencies of Th1 and Th17 subsets (y-axis) in allograft patients who suffered GvHD 
manifested in skin (A) or gut (B) as measured by intracellular cytokine staining on PBMCs 
isolated from whole blood.  The levels of subsets as determined by IL-17A or IFN-γ secretion 
are shown in samples taken during GvHD and before and/or after GvHD (x-axis).  
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Figure 5.3.3.2 Relationship between Th1 and Th17 subsets with acute GvHD severity 
T cell subset frequencies (x-axis) as determined by intracellular cytokine staining for IL-17A 
and IFN-γ in acute GvHD patients divided into groups based on severity of GvHD.  Samples 
were collected during, and before/after GvHD episodes (y-axis).  Clinical assessment of the 
grade of GvHD was made in clinic.   
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5.3.4 Expression of chemokine receptors by T cell subsets 
T cell subsets, including Th17 and Th1, have been shown to express varying levels of the 
chemokine receptors CCR4, CCR6 and CXCR3 (Lim et al., 2008).  Antibodies to these 
receptors were included in the staining panel for Th1 and Th17 cells with a view to 
comparing expression in the different subsets between normal conditions and chronic or 
acute GvHD.  However, one complication of studying cells from allograft patients is that 
there is a considerably disrupted immune environment and reconstitution can vary vastly 
between different individuals even when having undergone similar conditioning.  These 
difficulties are exacerbated when investigating relatively low frequency subsets such as 
Th17.  An example of CD3/CD8 and IL-17A/IFN-γ staining of cells from a patient at 8 weeks 
post-transplantation who had an extremely low frequency of CD4+ (0.6%) and CD8+ (0.24%) 
T cells, is shown in figure 5.3.4.1.  
This patient was excluded from all analysis due to the prohibitively low level of T cells.  
However, even in patients with considerably more robust T cell counts, the frequency of 
Th17 (and sometimes Th1) cells was often very low, and Th17-1 proved to be extremely rare.  
Very low numbers of cell in a particular subset gate could lead to high frequencies from very 
small numbers of cells.  For example, two ‘dots’ either side of a quadrant arm on the FACS 
plot would suggest that 50% of cells for that subset are positive for a certain chemokine 
receptor.  But with such small numbers, this would be very unreliable.  
As such, a lower limit of 20 events per subset gate was used.  This is still quite a low number 
of events and much of the data for the Th17 and Th17-1 is based on number of cells not 
much greater than that threshold, so caution should be exercised with interpreting these 
data.  Where data was available, comparisons between GvHD and non-GvHD samples 
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(before or after) were made.  In other cases, the median levels of chemokine receptors are 
shown for all samples regardless of GvHD status. 
Most data is available for Th1 subsets and can be split into acute (figure 5.3.4.2) and chronic 
patients (figure 5.3.4.3), with equivalent controls.  When considering the mean frequencies 
of cells expressing these chemokine receptors, there is no apparent difference between 
those samples taken at the time of GvHD and those taken when no disease was evident.  
However, this perception of no change in expression proves to not necessarily be the case, 
as the frequencies of cells expressing CCR4 and CXCR3 between these samples can vary 
considerably.  Frequencies of CCR6+ Th1 cells did not vary dramatically in acute GvHD 
patients or any controls.  Chronic GvHD samples did not reflect this, although CCR6+ cells 
both increased and decreased in different patients leading to no overall change in the 
medians.  Similar bidirectional changes were observed in other chemokine receptor 
expression, both within patient groups and control groups. 
As there does not appear to be a tendency to increase or decrease, and that similar patterns 
are evident in controls would suggest that whatever the reason for the changes, they are 
unlikely to be related to GvHD.  There may be natural fluctuations in chemokine receptor 
expression due to the disordered immune environment of these patients, or perhaps 
infections.  A colleague’s data on chemokine receptor expression in a healthy donor cohort 
also showed considerable variation between individuals (O Goodyear - personal 
communication). 
It is apparent that the frequency of cells expressing CCR6 in Th1 cells is generally higher than 
of those expressing CCR4 and CXCR3.  This is similar for the Th17-1 cells as compared to the 
Th17 population.  However, it should be noted that there is a wide range of expression of 
both receptors in this cell population.  Perhaps this is related to the apparent plasticity of 
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Th17/Th17-1/Th1 cells, although the potential for error due to small numbers of events 
could be the explanation. 
Median receptor expression does appear to decrease during GvHD, but conclusions cannot 
reliably be made about this as these frequencies are not in samples taken from the same 
patients.  The only linked samples do not show any change.  More samples with higher 
frequencies are needed to investigate this. 
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Figure 5.3.4.1 Flow cytometric plots showing gating for Th17/Th1 intracellular cytokine staining in a patient sample with low CD4+ and CD8+ T cell frequencies 
The sample was taken from a patient at 8 weeks post-transplantation and was stained 
according to the Th1/Th17 intracellular cytokine staining protocol.  The lymphocyte 
population was gated in the forward/side scatter plot (Gate P1 (A)) and live cells were 
selected with gate P2 (B).  CD4+ (P3) (identified as CD3+ CD8- cells) and CD8+ (P5) 
frequencies were 0.6% and 0.24% respectively.  From this low-frequency CD4+ gate, IL-17A 
and IFN-γ secreting cell levels were determined (D).  
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Figure 5.3.4.2 Chemokine receptor expression on Th1 cells in acute GvHD patients and time-matched controls 
Levels of Th1 cells were established in peripheral blood samples taken from acute GvHD 
patients either during, or before/after GvHD, by intracellular cytokine staining to measure 
the frequencies of IFN-γ secreting cells.  Chemokine receptor expression by cells in this 
subset was measured.  The frequencies of cells expressing CCR6, CCR4 and CXCR3 are shown 
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(y-axis) as medians of all patients in samples taken during GvHD and before/after GvHD (No 
GvHD) (x-axis) (A).  These data are shown again with each individual patient’s samples linked 
(B).  Chemokine receptor expression was also measured on Th1 cells in samples taken at 
similar times in control SCT patients who did not have GvHD, shown as grouped medians of 
samples taken at equivalent times to the GvHD samples or the before/after GvHD samples 
(C).  Individual patients’ samples are shown again as linked points (D). 
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Figure 5.3.4.3 Chemokine receptor expression on Th1 cells in chronic GvHD patients and time-matched controls 
Levels of Th1 cells were established in peripheral blood samples taken from chronic GvHD 
patients either during, or before/after GvHD, by intracellular cytokine staining to measure 
the frequencies of IFN-γ secreting cells.  Chemokine receptor expression by cells in this 
subset was measured.  The frequencies of cells expressing CCR6, CCR4 and CXCR3 are shown 
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(y-axis) as medians of all patients in samples taken during GvHD and before/after GvHD (No 
GvHD) (x-axis) (A).  These data are shown again with each individual patient’s samples linked 
(B).  Chemokine receptor expression was also measured on Th1 cells in samples taken at 
similar times in control SCT patients who did not have GvHD, shown as grouped medians of 
samples taken at equivalent times to the GvHD samples or the before/after GvHD samples 
(C).  Individual patients’ samples are shown again as linked points (D). 
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Figure 5.3.4.4 Chemokine expression on Th17 and Th17-1 cells 
Levels of Th17 cells were established in peripheral blood samples taken from chronic GvHD 
patients either during, or before/after GvHD, by intracellular cytokine staining to measure 
the frequencies of IFN-γ secreting cells.  Chemokine receptor expression in this subset was 
measured.  The frequencies of cells expressing CCR6, CCR4 and CXCR3 are shown (y-axis) as 
medians of all patients in samples taken during GvHD and before/after GvHD (No GvHD) (x-
axis) (A).  These data are shown again with each individual patient’s samples colour coded 
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and linked where data from both GvHD and non-GvHD was available (B).  One patient had 
data for both GvHD and non-GvHD samples.  Chemokine receptor expression data on Th17-1 
cells was only available from two patients (C).  Frequencies of chemokine receptor 
expression for chronic (D) and acute (E) controls is shown as means of all samples with 
sufficient Th17 cells.  No control patients had chemokine receptor expression data for more 
than one sample.  
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5.4 Detection of cytokines and chemokines in the serum of GvHD patients 
Serum was isolated from blood collected in coagulant-free tubes, which were taken at the 
same time as heparinised blood used for PBMC isolation.  Samples were available for most 
patients that were screened for Th17, Th1 and Treg frequencies.  These samples were 
analysed for the concentrations of 25 cytokines and chemokines by luminex assay.  The 
panel of analytes is detailed in table 5.4.1.  The method is explained in Chapter 2 (section 
2.5). 
Measurements for IL-10 and CCL27 (CTACK) fell below the threshold of detection (2.44 
pg/ml) in all samples, so are not included here.  Many cytokines or chemokines could not be 
detected in all samples. 
IL-1β, IL-4, IL-5, IL-13, IL-21, IL-22, IL-23, TNFα, CCL2 (MCP-1), CCL4 (MIP-1β), CCL20 (MIP-3α), 
and CCL5 (RANTES) could be measured in the patients’ serum but did not have any pattern 
between samples, with some patients having increased and some decreased levels in each 
cohort.  Key cytokines (eg IL-17A, IFN-γ), and those with any possible pattern are shown. 
IL-17A and IFN-γ were detected at very low concentrations (figure 5.4.1.1) and there was no 
discernable relationship between serum cytokine concentration and GvHD.  Control samples 
also contained variable levels of cytokine.  One patient in each of the acute and chronic 
cohorts had an increase in IFN-γ levels.  Concentrations in the acute patient increased from 
6.12 to 55.91 and then 58.03 pg/ml, which corresponded to a cellular Th1 increase from 
6.2% to 12.82%, then to 32.17%.  In the chronic GvHD patient, the serum concentration 
increased from 187.81 to 980.51 pg/ml whilst their Th1 frequency increased from 0.7% to 
3.08%.  Curiously, this Th1 frequency is very low in comparison with other patients who had 
much larger frequencies and greater changes in cell frequency that were not reflected in the 
serum concentration measurement. 
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IL-6, IL-7 and IL-15 were present at low concentrations (figure 5.4.1.2).  IL-6 concentrations 
were elevated from undetectable levels, to concentrations between 45 and 97 pg/ml during 
chronic GvHD, and decreased following GvHD, except in one patient where IL-6 
concentrations rose to around 21 pg/ml after GvHD, having previously been undetectable.  
No pattern was observed in time matched samples from control patients, although IL-6 was 
only detectable in a few control samples.  This may reflect that IL-6 levels were generally 
higher in GvHD patients.  IL-6 is a proinflammatory cytokine so may well be involved with the 
pathogenesis of GvHD.  IL-7 and IL-15 both promote T cell proliferation and concentrations 
of these cytokine decreased following acute GvHD in six of seven (IL-7) and five of eight (IL-
15), after chronic GvHD in four of four (IL-7) and three of four (IL-15) patients.  However, 
maximum detected IL-7 concentrations were <60pg/ml (acute GvHD patients) and <80pg/ml 
(chronic GvHD patients), and IL-15 concentrations were <80pg/ml (acute GvHD patients) and 
<200pg/ml (chronic GvHD patients).  Modest decreases at low concentrations may reflect 
intra-well variability. 
The chemokine ligands for CXCR3 are CXCL9 (MIG), CXCL10 (IP-10) and CXCL11 (I-TAC).  
There was no pattern to the concentrations of these chemokines (figure 5.5.1.3), but the 
cellular assays did not reveal any pattern of receptor expression either.  CCL20 (MIP-3α) is a 
ligand for CCR6, but was not detected.  Ligands for CCR4 (CCL17 (TARC) and CCL22 (MDC)) 
were not available for analysis by luminex. 
There were decreases in the concentrations of CCL7 (MCP-3), CXCL1 (fractalkine) and CCL3 
(MIP-1α) following acute GvHD.  All three chemokines are inflammatory and CXCL1 has a 
role in cell recruitment.  It is not surprising then, that these may be elevated during GvHD.  
There was insufficient data to draw conclusions about their role in GvHD, or to show an 
increase from concentrations prior to acute GvHD.  
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Cytokines Chemokines Alternate 
chemokine 
nomenclature 
Chemokine 
ligand 
TNF-α CXCL9 MIG CXCR3 
IFN-γ CCL3 MIP-1α CCR5 
IL-1β CCL4 MIP-1β CCR5 
IL-4 CCL20 MIP-3α CCR6 
IL-5 CCL5 RANTES CCR1 
IL-6 CXCL10 IP-10 CXCR3 
IL-7 CXCL11 ITACK CXCR3 
IL-10 CCL2 MCP-1 CCR2 
IL-13 CCL7 MCP-3 CCR10 
IL-15 CCL27 CTACK CCR10 
IL-17A CX3CL1 FRAC CX3CR1 
IL-21    
IL-22    
IL-23    
 
Table 5.4.1 Panel of cytokines and chemokine analytes used for 25-plex luminex assay 
Serum concentrations of 25 cytokines and chemokines in samples from stem cell transplant 
patients were measured by luminex assay.  Samples were screened for levels of fourteen 
cytokines (1st column) and 11 chemokines (2nd column) which are detailed with their 
alternate nomenclature (3rd column) and the chemokine receptor (4th column). 
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Figure 5.4.1.1 IL-17A and IFN-γ concentrations in serum of patients 
Concentrations of IL-17A and IFN-γ (y-axis) were measured in the serum of peripheral blood 
samples taken during GvHD episodes, and compared with levels in samples taken before or 
after GvHD, or taken at equivalent times from control patients who had not had GvHD.   
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Figure 5.4.1.2 Serum concentrations of IL-6, IL-7 and IL-15 in samples taken before/after and during GvHD, or from time-matched controls 
Concentrations of IL-6, IL-7 and IL-15 (y-axis) were measured in the serum of peripheral 
blood samples taken during GvHD episodes, and compared with levels in samples taken 
before or after GvHD, or taken at equivalent times from control patients who had not had 
GvHD.  IL-6 levels were below the level of detection of detection in all acute GvHD patient 
samples. 
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Figure 5.4.1.3 Serum concentrations of chemokine ligands for CXCR3 in samples taken before/after and during GvHD, or from time-matched controls 
Serum concentrations (y-axis) of chemokines CXCL9 (MIG) (A), CXCL10 (IP-10) (B), and 
CXCL11 (I-TAC) (C) were measured by luminex assay in the serum of acute and chronic GvHD 
patients from peripheral blood samples taken during and before/after GvHD.  Samples from 
time-matched control patients who did not have GvHD were also screened. 
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Figure 5.4.1.4 Serum concentrations changes of chemokines 
Serum concentrations (y-axis) of chemokines CCL7 (MCP3) (A), CX3CL1 (Fractalkine) (B) and 
CCL3 (MIP-1α) (C) were measured by luminex assay in the serum of acute and chronic GvHD 
patients from peripheral blood samples taken during and before/after GvHD.  Samples from 
time-matched control patients who did not have GvHD were also screened. 
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5.5 Case studies 
The data from the Th1/Th17/Foxp3 staining experiments and the luminex assay presented 
here do not show strong associations of any particular subsets with GvHD.  Few samples 
were taken at diagnosis when disease would be untreated, and therefore most active.  Four 
patients were screened at the time of diagnosis when they had active, untreated GvHD. 
KJ299PM 
This patient was diagnosed with chronic gut GvHD at 41 weeks post-transplantation, which 
was of sufficient severity to warrant hospital admission.  A sample was also available from 37 
weeks when there was no known GvHD.  The patient had previously had acute gut GvHD and 
a number of CMV disease complications.  The patient died 12 weeks later from a 
combination of GvHD and CMV disease.  There was an increase of both Th1 (from 4.18% to 
24.98%) and Th17 (from 0.05% to 0.4%) cells in the GvHD sample compared to the pre-GvHD 
sample and Treg frequencies increased with Th1 and Th17 during GvHD (figure 5.5.1.1A).  
CCR6 expression on the Th1 subset decreased from 91.46 to 64.92%.  The frequencies of 
chemokine receptor expression could be measured on all effector subsets in the GvHD 
sample, and CCR6 was around 63% on all subsets.  Th17 and Th17-1 cells had similar 
frequencies of expression of CXCR3 (11.76% and 9.17% respectively) and Th1 subset 
expression was lower at 1.7%.  Th17 cells had the highest frequency expression of CCR4 at 
10.22% compared with 5.07% in Th1 cells and 0.85% of Th17-1 cells. 
Despite there being very low frequency expression of CXCR3, which did not change in 
relation to GvHD, there was a marked decrease in serum CXCL10 (from 1727.7 to 267.45 
pg/ml) and CXCL9 (from 15335.7 to 430.639 pg/ml) during GvHD, both of which are ligands 
for that receptor (figure 5.5.1.1C). Serum concentrations of IL17A and IFN-γ were below the 
level of detection in all samples from this patient.  
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Figure 5.5.1.1 T cell subset frequencies, chemokine receptor expression, serum chemokine levels around the time of chronic gut GvHD in patient KJ299PM  
Th1, Th17 and Treg frequencies (y-axis) as determined by intracellular staining for IFN-γ 
(Th1), IL-17 (Th17) and Foxp3 (Tregs) (A), in peripheral blood samples taken at 37 weeks 
post-transplantation when there was no known GvHD (before) and at 41 weeks, when the 
patient was admitted to hospital with chronic gut GvHD (during).  Th1 and Th17 subsets 
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were also stained for chemokine receptors CCR4, CCR6 and CXCR3 (B).  Receptor frequencies 
in the Th1 subset are shown for samples taken before and during GvHD, but there were 
insufficient cells to determine receptor frequencies for Th17 and Th17-1 subsets in the pre-
GvHD sample.  Chemokine receptor frequencies for each T cell subset are shown for the 
sample taken during GvHD.  Serum IL-17A and IFN-γ were below the level of detection of the 
luminex assay, but there were large decreases in CXCL10 (IP-10) and CXCL9 (MIG) (C). 
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RA296PM 
Acute GvHD patient RA296PM was diagnosed with grade II skin GvHD at 5 weeks post-
transplantation (figure 5.5.1.2).  A post-GvHD sample was taken at 12 weeks post-
transplantation.  Th1 cells decreased (from 14.78% to 5.62%), as did Th17 cells (from 0.09% 
to 0.04%) from the GvHD sample to the non-GvHD sample (figure 5.5.1.2A).  The serum 
concentration of IFN-γ reflected this as it decreased from 17.44 to 9.28 pg/ml, but IL-17A 
concentration increased from 2.88 to 4.54 pg/ml.  However, these concentrations were so 
low and the changes so small, it is difficult to draw conclusions, and may reflect variability 
between wells in the assay.  Chemokine receptor expression was generally low frequency on 
Th1 cells, with CCR6 around 10-12%, both CCR4 and CXCR3 below 2%.  Ligands for the latter 
receptor, CXCL10 (IP-10) and CXCL9 (MIG) were low compared to other patients.  There was 
an increase in IP-10, but a decrease in MIG during GvHD.  A previous study also reported in 
increase in CXCL10 during acute GvHD, although CXCL9 levels were unchanged (Piper et al., 
2007a). 
JR302PM 
Acute GvHD patient was diagnosed with grade I skin GvHD at 7 weeks post-transplantation, 
and a post-GvHD sample was available at 16 weeks (figure 5.5.1.3). 
No Th17 cells were detected in either sample, but the luminex data shows an increase in IL-
17A concentration from below 0.76 to 6.03 pg/ml.  Th1 cells increased from 4.02% to 16.43% 
between the GvHD and post-GvHD samples.  Chemokine receptor expression frequency was 
low, despite this patient having considerably higher serum chemokine concentrations as 
compared with RA296PM.  The frequency of CCR6 expressing cells increased from 5.49% to 
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7.86% during GvHD.  A modest decrease in CXCR10 concentrations from 3174 to 2016 pg/ml 
was observed after GvHD and CXCL9 decreased from 7755 to 649 pg/ml.   
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Figure 5.5.1.2 T cell subset frequencies, chemokine receptor expression, and serum cytokine/chemokine levels around the time of acute skin GvHD in patient RA296PM 
Th1, Th17 and Treg frequencies (y-axis) as determined by intracellular staining for IFN-γ 
(Th1), IL-17 (Th17) (A) and Foxp3 (Tregs) (D), in peripheral blood samples taken 5 weeks 
post-transplantation at diagnosis of acute skin GvHD, and at 12 weeks post-transplantation 
when GvHD had been resolved.  Chemokine receptor frequencies of CXCR3, CCR4 and CCR6 
were measured on Th1 cells (C).  Serum cytokine and chemokine concentrations were 
measured by luminex (B, E).   
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Figure 5.5.1.3 T cell subset frequencies, chemokine receptor expression, and serum cytokine/chemokine levels around the time of acute skin GvHD in patient JR302PM 
Th1, Th17 and Treg frequencies (y-axis) as determined by intracellular staining for IFN-γ 
(Th1), IL-17 (Th17) (A) and Foxp3 (Tregs) (D), in peripheral blood samples taken 7 weeks 
post-transplantation at diagnosis of acute skin GvHD, and at 16 weeks post-transplantation 
when GvHD had been resolved.  Chemokine receptor frequencies of CXCR3, CCR4 and CCR6 
were measured on Th1 cells (C).  Serum cytokine and chemokine concentrations were 
measured by luminex (B, E).   
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CM308PM 
This patient was diagnosed with acute gut GvHD (grade III) at 3 weeks following 
transplantation and a follow up sample was obtained after resolution of GvHD at 16 weeks 
post-transplantation.  There was a slight decrease in Th1 frequencies, from 4.61% to 4.14% 
after GvHD and there was a four-fold increase in Th17 cells, from 0.04% to 0.17%.  Th1 levels 
were very low as was chemokine receptor expression on this subset, although CCR6 
expression increased following GvHD from 3.45% to 12%.  Serum was not available for 
cytokine analysis (figure 5.5.1.4). 
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Figure 5.5.1.4 T cell subset frequencies and chemokine receptor expression around the time of acute gut GvHD in patient CM308PM 
Th1, Th17 and Treg frequencies (y-axis) as determined by intracellular staining for IFN-γ 
(Th1) (A), IL-17 (Th17) (B) and Foxp3 (Tregs) (D), in peripheral blood samples taken 3 weeks 
post-transplantation at diagnosis of acute gut GvHD, and at 16 weeks post-transplantation 
when GvHD had been resolved.  Chemokine receptor frequencies of CXCR3, CCR4 and CCR6 
were measured on Th1 cells (C).  Serum samples were not available for the measurement of 
cytokines and chemokines. 
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5.6 Discussion 
This study sought to establish whether there was any relationship between frequencies of 
IFN-γ secreting Th1 cells, IL-17A secreting Th17 cells or Foxp3 expressing Tregs and GvHD.  
Fifty-three allograft patients were studied, of which 18 had acute GvHD, 14 were diagnosed 
with chronic GvHD and 21 did not suffer any GvHD.  Samples had been taken during GvHD 
episodes and frequencies of these subsets were compared with the levels in samples taken 
before and/or afterwards when there was no evident GvHD.  The frequencies of these T cells 
expressing chemokine receptors CCR4, CCR6 and CXCR3 were measured and levels of various 
cytokines and chemokines in the serum of patients were established.  Samples from allograft 
patients who did not have any GvHD were used as controls. 
These data did not show any clear associations between T cell subset frequencies, 
chemokine receptor expression, serum cytokine/chemokine concentrations and GvHD.  This 
was surprising as GvHD is a T cell-mediated inflammatory condition.  Therefore, one might 
expect that Th1 and Th17 cell frequencies would increase whilst Tregs may, certainly initially, 
be decreased, and that proinflammatory cytokines in the serum of patients would be 
elevated as compared to samples when no GvHD was evident. 
There may be a number of explanations for this counterintuitive result.  This was a 
retrospective study using previously collected, cryopreserved PBMC samples.  Clinical data 
was recorded at the time of the patients’ appointments by clinicians at a stem cell transplant 
patient clinic.  Selected information was then made available to the investigator via a 
database.  This study was part of a larger study investigating the immunology of stem cell 
transplantation for which patient samples were taken according to a collection schedule.  
The ethical approval allowed for ad hoc extra samples to be collected (subject to clinical 
approval and at not more than two week intervals).  Blood samples were collected prior to 
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consultation with the clinician.  There was an inherent complication caused by sample 
collection.  The opportunity for sample collection had already passed when a GvHD diagnosis 
was made, and a further sample could not be taken for two weeks.  Therefore, the majority 
of samples were taken at some time between diagnosis of GvHD and the time where a 
clinical assessment was made that there was no longer disease.  It was not possible to 
accurately know the degree of severity of disease at the time of sample collection.  It is likely 
that the patient would have had some form of treatment before the sample had been taken.  
Of 32 GvHD samples, only four were known to have been taken at the time of diagnosis.  The 
data for all four of these patients has been presented as case studies in section 5.5. 
Severity of GvHD was assessed by a clinician at diagnosis.  Acute GvHD has a grading system 
of increasing severity from grade I to grade IV.  However, there is no such system for chronic 
GvHD which made it difficult to retrospectively establish how severe the disease was.  As the 
grading was made at diagnosis, but most samples were collected some time afterwards, the 
initial grading may not reflect the severity of disease at the time when the sample was taken.  
Treatment drugs were recorded, but it was not possible to assess how the doses of steroids 
had affected the immune system of the patients.  However, if it was known that a patient 
had been on intravenous steroids such as prednisolone, then the sample was avoided as this 
would be likely to have a global immunosuppressive effect. 
Another potential confounding factor was that of infections.  Fungal infections have been 
associated with increased levels of Th17 cells (Huang et al., 2004).  One patient had relatively 
high frequencies of Th17 cells regardless of GvHD and had previously had CMV reactivation, 
although this had been resolved prior to the samples being taken for this study.  Another 
patient, also with higher Th17 levels had had a fungal infection early after transplantation.  
Although these infections had also long been cleared, there remains the possibility that 
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earlier infectious events could have skewed reconstitution towards having higher 
frequencies of Th17 cells.  A mouse study has shown that early fungal infections after stem 
cell transplantation are associated with increased likelihood of developing GvHD 
(Echtenacher et al, 2009 – Poster abstract, ECI 2009).  It would be tempting to speculate, 
that if Th17 cells were associated with GvHD, then the early infectious event could have pre-
empted development of the disease by increasing the overall frequency of Th17 cells.  
However, the data in this study does not support such an association. 
These confounding factors should be considered because the data collected in this study 
show many conflicting changes in patients.  Frequencies of all subsets studied could 
increase, decrease or remain unchanged in different patients with similar GvHD.  Control 
patients also followed these patterns.  Th17 levels changed in the same, or the opposite way 
to Th1 cells and indeed, Tregs.  The lack of patterns may be due to samples being collected 
at different stages of disease, effects of treatment or indeed natural resolution.  It may be 
that Th1 or Th17 levels increase at different times and one or other may already be in 
decline when a particular sample was taken.  Similarly, if Treg frequencies increase after the 
inflammatory subsets, then timing of sample collection from the onset of disease is crucial.  
Even if a sample is taken on the day of diagnosis, it was not known if the symptoms had 
appeared that day, or several days previously.  This study would have benefitted from having 
prospective sample collection by an allied clinician who could have more fully documented 
the patients’ experiences, symptoms and infectious events.  Another drawback to this study 
is that the non-GvHD samples may have been collected a long time prior to, or following 
GvHD, and was not consistent between patients. 
Fluctuations in cell populations may be normal, particularly for stem cell transplant patients, 
who have a profoundly disrupted immune environment.  It is not clear the extent to which 
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stability of T cell lineages could affect these populations.  There is increasing evidence of 
plasticity between suppressive or effector lineages (reviewed (Zhou et al., 2009)).  This 
concept may contribute to the apparent inconsistencies between patients in the levels of T 
cell subsets, and serum cytokines and chemokines.  Even in the patients where a sample was 
definitely taken on the day of GvHD diagnosis there are differences in the way T cell 
frequencies and serum chemokines changed.  These patients did not have any treatment 
bias. 
Two studies have recently claimed to show an association between Th17 cells and GvHD.  
One study apparently used prospectively collected samples (Dander et al., 2009).  However, 
their control samples used throughout were inconsistent as they claimed that samples from 
transplant patients who had not suffered GvHD were identical to samples from non-
transplanted healthy controls, although limited evidence was produced to support this 
claim.  In my study, the controls behaved in a similar way to the GvHD patients which 
suggests that changes seen may not be related to GvHD.  The Dander study indicated that 
the association between peripheral blood Th17 frequencies and GvHD was difficult to make, 
but that there was a localised increase when they studied biopsies.  Here, it may be possible 
to obtain prospective biopsy specimens from a similar cohort to investigate the levels of IL-
17A producing T cells at sites of GvHD.  Good control samples would be essential as reliable 
staining by immunohistochemistry is difficult to achieve with currently available antibodies 
(C. Schmutz - personal communication).  If sufficient cells could be obtained from biopsy 
samples, then Th17 levels at the sites of GvHD could be established by flow cytometry using 
the antibodies already tested in this study.  
Even the chemokines studied in diagnosis samples were inconsistent between patients.  
Serum concentrations of IFN-γ, CXCL10 and CXCL9 did not change the same way in both 
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patients, or even in the same patient.  In one patient, RA296PM, serum IFN-γ and CXCL9 
decreased whilst CXCL10 increased.  In JR302PM, IFN-γ increased whilst both CXCL10 and 
CXCL9 decreased. Secretion of both of these chemokines is induced by IFN-γ, so it would be 
expected that as IFN-γ increased, then so would CXCL10 and CXCL9.  However, IL-10 blocks 
these chemokines, so it is possible that a suppressive response was underway to counter the 
IFN-γ effects.  IL-10 concentrations were too low to detect in any sample.  It should be 
noted, however, that the concentrations of IFN-γ recorded were so low as to be close to the 
lower limit of detection of the assay, which could make the data unreliable. 
The chronic GvHD case study patient was diagnosed with GvHD in the gut which led to 
hospital admission.  Frequencies of both Th1 and Th17 cells were clearly elevated.  Tregs 
were also elevated.  This would suggest that the inflammatory subsets were increased 
because of the disease, and that Tregs were raised in order to combat the inflammation.  
However data from one patient is insufficient evidence.  It is interesting to note that a 
considerable decrease in serum concentration of both IP-10 and MIG occurred during GvHD.  
This was surprising as a previous study showed increase of IP-10 during acute skin GvHD 
(Piper et al., 2007a). In the two case studies here which had acute skin GvHD, one had 
increased and one had decreased CXCL10 serum concentrations.  The reason for these 
conflicting changes is unclear but could be related to transplant conditioning as RA296PM 
had myeloablative conditioning whereas JR302PM had a reduced intensity transplant.  Both 
of these patients had follow-up samples some weeks following GvHD.  There may be an 
unrecorded infectious event, or some other complication affecting reconstitution that 
affected the patient’s CXCL10 levels. 
Overall, it was not possible to make any association between frequencies of Th17, Th1 or 
Tregs with the occurrence of GvHD.  Serum IL-6, IL-7, IL-15, CCL7, CX3CL1 and CCL3 were 
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slightly elevated in a number of cases, although concentrations were low.  All of these are 
proinflammatory cytokines and chemokines.  There was no apparent relationship between 
chemokine receptors CCR4, CCR6 and CXCR3 and GvHD, despite changes in two CXCR3 
ligands, CXCL10 and CXCL9. 
In order to reduce the influence of treatment being given between diagnosis and the time of 
sample collection, a more structured prospective approach should be taken with samples 
collected at very regular intervals so that a sample would be available close to any incidence 
of GvHD, at diagnosis and immediately upon resolution of the disease.
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One of the most challenging issues facing stem cell transplantation research is how to 
enhance the GvL effect whilst abrogating GvHD.  Much of the effort made to elucidate 
natural GvL targets has been focussed on immunity against overexpressed tumour antigens 
such as WT1 or PRAME.  This study has shown that an immune response can be raised 
against CTAgs in AML and MM patients following allogeneic SCT.  Although the number of 
patients in whom a response could be detected was not as high as reported in myeloma 
patients who have not undergone transplantation (Goodyear et al., 2005), it is an important 
demonstration of tumour-directed immunity in the post-transplant setting.  The true 
frequency of patients with CTAg-specific T cell responses could also have been 
underestimated because of practical restrictions on the number of peptides that may be 
used in the screening panels, due to assay limitations and HLA-genotypes of the patients.  As 
the number of defined immunogenic CTAg epitopes increases, larger panels can be used that 
are tailored to each patient’s HLA-genotype.  In addition, inclusion of peptides recognised by 
CD4+ T cells would allow investigation of the wider immune response to CTAgs by including 
assays that measure IL-10 and IL-17, as well as IFN-γ.  Understanding of potential roles of 
Th1, Th2, Th17 and Treg subsets in a CTAg response may help devise therapeutic strategies 
for boosting an anti-tumour response.  
Whilst it may be possible to develop a vaccine strategy that could be used to augment an 
anti-tumour response in patients following transplantation, it remains to be seen when the 
optimum time for such a strategy would be.  In the very early period post-transplantation, 
the disrupted immune environment may prevent the development of a robust T cell 
response, particularly where conditioning agents lead to delayed T cell reconstitution.  An 
alternative strategy, although controversial, may be to vaccinate the stem cell donors, 
enabling either tumour-specific cells to be present in the graft, or to be expanded and 
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adoptively transferred at a suitable time.  Such an approach could not be considered with an 
overexpressed antigen due to the risk of toxicity to the healthy donor.  However, as CTAgs 
should not be expressed in any immunogenic capacity in healthy individuals, this would not 
be expected to cause tissue damage.  One might even speculate that there could be some 
potential benefits to inducing an anti-tumour immune response in a healthy individual. 
Another potential strategy for the immunotherapeutic targeting of tumours is adoptive 
transfer of tumour antigen-specific T cells to patients.  Such an approach has already been 
used to prevent of combat EBV-related lymphomas (Rooney et al., 1995) and CMV infections 
(Peggs et al., 2003, Walter et al., 1995) by transferring virus-specific T cells to the patients, 
and the expansion of these cells has been shown (Heslop et al., 1996).  It may be possible to 
transfer T cells specific for tumour antigens to create, or enhance anti-leukaemic immunity.  
One method of generating these cells is to transduce T cells with a TCR which will recognise 
peptides from a tumour antigen.  A murine model using a WT-1-specific TCR has shown that 
this approach is effective in killing leukaemic cells in NOD-SCID mice (Xue et al., 2005, Xue et 
al., 2010).  However, although WT-1 is overexpressed by tumour cells, it is not restricted to 
malignant cells in the same way as CTAg-specific cells, so carries the potential risk of tissue-
directed responses leading to GvHD.  If commonly recognised CTAg targets can be identified 
by building on the work in this study, then suitable TCRs could be cloned for an adoptive 
transfer approach which would limit GvHD risk.  It may be that mixed populations of T cells 
with TCRs for different CTAgs, both CD4+ and CD8+ T cells, could be generated which were 
tailored for the patient’s HLA-type and transferred to prevent relapse. 
Alternatively, there is the possibility of epigenetically upregulating the expression of CTAgs 
on any residual tumour, in order to increase the opportunity for the transplanted immune 
response to mount a response against the malignant cells.  As this study has already 
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demonstrated the ability of the transplanted donor immune system to mount a response to 
CTAgs, then it is conceivable that this component of the GvL response would be of a greater 
magnitude if antigen concentration was higher.  
Expression of CTAg genes is suppressed by hypermethylation.  Studies have shown that 
hypomethylating agents such as 5-aza-2-deoxycytidine can upregulate CTAg expression on 
solid tumours (Guo et al., 2006, Weber et al., 1994), and also in chronic myeloid leukaemia 
(Dubovsky et al., 2009).  Azacitidine can upregulate the expression of a number of CTAgs in 
AML and MM cell lines, an effect which is enhanced by the administration of the histone 
deaceylase inhibitor (HDACi) sodium valproate.  Induction of a CTAg-specific CD8+ T cell 
response was demonstrated in AML patients following combination therapy with azacitidine 
and sodium valproate (Goodyear et al., 2010).  Trials are ongoing to establish whether this 
effect can be brought about following stem cell transplantation.  Use of these agents for 
anti-cancer therapy is already established and they have been used as a treatment for 
leukaemia (Soriano et al., 2007).  It has been proposed that they have a direct cytotoxic 
effect on malignant cells by inducing apoptosis through expression of DNA-damage pathway 
genes (Gomyo et al., 2004).  However, given the observations of a CTL response to tumour 
antigens following treatment, their therapeutic effect may be two-fold – both via direct 
cellular cytotoxicity and through enhancement of tumour immunogenicity.  It remains to be 
seen if the immunological response generated against these epigenetically manipulated 
tumours can confer any long term benefit or will be hampered by establishment of 
tolerance.  Nevertheless, current literature does allow the possibility that the GvL effect 
could be enhanced in some patients using epigenetic manipulation to induce CTAg 
expression. 
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One of the main challenges to GvHD therapy is suppression of the immune response 
directed against patient tissues without compromising general immunity in order that a GvL 
effect can be established, and to prevent infections.  Currently, patients are given 
prophylactic immunosuppressive therapy in the early transplant period.  This is withdrawn at 
the earliest opportunity in order not to compromise anti-leukaemic immunity.  Patients who 
subsequently present with GvHD like symptoms are generally treated with broad effect 
immunosuppressant drugs.  Prolonged, high-dose steroid treatment carries the risk of 
infection, viral reactivations, treatment-related toxicity or relapse.  Patients are often given 
antibacterial, antifungal and antiviral drugs along with steroids.  An alternative treatment is 
extracorporeal photopheresis whereby white blood cells are collected from the patient, 
incubated with a DNA-intercalating agent and exposed to ultraviolet (UV) light.  Murine 
models showed that this had the effect of increasing the number of Tregs which suppressed 
GvHD (Gatza et al., 2008).  Therefore, there is interest in the immune mechanisms 
underpinning the pathophysiology of the disease to develop treatment strategies. 
As described in Chapter 1, previous studies have produced conflicting evidence for the role 
of T cell subsets in GvHD and whether they inhibit or exacerbate the condition.  The data in 
this study did not show any definite correlations between Treg frequencies, effector T cell 
subsets, cytokine concentrations and GvHD occurrence.  As discussed in Chapter 5, this may 
be due in part to the timing of sample collection.  The primary aim of this arm of the study 
was to establish whether there was a particular role for IL-17A producing T cells in the 
pathogenesis of the disease and there was no apparent relationship.  A recent publication 
found that Th17 cells were elevated in peripheral blood of patients with active GvHD, 
decreased in patients with inactive GvHD and that there was an increased Th17 infiltrate into 
skin, gut and liver tissues in patient biopsies (Dander et al., 2009).  The use of controls in this 
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paper is curious, as they claim that blood samples from healthy donors are comparable to 
those from SCT patients without GvHD, and proceed to only show healthy control data in all 
but one figure.  Here, little difference was seen between GvHD and non-GvHD patients, 
begging the question as to whether use of non-GvHD SCT patient controls would have 
showed the same significances in that paper.  Nevertheless, it is interesting that they show 
decreased Th17 frequencies in GvHD patients with inactive disease.  Indeed, the author did 
state that having samples taken during active disease was crucial for detection of elevated 
Th17 (E. Dander - personal communication).  This further suggests that the samples available 
here, which cannot be directly related to disease status at the time of collection, may cause 
the data to be difficult to interpret. 
Iclozan and colleagues, as described in Chapter 1, found that the Th17 subset had a role in 
GvHD, but was not essential, and that in the absence of IL-17A secreting cells, other T cell 
subsets would compensate (Iclozan et al., 2010).  This suggests that the Th17 subset is part 
of a normal inflammatory response in GvHD, and therapeutic interventions targeting IL-17A 
secreting cells would be of little benefit if that led to increased contributions of other 
subsets. 
As the current broad immunosuppressive approach is not optimal, better prediction or 
targeted therapies are required.  Very regular sampling of SCT patients might allow the 
detection of a predictive marker, such as a population of T cells or perhaps a soluble factor.  
One study addressed this by screening all SCT patients for Th17 levels and looking for 
increases prior to symptoms of GvHD (Lange, et al., 2008. Poster, ASH).  The author stated 
that it was difficult to establish a clear pattern (Lange - personal communication), and as yet, 
the work has not been published.  The poster showed that Th17 frequencies were often 
increased in the week prior to GvHD diagnosis, but had reduced by the time disease was 
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diagnosed. In some cases, the frequencies were below previous measurements and Treg 
levels were elevated. This would suggest that transient increases in Th17 populations had 
already occurred before patients in this study were diagnosed with GvHD. A sample 
collection strategy based on regular, prospective monitoring could lead to an informative 
study, particularly if a broad range of investigations could be carried out.  For example, 
luminex assays of patient serum could establish an early increase in cytokines or 
chemokines.  If treatment was started at an early stage, before symptoms had been 
established, then potentially lower doses of drugs may be required for disease control and 
resolution.  
As Dander and colleagues reported, there may be an accumulation of Th17 cells in the 
tissues of GvHD patients (Dander et al., 2009).  However, further studies on the roles of T cell 
subsets at the site of GvHD, along with the mechanisms of chemoattraction by chemokines 
and the dynamics of regulation at these sites, may allow the development of targeted 
therapies for GvHD to allow swift resolution of disease without a global impairment of 
immune function.  Dander reported considerable technical difficulties with 
immunohistochemistry (IHC) staining for IL-17A secreting cells (E. Dander - personal 
communication), and colleagues have also described problems with Th17 IHC staining.  If 
sufficient biopsy samples can be collected locally, and an IL-17A antibody can be 
satisfactorily validated, then the presence of Th17 cells at GvHD sites could be further 
investigated by IHC, or preferably using flow cytometry if adequate numbers of T cells can be 
isolated.  However, a recently published, extensive study of biopsy samples from GvHD sites 
in gut and skin found that was difficult to determine whether Th17 cells were particularly 
elevated in GvHD as compared to non-GvHD patients, or whether elevated IL-17 secreting 
cells were causative in GvHD episodes or contributed to tissue damage, although the ratio of 
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Th17/Tregs at these sites may be indicative of GvHD (Ratajczak et al., 2010).  One limitation 
of their study was that biopsy material from the study cohort was not available from times 
when there was no evidence of GvHD.  Therefore, whether Th17 frequencies increased 
during GvHD could not be determined.  The authors suggest that comparing frequencies 
between different patients is not necessarily informative, as baseline levels can vary 
considerably without evidence of pathology.  Again, if biopsy samples could be obtained 
before and after GvHD as well as during disease episodes, a clearer picture of whether Th17 
cells do indeed play a role in GvHD may emerge.  Such an investigation would depend on 
obtaining appropriate ethical approval, and the willingness of patients to provide additional 
skin biopsy samples. 
It could be interesting to relate early infectious events to GvHD and the immune repertoire.  
In this study, it was observed that one patient had comparatively high levels of Th17 cells 
even before the onset of GvHD.  The patient had had a fungal infection early in the post-
transplant period, and Th17 responses are thought to have a role in anti-fungal defences.  A 
murine study showed that early Aspergillus spp. infections following SCT led to increased 
incidence of GvHD (Echtenacher et al, 2009 – Poster Abstract, ECI 2009).  A human study 
related Candida spp colonisation to occurrence of GvHD and it may be that early infectious 
events could shape immune reconstitution, and potentially be a predictor of GvHD.  Certain 
patients could potentially be deemed as higher risk for GvHD and could be targeted for 
prophylactic treatment. 
The main conclusion of this project was the demonstration of T cell immunity to CTAgs 
following stem cell transplant, and this established for the first time that MAGE family 
proteins are immunogenic in AML patients.  These findings lead to the possibility that this 
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family of tumour-specific genes could be manipulated to enhance the GvL effect in allo-SCT 
patients.  
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Background
Allogeneic stem cell transplantation is associated with a powerful ‘graft-versus-leukemia’ effect
that is generally considered to result from an alloreactive T-cell immune response. However,
disease remission can also be observed after syngeneic transplantation and we investigated
whether a T-cell immune response to cancer-testis antigens can be detected in patients in the
post-transplant period.
Design and Methods
The T-cell immune response against cancer-testis antigens was studied in a cohort of 41
patients who underwent allogeneic stem cell transplantation for the management of acute
myeloid leukemia or multiple myeloma. The cytokine secretion assay was combined with
magnetic selection to allow detection of an interferon-γ-secreting T-cell response to a panel of
cancer-testis antigen peptides. 
Results
A cancer-testis antigen-specific CD8+ T-cell immune response was observed in the peripheral
blood of five patients with an average magnitude of 0.045% of the CD8+ T-cell repertoire. Four
of these patients had undergone reduced intensity conditioning transplantation with alem-
tuzumab for the treatment of acute myeloid leukemia and three remain in long-term remission.
T-cell immunity was focused against peptides derived from MAGE proteins and was marked-
ly increased within the bone marrow.
Conclusions
Functional cancer-testis antigen-specific CD8+ T-cell immune responses develop in the early
period following reduced intensity allogeneic stem cell transplantation and are preferentially
localized to bone marrow. These immune responses are likely to contribute to the cellular basis
of the graft-versus-leukemia effect. 
Key words: allogeneic stem cell transplantation, antigen-specific, CD8+ T cell, graft-versus-
leukemia effect.
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G, Craddock C, and Moss PAH. CD8+ T-cell immunity against cancer-testis antigens develops fol-
lowing allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-
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CD8+ T-cell immunity against cancer-testis antigens develops following 
allogeneic stem cell transplantation and reveals a potential mechanism
for the graft-versus-leukemia effect
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Introduction
Allogeneic stem cell transplantation is used widely in
the management of hematologic malignancies but the
frequency of disease relapse remains a major challenge.
The ‘graft-versus-leukemia’ (GvL) effect of allogeneic
transplantation results from the recognition of host
tumor cells by the donor immune system1-4 and an
improved understanding of the cellular targets of this
response would facilitate the development of novel
immunotherapeutic approaches. 
The magnitude of the GvL effect is related to the
degree of histoincompatibility between the donor and
recipient and this has focused interest on minor histo-
compatibility antigens as the predominant target for T
cells which mediate allogeneic immune responses.5-7
However, it is now appreciated that GvL responses may
also be observed in the setting of syngeneic transplanta-
tion in which there is no genetic mismatch between
donor and recipient8 and this has concentrated attention
on the possibility that stem cell transplantation may be
associated with immune responses against ‘tumor-spe-
cific’ antigens.9
Cancer-testis antigens (CTAg) are proteins whose
physiological expression is restricted to germline tissue
and are, therefore, not exposed to the systemic immune
system so that immunological tolerance is not estab-
lished. CTAg expression is often observed in malignant
cells and may reflect induction of a ‘germline transcrip-
tion’ profile during cell transformation.10-13 CTAg-specific
humoral and cellular immune responses have been
reported in patients with a variety of solid tumors14-16 and
there is increasing interest in their potential role in
hematopoietic malignancies.17-21
CTAg may also represent an important target for the
GvL effect of allogeneic transplantation and antibodies to
CTAg proteins have been demonstrated in patients who
have undergone stem cell transplantation for the treat-
ment of myeloma.21 A T-cell response to the CTAg protein
NY-ESO was also observed in one patient in this cohort
but this was coincident with disease relapse. In this study
we screened 41 patients for the presence of a CD8+ T-cell
immune response to CTAg peptides in the post-transplant
period and related this to clinical outcome. Such immune
responses were observed in five patients and, when pres-
ent in the early period after transplantation, were associat-
ed with long-term disease control.
Design and Methods
Patients
Forty-one patients with a primary diagnosis of acute myeloid
leukemia (AML) or multiple myeloma (MM) who were under-
going allogeneic stem cell transplantation were studied. Written
informed consent was obtained prior to enrolment in the study
and appropriate ethical approval was obtained from the South
Birmingham Regional Ethics Committee. Thirty-five patients
had a diagnosis of AML, while the remaining six were undergo-
ing treatment for MM. Twenty patients received a myeloabla-
tive conditioning regimen consisting of cyclophosphamide (60
mg/kg x 2 days) and 14.4 Gy total body irradiation, and 21
received a reduced intensity conditioning regimen incorporat-
ing fludarabine (25 mg/m2 x 5 days), alemtuzumab (140 mg/m2)
and melphalan (10 mg x 5 days) (Table 1).
Patients’ samples
Heparinized peripheral blood samples of 50 mL were taken
prior to the transplant and then at several time points in the
post-transplant period. Bone marrow samples were obtained at
the time of routine clinical monitoring and mononuclear cells
were isolated from all samples by density gradient centrifuga-
tion using Lymphoprep (Nycomed, Oslo, Norway). All assays
were carried out using freshly isolated peripheral blood  or bone
marrow samples.
Detection of cancer-testis antigen-specific T cells
A panel of 20 peptides (Alta Biosciences, Birmingham, UK) from
ten CTAg gene families was chosen on the basis of having been
previously identified as T-cell epitopes (as detailed on the website
of the Academy of Cancer Immunity) and also shown to have
RNA expression in AML and/or MM.22,23 The peptides, their HLA
restriction and gene derivation are detailed in the Online
Supplementary Table S1. Peptide-specific T cells were identified
from peripheral blood mononuclear cells using detection of inter-
feron-gamma (IFN-γ) cytokine secretion and an enrichment assay
kit (CSA, Miltenyi Biotec, Bergisch Gladbach, Germany) according
to the manufacturer’s instructions. Freshly isolated peripheral
blood mononuclear cells were seeded into wells of tissue culture
plates (Iwaki) in RPMI 1640 media (Invitrogen) supplemented with
10% human serum (H+D Supplies) and L-glutamine (Invitrogen) at
a cell density of 1¥107/mL and left overnight without stimulation
at 37°C in 5% CO2. Peptides were then added either individually
or in pools of not more than six at a final concentration of 10
mg/mL. An equivalent volume of dimethylsulfoxide (Sigma, UK)
was added to a negative control well which was then used to
determine gate positioning for FACS analysis, as shown in Figure
1. Staphylococcal enterotoxin B (Sigma, UK) was used as a positive
control at a concentration of 1 mg/mL. Following a 3-h stimulation
period, the cells were labeled for 5 min with IFN-γ catch reagent
and incubated under continuous rotation for 45 min at 37°C. The
cells were then labeled with IFN-γ detection reagent conjugated to
a phycocerythrin fluorochrome, followed by anti-phycoerythrin
magnetic beads. Magnetic selection was carried out either manu-
ally using MS columns (Miltenyi Biotech) for double positive selec-
tion, or using the equivalent “posseld” selection program on an
autoMACs (Miltenyi Biotech). Pre- and post-selection samples
were labeled with CD4-fluorescein isothiocyanate, CD8-phyco-
erythrin cyanin 5.1 monoclonal antibodies (Beckman Coulter,
High Wycombe, UK) and propidium iodide (1 mg/mL, Sigma, UK)
to exclude dead cells. Flow cytometric analysis was carried out
using either a Beckman Coulter XL-2 flow cytometer (Beckman
Coulter, High Wycombe, UK) with WinMDI software for analysis
(Scripps Institute, La Jolla, USA) or a BD LSRII with FACS DIVA
analysis software (BD Biosciences). The percentage of antigen-spe-
cific T cells in the CD4+ or CD8+ pool was calculated using the
number of cytokine-secreting cells in either the positively selected
fraction or pre-selected samples gated on CD4+ or CD8+ cells with-
in the peripheral blood mononuclear cells. Any IFN-γ-secreting
cells detected in the unstimulated negative control were consid-
ered to be background and subtracted from the frequency of cells
producing IFN-γ following peptide stimulation.
Results
Cancer-testis antigen-specific CD8+ T-cell responses
can be detected in patients following stem cell 
transplantation
The IFN-γ cytokine secretion assay was used to identi-
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fy CTAg-specific T-cell responses to a panel of 20
immunodominant peptides derived from ten CTAg
genes (Online Supplementary Table S1). Peptides were
selected on the basis that they were derived from pro-
teins for which RNA expression had previously been
demonstrated in AML and/or MM, and immunogenicity
had been previously documented in patients with solid
tumor malignancies.24 Peripheral blood lymphocytes
were isolated from patients at several time points follow-
ing transplantation and were stimulated with CTAg pep-
tides appropriate to the HLA genotype of the patient.
Overall, CTAg-specific CD8+ T cells were identified in
five patients who were screened at a wide variety of
time points in the post-transplant period. The frequency
of the CTAg-specific CD8+ T-cell response was variable
and ranged between 0.0005% and 0.2% of the total
CD8+ T-cell pool. The mean frequency of responses was
0.045%, which equates to approximately 1 in 2000 CD8+
T cells and is comparable to the magnitude of many
virus-specific immune responses. Of the 20 patients who
received reduced intensity conditioning with alem-
tuzumab, four had detectable CD8 responses to CTAg
peptides, whereas of the 21 who underwent myeloabla-
tive conditioning only one had CTAg-specific CD8
(Figure 2).
The majority of CTAg-specific immune responses
could be detected without the requirement for magnetic
enrichment, although selection was used to increase the
reliable sensitivity of the IFN-γ cytokine secretion assay
down to 0.0001%.25 If a CTAg-specific response was
only apparent after magnetic selection then the precursor
frequency was calculated on the basis of the post-selec-
tion sample, although this approach tends to underesti-
mate the true value due to cell loss during selection. An
example of flow cytometric analysis before and after
magnetic enrichment is shown in Figure 1. These
responses could be detected serially in some cases and
the absolute magnitude of the response varied at differ-
ent time points in the post-transplant period. 
Patients were recruited to the study at a range of dif-
ferent time points in the post–transplant period (Figure 2)
and the association between CTAg-specific immunity
and time post-transplant is discussed below.
Cancer-testis antigen-specific CD8+ T-cell responses
were observed in two patients with long-term 
disease-free survival
CTAg-specific CD8+ T cells were detected in two
patients within the first year following transplantation
and both of these had undergone reduced intensity con-
ditioning allografting for AML (Figure 3). AML patient
189A (Figure 3A) had a T-cell response to peptide RAGE-
111-20 and also to the peptide pool comprising MAGE-
C2336-344/MAGE-A1289-298. These responses were observed
at 9 weeks post-transplant which was the first time point
of analysis. Of note, the patient had suffered from grade
IV graft-versus-host disease (GvHD) of the skin 3 weeks
after transplantation and this had been treated with oral
prednisolone. The T-cell response to RAGE-111-20 was
present at five separate times of analysis until 51 weeks
post-transplant although the magnitude of the response
was variable and was undetectable on four occasions.
Cyclosporine A treatment had been discontinued at 27
weeks post-transplantation and this coincided with a
transient increase in the RAGE-specific T-cell response
(Figure 3A). 
CTAg-specific T cells were detected in patient 235A at
A. McLarnon et al.
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Table 1. Clinical characteristics of the patients undergoing stem cell
transplantation.
Age (years): median (range) 50 (23-63)
Gender, number (%)
Male 21 (51)
Female 20 (49)
Underlying disease, number (%)
Acute myeloid leukemia 35 (85.4)
Multiple myeloma 6 (14.6)
Transplant type, number (%)
Myeloablative
Sibling 14 (34.2)
Unrelated donor 6 (14.6)
Non-myeloablative
Sibling 11 (26.8)
Unrelated donor 10 (24.4)
HLA-types of patients, number (%)
A1 20 (44.4)
A2 26 (57.7)
A3 11 (24.4)
A24 4 (8.8)
B7 16 (35.5)
B18 2 (4.4)
B44 17 (37.7)
Cw7 30 (66.6)
Cw16 4 (8.8)
Disease state, number (%)
Relapsed 8 (19.5)
Non-relapsed 33 (80.5)
Figure 1. Flow cytometric enumeration of frequency of CTAg
responding CD8+ cells. Following the IFN-γ cytokine secretion assay
and enrichment, perioheral blood mononuclear cells incubated with
dimethylsulfoxide only during the stimulation period are shown,
prior to (A) and following (C) magnetic selection, along with IFN-γ
responses to MAGE-A2-212-220 prior to (B) and following (D) magnetic
selection. 
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17, 23 and 29 weeks after transplantation and this also
coincided with tapering of cyclosporine A therapy,
which was finally discontinued by 25 weeks. However,
at 20 weeks, no response was detected (Figure 3B). This
patient was one of 13 also screened prior to beginning
conditioning for transplantation, although no pre-trans-
plant responses were detected.
Importantly, patients 189A and 235A have remained in
remission since transplantation and now remain disease-
free at 52 and 37 months post-transplant, respectively.
Overall, there were 14 patients who were screened for
CTAg-specific immune responses on two or more occa-
sions within the first year post-transplant and who are
alive without relapses. As CTAg-specific T cells were
observed in two of these, we were able to demonstrate
immunity to this relatively limited CTAg peptide panel
in 14.3% of this group. Screening began on an addition-
al AML patient (138A) at 92 weeks post-transplant and a
T-cell response was observed against peptides MAGE-
C2336-344 and MAGE-A1161-169 but not detected thereafter
(data not shown). This patient has also remained relapse-
free during follow-up. 
Cancer-testis antigen-specific T-cell responses can
also be detected at the time of disease relapse
Our previous studies of CTAg-specific immunity in
patients with myeloma revealed that CD8+ responses are
often observed around the time of disease relapse and
Detection of CTAg-specific T cells post-allograft
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Figure 2. Summary of the
screening of all patients’
samples. The times of all
screens are shown in
weeks post-transplanta-
tion (y-axis). Assays in
which no responses were
seen are shown as black
squares and positive
responses are shown as
open circles. Samples
screened more than 165
weeks post-transplanta-
tion are indicated by a
number representing the
week at which the sample
was screened. A cross (†)
denotes time of death of
patients who died due to
relapse, and a letter R
shows when patients suf-
fered relapse but were
successfully treated and
have survived. The gray
area shows those patients
who received reduced
intensity conditioning.
Response frequencies in
patients 15 and 8 are
shown in Figure 3 (A and
B, respectively), and
patients 37 and 13 are
detailed in Figure 4 (A and
B, respectively). 
Figure 3. Responses to CTAg peptides were detected at various times post-transplantation in AML patients The frequencies over time of
CTAg-specific T cells in two AML patients who had responses are shown. The gray area indicates prophylactic tapered cyclosporine treat-
ment given during the early weeks following transplantation. Patient 189A (A) suffered grade IV acute graft-versus-host disease during week
7 post-transplantation which was treated with prednisolone. Patient 235A (B) had fluctuating responses between weeks 17 and 29 which
were undetectable at week 20 post-transplantation. 
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probably reflect immune response to increased tumor
load.19 A similar pattern was observed in patient 125M
with a diagnosis of MM who was initially studied more
than 2 years after stem cell transplantation with a mye-
loablative conditioning regimen. The serum paraprotein
level had risen at 124 weeks post-transplant and indicat-
ed the onset of disease relapse. The first CTAg analysis
was undertaken 10 weeks after this point and revealed a
broad CTAg peptide-specific immune response with
specificity for peptides in three different peptide pools
and included reactivity against the peptide MAGE-A2-212-
220. The patient was treated with thalidomide and the
next sample was taken at 143 weeks at which time the
magnitude of the MAGE-A2212-220 -specific response had
fallen by 60% and responses to other peptide pools were
not observed. Interestingly, the patient responded well to
thalidomide with a reduction in the paraprotein level and
no CTAg-specific immune response could be detected in
subsequent analyses (Figure 4A). 
Patient 172A with a pre-transplant diagnosis of AML
was screened from 38 weeks post-transplant and
responses were seen at 53 weeks to peptides MAGE-
A196-104, MAGE-A2212-220 and MAGE-A3167-176. At 55 weeks
the patient was diagnosed with a relapse of AML and
died shortly afterwards (Figure 4B). 
RAGE-1-specific T cells can be detected at higher 
frequency within bone marrow than within 
peripheral blood
Paired blood and bone marrow samples from patient
189A were obtained at 35 and 51 weeks post-transplan-
tation. T cells specific for RAGE-111-20 were detected by
the IFN-γ cytokine secretion assay and the frequency
was found to be up to seven times higher in bone mar-
row than in peripheral blood mononuclear cells. In
peripheral blood, at both 35 and 51 weeks, 0.0006% of
CD8+ T cells were specific for RAGE-111-20, whereas in the
bone marrow, the frequencies were 0.0021% at 35
weeks and 0.0042% at 51 weeks (Online Supplementary
Figure S1).
The cancer-testis antigen-specific CD8+ T-cell response
post-transplantation is preferentially focused 
on peptides derived from the MAGE family of proteins
Twenty CTAg peptides were used in this study and T-
cell responses within patients undergoing stem cell trans-
plantation were detected in response to six of these.
Interestingly, responses were focused on peptides
derived from the MAGE family of proteins and four
patients showed T-cell immune responses against pep-
tide MAGE-A2212-220 (Online Supplementary Figure S2).
Overall, CD8+ T-cell responses were observed against
peptides derived from the MAGE subfamily proteins A1,
A2, A3 and C2, and a strong immune response against
RAGE-1 was also observed in one patient. 
Discussion
Almost all experimental studies of GvL have focused
on minor histocompatibility antigens and the potential
role of ‘tumor-associated’ proteins has been relatively
ignored. CTAg are important targets in autologous can-
cer-specific immune responses and have the capacity to
contribute to the allogeneic GvL response. The develop-
ment of a humoral immune response against CTAg pro-
teins has been reported as a frequent event in patients
undergoing stem cell transplantation for MM, and T-cell
clones against NY-ESO have been reported in one patient
at the time of disease relapse.21
We studied CTAg-specific T-cell immunity in a large
cohort of patients undergoing allogeneic stem cell trans-
plantation for AML and MM, and observed CTAg-specif-
ic CD8+ T cells in five of the 41 patients. While this may
seem a relatively low frequency it must be appreciated
that the peptide pool only contains a small fraction of the
potential immune epitopes from CTAg proteins, and in
addition the potential relevance of each peptide is limit-
ed by the HLA genotype of the patient. As such the use
of a broader range of CTAg peptides would be expected
to facilitate the detection of many more CTAg-specific T-
cell responses within this group of patients. The magni-
tude of individual CTAg peptide-specific immune
responses averaged 0.045%, or around 1 in 2000 of the
CD8+ T-cell repertoire. This is comparable to the level of
T-cell response to many viral epitopes26 and indicates
that the immunogenicity of these proteins can be quite
considerable in this setting. The range of responses var-
ied between 0.0005% and 0.2% of the CD8+ T-cell pool
and suggests that individual peptides are likely to reflect
A. McLarnon et al.
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Figure 4. Responses to CTAg peptides were detected post-transplantation in relapsed patients The frequencies over time of CTAg-specific T
cells in relapsed myeloma patient 125M are shown (A). The gray area indicates prophylactic tapered cyclosporine treatment given during
the early weeks following transplant. Paraprotein levels are plotted on the right-hand axis. CTAg-specific responses were detected in AML
patient 172A shortly before relapse (B). 
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either dominant or subdominant epitopes within each
patient. 
Interestingly, the strength of the CTAg-specific
immune responses also varied over time within individ-
ual patients and seemed to correlate with clinical events.
The reduction in prophylactic immune suppression after
stem cell transplantation is often associated with
increased allogeneic immune responses and in two
patients (189A and 235A) we were able to detect CTAg-
specific T cells immediately following cessation of
cyclosporine A  treatment. The magnitude of CTAg-spe-
cific immunity that is required for clinical efficacy is
unclear but in CTAg vaccine trials for metastatic
melanoma, tumor regression has been demonstrated
even though it is not always possible to detect tumor-
specific T cells. This has led to the belief that very low
numbers of T cells are required for an effective anti-
tumor response16,27 and the levels within our cohort of
patients are certainly in this range. In the setting of allo-
geneic transplantation it is well documented that
patients can achieve durable remissions on withdrawal
of immunosuppression.28
The CTAg-specific immune response in patient 235A
was interesting in that it fluctuated quite markedly in
magnitude. Two strong positive responses were seen at
weeks 17 and 29 post-transplantation but on two occa-
sions between these dates the response was much lower,
and in one case undetectable. The reason for this is
unclear but is possibly related to biological factors such as
T-cell homing and tissue distribution which frequently
results in some degree of fluctuation in T-cell responses.
However, although the IFN-γ cytokine secretion assay has
been validated in our laboratory, we cannot rule out the
possibility that the lack of a detectable response on that
occasion could have been due to a technical problem with
the assay. The IFN-γ secretion assay is a powerful tech-
nique but the sensitivity of detection that was required
for this study is at the limit of current technology.
Interestingly, all of the AML patients who developed
CTAg-specific immune responses had undergone
reduced intensity conditioning which includes the use of
alemtuzumab. This regimen is strongly immunosuppres-
sive and provides valuable prophylaxis against GvHD.
However, the clinical outcome for AML patients after
reduced intensity conditioning has been very encourag-
ing29 and it is tempting to speculate that induction of a
CTAg-specific immune response could provide one
explanation for this. 
Although our studies were performed largely on
peripheral blood samples, CTAg-specific T cells are only
likely to be effective in the control of hematopoietic
malignancies if they are able to enter the bone marrow.
We found that CTAg-specific CD8+ T cells were selec-
tively recruited to marrow such that their frequency was
up to seven-fold higher at this site. We have recently
described a unique ‘bone marrow homing’ chemokine
receptor profile on CD8+ T cells30 and in future studies it
will be important to determine the phenotype of CTAg-
specific T cells at these sites. Interestingly, a recent study
investigated T-cell immunity to the leukemia-associated
antigens WT1 and proteinase-3 in patients with myeloid
malignancy and also found higher frequencies in the
bone marrow than in peripheral blood.31
The major clinical question must relate to the potential
contribution of the CTAg-specific T-cell response to the
GvL effect. It seems clear that such responses were
induced as a result of the allogeneic transplant as no
immune response was observed in the 13 patients who
were screened prior to transplantation, and the magni-
tude of the CTAg-specific population was increased in
association with withdrawal of immune suppression in
two patients. CTAg-specific T cells have been shown to
have the capacity to kill primary tumor cells in vitro32 and
it is, therefore, tempting to speculate that such immune
responses do indeed contribute to disease control. 
However, CTAg-specific T-cell immune responses
were also seen in two patients at the time of disease
relapse. We have seen this pattern previously in patients
with MM and believe it reflects the response of CD8+ T
cells to increased availability of CTAg protein from
recurrent tumor.18 Interestingly, the allogeneic NY-ESO-
specific T-cell response reported by Atanackovic et al.
was also observed at the time of relapse of MM.21 Future
studies will need to address the phenotype and magni-
tude of T-cell responses in relation to relapse.
Interestingly, the AML patient in our study in whom we
detected a CTAg-specific CD8+ response at relapse had
very low levels of donor chimerism prior to relapse and
it will be important to address whether CTAg-specific
immunity at relapse reflects expansion of recipient-
derived T cells. 
Somewhat to our surprise, the majority of T-cell
responses were specific for peptides derived from MAGE
proteins. Although it was initially felt that MAGE was
not expressed in AML,33 mRNA expression has recently
been reported.34 The fact that MAGE expression is high-
ly restricted to germ cells and malignant tissue is likely to
dictate that MAGE-specific immune responses are mani-
fest as a GvL response rather than GvHD.35,36
In conclusion we have demonstrated frequent occur-
rence of CTAg-specific CD8+ T cells in patients following
reduced intensity stem cell transplantation. The associa-
tion between the early detection of such an immune
response and prolonged disease remission provides sup-
port for the concept that CTAg-specific immunity plays
an important role in GvL. Further studies are now indi-
cated to explore the potential for enhancing CTAg-spe-
cific immunity in the post-transplant setting. 
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